Design of tympanic membrane puncture catheters or subannular ventilation catheters and other medical and fluid catheters
By designing an tympanic membrane puncture tube with antifouling characteristics and guiding fluid transportation, the problems of catheter blockage and biofilm formation are solved, and efficient fluid transportation and patient comfort are improved.
Patent Information
- Application Number
- CN201980033790.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-03-20
- Filing Date
- 2019-03-20
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2039-03-20
AI Technical Summary
The existing tympanic membrane puncture tubes and under-ring ventilation tubes are prone to blockage, premature extrusion, biofilm formation and environmental water entering the middle ear space during use, resulting in poor treatment results and reduced patient comfort.
Designed a conduit with antifouling properties, directing fluid transport, minimal invasiveness and programmable shapes, using lubricating fluid layers and chemical gradients to reduce blockage and biofilm formation and improve fluid transport efficiency by optimizing geometric and surface properties. , and control fluid transport through dynamic flanges and built-in sensors.
It effectively reduces the obstruction and biofilm formation of the catheter lumen, improves the efficiency of fluid transportation, reduces the risk of ambient water entering the middle ear, and improves patient comfort and treatment effect.
Smart Images

Figure CN112188877B_ABST
Abstract
Description
[0001] Copyright Notice
[0002] This patent disclosure may contain material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise reserves any and all copyright rights whatsoever.
[0003] Incorporated by Reference
[0004] All patents, patent applications, and publications cited herein are hereby incorporated by reference in their entirety in order to more fully describe the state of the art as of the date of the invention described herein. Field of the Invention
[0005] The present application relates to catheters that can be used for medical applications, such as tympanic membrane puncture catheters and subannular ventilation catheters, or catheters for non-medical applications. More specifically, the present application relates to catheters with anti-fouling properties, guided fluid transport, minimal invasiveness, and / or programmable shape and chemical information.
[0006] background
[0007] I. Incidence and impact of otitis media
[0008] Acute otitis media (AOM), also known as ear infection, and otitis media with effusion (OME) are the leading causes of healthcare visits worldwide. Otitis media (OM) occurs in the middle ear space behind the eardrum, usually after a cold or other upper respiratory infection has been present for several days. During this infection, the Eustachian tube swells, blocking air from entering the middle ear and drawing fluid into the middle ear space. This trapped fluid, which contains mucin, contains bacteria and viruses.
[0009] II. Placement of tympanostomy tube and subannular ventilation tube
[0010] Acute otitis media (AOM), also known as ear infections, and otitis media with effusion (OME) are the leading causes of healthcare visits worldwide and result in considerable patient morbidity and a significant healthcare burden of more than $5 billion per year in direct and indirect costs in the United States. Globally, AOM affects more than 700 million people per year; children are often disproportionately affected relative to adults, with an estimated global prevalence peaking at 61% between the ages of 1-4 years. AOM is the most common infection in pediatric patients, affecting more than 8.8 million American children in the United States and resulting in 12 to 16 million physician visits per year. The prevalence of acute OM is 60% within the first 5 years of life. OM occurs in the middle ear space behind the tympanic membrane, usually after a cold or other upper respiratory tract infection has been present for several days. During this infection, the Eustachian tube swells, blocking air from entering the middle ear and drawing fluid into the middle ear space. This mucin-containing trapped fluid contains bacteria and viruses. Because children younger than 7 years of age have shorter and more horizontal Eustachian tubes, they are more susceptible to obstruction, resulting in a higher incidence of ear infections.
[0011] If left untreated, OM can cause symptoms including pain, fever, vomiting, loss of appetite, difficulty sleeping, dizziness, recurrent acute infections, hearing loss, and delayed speech development. Severe complications of acute OM include disabling acute mastoiditis, subperiosteal abscesses, intracranial suppuration, meningitis, and facial nerve palsy. In developing countries, chronic OM often results in these permanent auditory sequelae and, when untreated, is estimated to cause more than 28,000 deaths worldwide due to these complications, according to a WHO report.
[0012] In 2006, a total of $2.8 billion was spent on the treatment of OM, not including over-the-counter medications. The current standard of care consists of a 10-day course of broad-spectrum oral antibiotics. OM is the most common reason antibiotics are prescribed to children in the United States. Treatment of acute otitis media in children under 2 years of age. As a result, it is believed that OM treatment contributes to the continued increase in antibiotic resistance among pathogenic bacteria. Systemic antibiotic administration often results in side effects, which include diarrhea, dermatitis, vomiting, and thrush. Even after the middle ear cavity is no longer infected, fluid remains in the ear. About 30% of children still have fluid in the middle ear one month after an ear infection, and 20% still have fluid after two months. This fluid causes recurrent infections, with 40% of children suffering from 4 or more episodes of acute OM.
[0013] To treat the fluid buildup, a small incision can be made in the eardrum (commonly called the eardrum) in a procedure called a "myringotomy." During the tympanotomy, the fluid can be removed by a surgeon with a needle. However, after the incision heals, OM can recur, and fluid can accumulate again. Therefore, tympanostomy tubes (commonly called ear tubes) are used to create a semi-permanent passage for mucus to escape from the middle ear space and allow air to enter, thereby equalizing pressure and preventing pain. They also help restore the patient's hearing to normal because the damping effect of the viscous fluid on the ossicles during "glue ear" is no longer present. Grommets (vent tubes) are used in children for hearing loss associated with otitis media with effusion. Smaller amounts of fluid in the ear can also prevent OM from recurring.
[0014] Tympanostomy tube placement is often recommended for patients with recurrent acute OM (generally defined as 3 or more episodes of OM within 6 months). Tube placement may also be recommended for chronic OM, where fluid is continuously present in the middle ear for more than 4 months, the fluid causes a documented hearing loss greater than 20 dB, the infection fails to clear after multiple antibiotic trials, or complications of ear infection occur including mastoid infection. Nearly 700,000 tympanostomy tube placements are performed each year in the United States alone, making it the most common procedure performed on children under anesthesia. It is estimated that 26% of children will require a tympanostomy tube insertion before the age of 10 years. The prevalence of recurrent otitis media in children is increasing in the United States.
[0015] To place a tympanostomy tube, a small, usually cylindrical, grommet is inserted into the small perforation of the tympanic membrane created during the myringotomy. Tympanostomy tubes are usually made of silicone or fluoroplastics, although variants consist of titanium and stainless steel. They come in a variety of shapes and sizes, and the surgeon's choice of tube is based on pathophysiology, the patient's age, the number of previous sets of tubes, the surgeon's preferences, and the duration of placement. Tubes for short-term use are smaller and typically stay in place for 2 to 18 months before falling off on their own. Tubes for long-term use are larger, have flanges that ensure they remain in place for up to three years, and usually need to be removed by an otolaryngologist.
[0016] In addition to direct placement in the hole in the tympanic membrane, another option is subannular placement through a channel located beneath the skin of the external auditory canal and annulus (which is a bony ring surrounding the tympanic membrane). This technique can be used for atrophic and retracted tympanic membranes where there is not enough fibrous tissue to retain a standard tympanostomy tube. It may also be beneficial for patients who have undergone myringoplasty or tympanic membrane tissue replacement. The materials and design of subannular ventilation tubes are similar to those of tympanostomy tubes. For both types of tubes, antibiotic drops are generally recommended to allow local delivery and treat recurrent infections.
[0017] BRIEF DESCRIPTION OF THE DRAWINGS
[0018] These objects and advantages will become apparent upon consideration of the following detailed description taken in conjunction with the accompanying drawings, wherein like reference numerals refer to like parts throughout, and wherein:
[0019] Figure 1A Desirable features of a catheter for controlled fluid transport are shown. Figure 1B This concept is shown for an exemplary case of a tympanostomy catheter in accordance with certain embodiments. Figure 1C The advantages of using a tympanostomy tube as described in certain embodiments of the present disclosure are shown.
[0020] Figure 2 A tympanostomy catheter is shown in accordance with certain embodiments. Figure 2 (View a) shows a tympanostomy catheter with its lumen blocked and biofilm adhered to the inner and outer surfaces of the catheter. Figure 2 (View b) shows a tympanostomy catheter according to certain embodiments, with fixed liquid interfaces on both sides (View I) or one side (View II) of the tube base.
[0021] Figure 3A is a schematic diagram of a patterned catheter surface according to certain embodiments. Figure 3B (View a) shows a photograph of a patterned surface, and Figure 3B (View a) shows a tympanostomy catheter according to certain embodiments, featuring a grooved surface manufactured by additive manufacturing. Figure 3C (View a) shows a 3D printed silicon wafer without an infused cover layer. Figure 3C (View b) shows a silicone sheet with an infused cover layer to improve the smoothness of the 3D printed silicone sheet, according to certain embodiments. Figure 3D Shown is a silicone oil wrap around the fluid entering the tube.
[0022] Figure 4A Sliding angles of water and mucus on infused and uninfused materials are shown according to certain embodiments. According to certain embodiments, the sliding angle is measured using a goniometric setup schematically depicted in the inset. Figure 4B Sliding angles and contact angle hysteresis of water on infused and uninfused materials are shown according to certain embodiments.
[0023] Figure 5A Shown is the adhesion of primary human epidermal keratinocytes on perfused and non-perfused surfaces according to certain embodiments. Figure 5B Adhesion of human neonatal dermal fibroblasts on perfused and non-perfused surfaces is shown according to certain embodiments. Figure 5CShown is the maximum adhesion force of HNDF measured by lateral pull-off using atomic force microscopy.
[0024] Figure 6 The cytotoxicity of non-infused and oil-infused silicone materials to human epidermal keratinocytes is shown.
[0025] Fig. 7A Shown is the adhesion of Staphylococcus aureus (S. aureus) bacteria on perfused and non-perfused surfaces according to certain embodiments. Figure 7B Adhesion of S. pneumoniae and M. catarrhalis bacteria on perfused and non-perfused surfaces is shown according to certain embodiments.
[0026] Figures 8A-8E Bidirectional fluid transport through a tympanostomy catheter is shown according to certain embodiments.
[0027] Fig.9A Catheter designs according to certain embodiments are shown. Fig.9A (View a) shows an unfilled symmetrical tube, Fig.9A (View b) shows a symmetrical tube filled with liquid, while Fig.9A (View c) shows an asymmetric tube. Fig. 9B A multi-component assembly with a functional add-on / insert that enables preferential transport of a given liquid in one direction while inhibiting transport of that liquid in the opposite direction is shown according to certain embodiments.
[0028] Fig.10 Design principles for optimizing bidirectional flow in a tympanostomy catheter according to certain embodiments are shown, including the size and shape of the flange, the radius and length of the tube lumen, and the surface tension of the liquid and tube.
[0029] Figures 11A-11D Shown is a comparison of a cylindrical catheter (view a), a conical catheter (view b), and a curved catheter (view c) according to certain embodiments. Fig.11A A schematic diagram is shown for optimizing parameters (e.g., initial radius, initial flange angle, and lumen length, lubricant) of a pressure barrier for transportation according to certain embodiments. According to certain embodiments, Fig. 11B shows the fluid entering the catheter, Fig. 11C shows fluid leaving a tube made of a hydrophobic material, and Fig.11D Fluid is shown leaving a catheter made of a hydrophilic material.
[0030] Fig. 12AThe pressure reduction of aqueous antibiotic droplets flowing through optimized catheters of various radii compared to cylindrical and conical catheters is shown. Fig. 12B An exemplary optimized curved tube geometry is shown with a length limited to 2 mm according to certain embodiments. An exemplary inner distal radius is selected to be 0.275 mm.
[0031] Fig.13 Young-Laplace pressures of water and aqueous antibiotics flowing through various tube geometries: curved tube (view a), cone (view b), and cylinder (view c) according to certain embodiments are compared.
[0032] Fig.14A Simulated Young-Laplace pressures are shown along the length of tubes of various geometries: curved (views a and d), conical (views b and e), or cylindrical / collar button (views c and f), according to certain embodiments. Views ac show the pressure of aqueous antibiotics. Views df show the pressure of water. Fig. 14B Simulated Young-Laplace pressures along the length of tubes of various geometries are shown: curved (views a and d), conical (views b and e), or cylindrical or button-shaped (views c and f) according to certain embodiments. In this case, the radius of all tube inlets is chosen to be the same. Views ac show the pressure of the antibiotic. Views df show the pressure of water. Fig. 14C The dependence of the ratio of the maximum pressures of water and antibiotic droplets (selectivity) in various conduits (curved, conical and cylindrical) on the conduit radius is shown.
[0033] Fig.15A (Views a1-a6) are schematic diagrams of injection molding fabrication of a tube having a cylindrical shape according to certain embodiments. Fig.15A (View b) is a schematic diagram of a molded cylindrical tube, Fig.15A (Views c1 and c2) are computed tomography images of the molded cylindrical tube. Fig. 15B (View a) is a schematic diagram of injection molding fabrication of a tube having a curved optimized shape according to certain embodiments. Fig. 15B (Views bl and b2) illustrate a bending mold according to certain embodiments. Fig. 15B (Views c1 and c2) show computed tomography images of a molded curved tube according to certain embodiments.
[0034] Fig.16 (View a) is a schematic diagram of an experimental setup for measuring water breakthrough pressure in a catheter, according to certain embodiments. Fig.16 (View b) is a photograph of two setups running different liquids in parallel, according to certain embodiments.
[0035] Fig.17 Shown is a comparison of Young-Laplace pressure of aqueous antibiotic droplets through uninfused and oil-infused (100 cP) medical-grade silicone collar tubes (ID=0.51 mm, dark gray and black bars) and a curved optimized tube (ID=0.55 mm, patterned bars), according to certain embodiments.
[0036] Fig.18 An "hourglass" shaped conduit formed by two curved sections is shown.
[0037] Fig.19 A chemically patterned tympanostomy catheter is shown, according to certain embodiments.
[0038] Fig. 20 A catheter having a gradient wettability pattern achieved by a combination of hydrophobic and hydrophilic materials is shown in accordance with certain embodiments.
[0039] Fig.21A is a schematic diagram of a catheter having dual chemically and geometrically patterned channels for directing fluid transport through the tube, according to certain embodiments. Fig.21B A catheter having multiple chemically and geometrically patterned channels is shown according to certain embodiments. Fig. 21C A catheter having a porous lumen is shown according to certain embodiments.
[0040] Fig. 22 is a schematic diagram of gravity-assisted delivery of antibiotic drops to the middle ear, according to certain embodiments.
[0041] Figures 23A-23C A catheter with a pinning site is shown according to some embodiments. Fig.23A Pinning by modulation of the lumen shape is shown. Fig. 23B Pinning by surface modulation is shown. Fig.23C Pinning via a cage handle on the top of the catheter or inside the lumen is shown, which reduces and / or prevents ambient fluid from entering the catheter, according to certain embodiments.
[0042] Fig.24A is a schematic diagram of a method of minimizing invasiveness during a myringotomy, according to certain embodiments, wherein the catheter is reduced in size prior to insertion and expanded after insertion. Fig. 24B Shown are the expansion kinetics of medical grade silicone (MED 4960D, radial dimension) according to certain embodiments when expanded in medical grade silicone oils of various viscosities at 85°C.
[0043] Fig.25A Compression of a silicone catheter under an applied load is shown according to certain embodiments. Fig.25BThe compressive integrity of the "test" tubing is shown for a control Baxter bevel tube silicone with tapered geometry and unirrigated and irrigated curved catheters of the same dimensions along both axes, along the lumen (view a) and across the lumen (view b). Fig.25C The elasticity and fatigue resistance of a silicone tympanostomy tube along two axes are shown according to certain embodiments.
[0044] Fig.26 (View a) shows exemplary mechanical deformation of a cylindrical tube during an expansion process, according to certain embodiments, as calculated by a finite element analysis (FEA) model using commercial ABAQUS / Standard software. Fig.26 (View b) illustrates exemplary mechanical deformation of the curved tube during expansion, according to certain embodiments.
[0045] Fig. 27 A catheter having a reduced size prior to insertion is shown, according to certain embodiments, the catheter expanding after insertion to minimize invasiveness during a myringotomy.
[0046] Fig.28 Schematic diagrams of several examples of shape-changing tympanic catheters according to certain embodiments, whose flanges can expand in size (view a), expand in size and change shape (view b), spread out (view c), or change shape to allow fluid transport through a funnel structure or other flow-directing design (view d).
[0047] Fig.29 Shown is a simulation of an embodiment of the shape-changing behavior of a tympanostomy catheter having a bilayer structure comprising layers with different cross-linking densities.
[0048] Figures 30A-30B A deformable flange is shown according to certain embodiments. Fig. 30A A deformable flange is shown which expands to clamp the two sides of the tympanic membrane after expansion. Fig. 30B A deformable flange is shown which, after expansion, locks into the middle ear cavity in place.
[0049] Fig.31 A stent-like design of a catheter is shown according to certain embodiments, which expands to form a larger structure as it changes shape.
[0050] Fig.32 A handle and flange composed of a material different than that of the tube are shown for ease of insertion of the ear tube, according to certain embodiments.
[0051] Fig.33A dual injection system with a tip having an unprimed cannula and an oil reservoir is shown according to certain embodiments.
[0052] Fig.34 A tympanostomy catheter having a flange stiffness that matches the portion of the tympanic membrane upon which it is placed is shown in accordance with certain embodiments.
[0053] Figures 35A-35B A tympanostomy catheter with a sensing component is shown in accordance with certain embodiments. Fig.35A Shown is a tube with an adjustable printed antenna for sensing changes in temperature, pH, and pressure, according to certain embodiments. Fig.35B A tube with built-in sensors for monitoring changes in the middle ear is shown in accordance with certain embodiments.
[0054] Fig.36 A tympanostomy catheter that changes color when exposed to certain stimuli is shown in accordance with certain embodiments.
[0055] Fig.37 A tympanostomy catheter capable of molecular detection, capture, and release of relevant biomarkers is shown according to certain embodiments.
[0056] Fig.38A A dynamically programmable catheter that can be actuated on demand by external stimulation is shown in accordance with certain embodiments. Figures 38B-38C Shown are examples of activation paths for a programmable catheter according to certain embodiments.
[0057] Fig.39 Shown is a wide flange catheter structure with a vascular network indicated by a black bar in the tube for prolonged delivery of drugs directly onto the tympanic membrane, according to certain embodiments.
[0058] Fig.40 Shown is a catheter for delivering tympanic membrane drugs to the cochlear window membrane (view a) through a series of microneedles (view b) according to certain embodiments.
[0059] Fig.41 An expandable reservoir on the middle ear side of the tube is shown according to certain embodiments.
[0060] Fig.42 A chemically actuated design of a tympanostomy catheter for targeted lumen opening is shown, according to certain embodiments.
[0061] Fig.43 Shown is a light-actuated design of a tympanostomy catheter for targeted lumen opening, according to certain embodiments.
[0062] Fig.44Shown is a breathable gating design for a tympanostomy catheter with targeted lumen opening, according to certain embodiments.
[0063] Fig.45A -C shows a solution for controlled extrusion of catheters according to certain embodiments. Fig.45A The change in shape of the flange is shown. Fig.45B The shape transformation of the outer surface of the catheter is shown. Fig.45C An actuator is shown that expands or collapses or undergoes another type of size / shape and / or chemical transformation according to certain embodiments.
[0064] Fig.46 Endoscopic images obtained during a myringotomy using a tympanostomy tube insertion procedure in chinchillas (Chinchila Lanigera) according to certain embodiments are shown for a control Summit Medical collarbone tube (view a) and an oil-infused silicone transition tube (view b) of the same size (ID = 1.27 mm).
[0065] Fig.47 Auditory brain responses and distorted product otoacoustic emissions of an animal with a tympanostomy tube are shown.
[0066] Fig.48 Bacterial adhesion to irrigated and unirrigated tympanostomy tubes is shown.
[0067] Overview
[0068] In certain embodiments, the present disclosure is intended to provide guidance for designing medical and fluid conduits for medical and biological applications, microfluidic devices, membranes, nozzles, bioreactors, transporting coolants and other chemicals through machinery, draining reaction waste, sensors, food and beverage industry, cosmetics and perfumes, and other applications.
[0069] Certain embodiments of the present disclosure describe ventilation or tympanostomy tubes that reduce and / or prevent blockages caused by various biological fluids, debris, cells, and bacteria.
[0070] Certain embodiments of the present disclosure describe tubes that reduce and / or prevent growth of human cells on the outer surface of the tube and flanges that prevent premature extrusion.
[0071] Certain embodiments of the present disclosure describe surfaces that reduce and / or prevent biofilm formation thereon to prevent infection in general or otorrhea in the case of ear tubes.
[0072] Certain embodiments of the present disclosure recognize that an ideal vent or ear tube would be composed of a material with a low advancing contact angle and an optimized shape for a selected antibiotic liquid suspension to prevent them from entering the tube. As described more fully below, according to certain embodiments, this can be achieved by changing the material of the tube, changing the shape of the tube, and / or changing the composition of the therapeutic droplets themselves to include more surfactant or use oil-based droplets.
[0073] Certain embodiments of the present disclosure describe tube designs that allow water to be passively repelled or actively induced to swell inside the tube to close it off prior to swimming or bathing to improve patient comfort and encourage ear tube use, including during the summer months.
[0074] Certain embodiments of the present disclosure describe droplets of various materials that can be used to temporarily change the shape of a tube or the properties of a fluid.
[0075] Certain embodiments of the present disclosure describe the creation of ventilation tubes that can be easily inserted into smaller perforations via a dynamic flange, or incorporate a size-changing capability that would alleviate these problems and potentially make it easier for the surgeon to insert a tympanostomy tube or subannular ventilation tube.
[0076] According to some embodiments, the system includes a device having a catheter, the catheter having a proximal end (the proximal end has a proximal radius), a distal end opposite the proximal end (the distal end has a distal radius), an inner surface connecting the proximal end and the distal end (the inner surface forms a proximal angle at the proximal end) and a distal angle at the distal end, the inner surface having surface properties, and an outer surface connecting the proximal end and the distal end; the distal radius, the proximal radius, the distal angle, the proximal angle and the surface properties of the inner surface are selected to: allow a first material to enter the distal end of the catheter, allow the first material to be transported through the catheter along the inner surface toward the proximal end, and allow the first material to leave the proximal end of the catheter, and prevent a second material from entering the proximal end of the catheter; and the Young-Laplace pressure of the first material is less than the Young-Laplace pressure of the second material.
[0077] In some embodiments, the difference between the Young-Laplace pressure of the first material and the Young-Laplace pressure of the second material is in the range of 1 to 1,000 Pa.
[0078] In some embodiments, the conduit has a selectivity between 1 and 10, the selectivity being the normalized pressure difference between the Young-Laplace pressure of the first material and the Young-Laplace pressure of the second material.
[0079] In some embodiments, at least one of an angle or a surface characteristic of the inner surface changes to maintain a substantially constant or decrease Young-Laplace pressure of the first material from the distal end to the proximal end.
[0080] In some embodiments, at least one of an angle or a surface characteristic of the inner surface is changed such that there is substantially no pinning of the first material from the distal end.
[0081] In some embodiments, at least one of an angle or a surface characteristic of the inner surface is varied to maintain a Young-Laplace pressure of the first material that varies by 10% or less from the distal end to the proximal end.
[0082] In some embodiments, as the first material enters the distal end, the advancement angle of the first material at the distal end is less than 90°.
[0083] In some embodiments, as the second material enters the proximal end, the advancement angle of the second material at the proximal end is greater than 90°.
[0084] In some embodiments, the proximal angle is increased to reduce the breakthrough pressure of the first material at the proximal end.
[0085] In some embodiments, the inner diameter of the catheter is 3 mm or less.
[0086] In some embodiments, the catheter is a tympanostomy tube or a ventilation tube.
[0087] In some embodiments, the shape of the conduit is selected from the group consisting of cylindrical, conical, and curved.
[0088] In some embodiments, the diameter of the proximal end is greater than the diameter of the distal end.
[0089] In some embodiments, the catheter comprises a distal flange disposed on the distal end of the catheter.
[0090] In some embodiments, the catheter comprises a proximal flange disposed on the proximal end of the catheter.
[0091] In some embodiments, the device is a tympanostomy tube and at least one of the proximal flange and the distal flange has a radial stiffness that matches a portion of the tympanic membrane.
[0092] In some embodiments, the device further comprises a portion of a catheter provided with a slippery surface, the slippery surface comprising: a partially or completely stable lubricating liquid layer on at least a portion of the inner surface or outer surface of the catheter, the lubricating liquid layer wetting and adhering to at least a portion of the catheter to form a slippery surface on the portion of the catheter.
[0093] In some embodiments, the lubricating fluid reduces the advancing angle of the first material.
[0094] In some embodiments, the lubricating fluid increases the advancing angle of the second material.
[0095] In some embodiments, the first material has a diffusion coefficient on the lubricating fluid that is greater than zero, and wherein the lubricating fluid forms a sheath around the first material.
[0096] In some embodiments, the lubricating liquid reduces the effective surface tension of the first material.
[0097] In some embodiments, the lubricating liquid increases the effective surface tension of the second material.
[0098] In some embodiments, the lubricating fluid is on the inner surface of the catheter.
[0099] In some embodiments, the lubricating fluid is on the outer surface of the catheter.
[0100] In some embodiments, the lubricating fluid is on an inner surface of at least one of the proximal flange and the distal flange.
[0101] In some embodiments, the lubricating fluid is one or more of the following: silicone oil, partially or fully fluorinated oil, mineral oil, carbon-based oil, castor oil, fluocinolone acetonide oil, food-grade oil, water, surfactant / surfactant solution, organic solvent, perfluorinated hydrocarbon, and mixtures thereof.
[0102] In some embodiments, the surface characteristic comprises a chemical gradient or pattern on at least a portion of at least one of the inner surface and the outer surface.
[0103] In some embodiments, a chemical gradient or pattern is disposed on the interior surface of the conduit.
[0104] In some embodiments, a chemical gradient or pattern is disposed on the outer surface of the conduit.
[0105] In some embodiments, the chemical gradient or pattern is disposed on at least one of a proximal flange at the proximal end of the catheter and a distal flange at the distal end of the catheter.
[0106] In some embodiments, when the first material is disposed on a chemical gradient, the chemical gradient or pattern reduces the effective surface tension of the first material.
[0107] In some embodiments, when the second material is disposed on a chemical gradient, the chemical gradient or pattern increases the effective surface tension of the second material.
[0108] In some embodiments, the chemical gradient or pattern comprises a wicking layer configured to transport fluid along the wicking layer from one of the proximal and distal ends to the other of the proximal and distal ends or a central portion of the catheter.
[0109] In some embodiments, a portion of a conduit has a gradient or pattern disposed thereon.
[0110] In some embodiments, the gradient or pattern reduces the effective surface tension of the first material.
[0111] In some embodiments, the gradient or pattern increases the effective surface tension of the second material.
[0112] In some embodiments, a gradient or pattern is provided on at least a portion of the interior surface of the conduit.
[0113] In some embodiments, the gradient or pattern is disposed on at least a portion of the outer surface of the catheter.
[0114] In some embodiments, the gradient or pattern is provided on at least one of the distal flange and the proximal flange at the distal end of the catheter.
[0115] In some embodiments, the gradient or pattern is selected from: geometrically patterned channels, macroporous channels, microporous channels, a three-dimensional periodic network of pores, a sponge-like network of pores, surface roughness, grooves, ridges, indentations, micropillars, and microridges.
[0116] In some embodiments, the catheter comprises a stimuli-responsive portion, the stimulus being selected from one or more of light, temperature, pressure, electric field, magnetic field, expansion, deswelling, or a chemical composition.
[0117] In some embodiments, the stimuli-responsive portion is selected from a thermostrictive, piezoelectric, electroactive, chemistrictive, magnetostrictive, photostrictive, swellable, or pH-sensitive material.
[0118] In some embodiments, the stimulus is a chemical composition, and the chemical composition includes a lubricating fluid.
[0119] In some embodiments, the stimulus-responsive portion comprises a proximal flange disposed at or near a proximal end of the catheter; and wherein the distal flange is capable of transitioning between a first configuration and a second configuration in response to a stimulus.
[0120] In some embodiments, the distal flange changes at least one of a size of the distal flange or a shape of the distal flange when transitioning between the first configuration and the second configuration.
[0121] In some embodiments, one of the distal end and the distal flange comprises a protrusion comprising a shape-consistent material to facilitate insertion of the distal end of the catheter.
[0122] In some embodiments, the stimulus-responsive portion is a valve disposed within the catheter that is capable of closing in response to a stimulus.
[0123] In some embodiments, the valve is selected from one of a stimuli-responsive polymer, a gas selective movement membrane, a stimuli-responsive ciliated and hair-like fiber, a lamellae, a pillar, a reconfigurable and tunable nanostructure or microstructure with a functionalized tip, and combinations thereof.
[0124] In some embodiments, the stimulus-responsive portion further comprises a proximal flange disposed at or near the proximal end of the catheter, and wherein the proximal flange is capable of transitioning between the first configuration and the second configuration in response to a stimulus.
[0125] In some embodiments, the stimuli responsive portion comprises a first layer of a first stimuli responsive material and a second layer of a second stimuli responsive material.
[0126] In some embodiments, the stimulus is swelling, and the first stimulus responsive material and the second stimulus responsive material have different cross-link densities.
[0127] In some embodiments, the catheter has a first diameter in the first configuration and the catheter has a second diameter in the second configuration.
[0128] In some embodiments, the stimulus responsive portion is disposed on an inner surface of the catheter.
[0129] In some embodiments, the stimulus-responsive portion expands in response to a stimulus.
[0130] In some embodiments, the catheter further comprises a lumen defined by the inner surface and extending from the distal end to the proximal end, wherein the stimulus responsive portion is disposed in the lumen.
[0131] In some embodiments, the stimulus-responsive portion comprises pores disposed throughout the lumen, and the pores close in response to a stimulus.
[0132] In some embodiments, the lumen is open to the first material in the first configuration and closed to the first material in the second configuration.
[0133] In some embodiments, the stimulus-responsive portion is disposed on an outer surface of the catheter.
[0134] In some embodiments, the stimulation causes the stimulus-responsive portion to separate from the catheter.
[0135] In some embodiments, the stimulus-responsive portion comprises an actuator configured to expand when exposed to a stimulus.
[0136] In some embodiments, the catheter comprises a tube, and wherein the device further comprises a second catheter, the second catheter comprising a tube having a proximal end and a distal end, the proximal end of the second catheter being disposed near the proximal end of the catheter and the distal end of the second catheter being disposed near the distal end of the catheter.
[0137] In some embodiments, the distal radius, proximal radius, distal angle, proximal angle, and surface properties of the inner surface are selected to allow a third material to enter the proximal end of the catheter, allow the third material to be transported through the catheter along the inner surface toward the distal end, and prevent the third material from leaving the proximal end of the catheter; wherein the Young-Laplace pressure of the third material is less than the Young-Laplace pressure of the second material, but lower than the breakthrough pressure at the distal end.
[0138] In some embodiments, at least a portion of the inner surface is configured to pin the third material thereon.
[0139] In some embodiments, at least a portion thereof comprises one of a surface chemistry or a texture that promotes pinning of a third material.
[0140] In some embodiments, the catheter further comprises a valve configured to prevent the third material from exiting the proximal end of the catheter.
[0141] In some embodiments, the difference between the Laplace pressure of the second material and the Laplace pressure of the third material is between 1 Pa and 1000 Pa.
[0142] In some embodiments, the distal end is configured to have a breakthrough pressure at least 1 Pa higher than the Young-Laplace pressure of the third material at the location of the distal end to prevent the third material from escaping from the distal end.
[0143] In some embodiments, when the third material enters the proximal end, the advancement angle of the third material at the proximal end is less than 90°.
[0144] In some embodiments, the angle of the inner surface decreases at the distal end to increase the breakthrough pressure of the third material at the proximal end.
[0145] In some embodiments, the distal radius, proximal radius, distal angle, proximal angle, and surface properties of the inner surface are selected to allow a fourth material to enter the proximal end of the catheter, allow the fourth material to be transported through the catheter along the inner surface toward the distal end, and allow the first material to exit from the distal end of the catheter; and wherein the Young-Laplace pressure of the fourth material is less than the Young-Laplace pressure of the second material.
[0146] In some embodiments, the difference between the Young-Laplace pressure of the second material and the Laplace pressure of the fourth material is in the range of 1 Pa to 1000 Pa.
[0147] In some embodiments, at least one of an angle or a surface characteristic of the inner surface changes to maintain a substantially constant or decrease Young-Laplace pressure of the fourth material from the distal end to the proximal end.
[0148] In some embodiments, at least one of an angle or a surface characteristic of the inner surface changes such that there is substantially no pinning of the first material from the proximal end to the distal end.
[0149] In some embodiments, when the fourth material enters the proximal end, the advancement angle of the fourth material at the proximal end is less than 90°.
[0150] In some embodiments, the distal end is configured to have a breakthrough pressure for the fourth liquid that is at least 1 Pa lower than the Young-Laplace pressure of the fourth liquid at the location of the distal end to enable it to exit.
[0151] In some embodiments, the angle of the inner surface increases at the proximal end to reduce a breakthrough pressure of the fourth material at the proximal end.
[0152] In some embodiments, the first material is selected from the group consisting of: effusion, pus, blood, plasma, tears, breast milk, amniotic fluid, serum, synovial fluid, cerebrospinal fluid, urine, saliva, sputum, sweat, other body fluids, water, water containing surfactant, perilymph, endolymph, mucus, and any combination thereof.
[0153] In some embodiments, the second material is selected from water, aqueous solutions, foams and emulsions, ototoxic agents, soap, pool water, fresh water, saline water or sediment, foams and emulsions, ototoxic agents.
[0154] In some embodiments, the third material is selected from: lubricating fluids, cross-linking agents, water-based and oil-based solutions of antibiotics, preservatives, antivirals, anti-inflammatory agents, small molecules, immunological agents, nanoparticles, genetic therapies including viral-based and lipid-based therapies, chemotherapy, stem cells, cell therapeutics, growth factors, proteins, radioactive materials, other liquid or gas-based pharmaceutical compounds and combinations thereof, cerumen dissolving agents such as squalene, chlorhexidine and EDTA, deferoxamine, dihydroxybenzoic acid, glutathione, D-methionine and N-acetylcysteine, also in the form of foams and emulsions.
[0155] In some embodiments, the fourth material is selected from oil-based, water-based, and other solvent-based therapeutic agents comprising at least one of the following: antibiotics, preservatives, antivirals, antivirals, anti-inflammatory agents, small molecules, immunological agents, nanoparticles, air for ventilation, genetic therapies including viral-based and lipid-based therapies, chemotherapy, stem cells, cell therapeutics, growth factors, proteins, radioactive materials, other liquid or gas-based pharmaceutical compounds, and combinations thereof.
[0156] In some embodiments, the conduit comprises one or more of the following: hydrogels, chemically cross-linked polymers, supramolecular polymers, metals, metal oxides, porous materials, geometrically patterned pores or channels in materials, membranes and sponges, colloid and surfactant templated pores, grooves and ridges, periodic and non-periodic arrays of indentations, nano- and microstructures: nanoforests, nanoscale patterned films, microplatelets, micropillars, and microridges.
[0157] In some embodiments, the catheter comprises one or more of the following: biostable or bioabsorbable polymers, isobutylene-based polymers, polystyrene-based polymers, polyacrylates and polyacrylate derivatives, vinyl acetate-based polymers and copolymers thereof, polyurethanes and copolymers thereof, silicones and copolymers thereof, ethylene vinyl acetate, polyethylene terephthalate, thermoplastic elastomers, polyvinyl chloride, polyolefins, cellulosics, polyamides, polyesters, polysulfones, polytetrafluoroethylene, polycarbonates, acrylonitrile butadiene styrene copolymers, acrylics, polylactic acid, polyglycolic acid, polycaprolactone, polylactic acid-polyethylene oxide copolymers, cellulose, collagen, alginate, gelatin, and chitin.
[0158] In some embodiments, the catheter comprises one or more of: dacron polyester, poly(ethylene terephthalate), polycarbonate, polymethyl methacrylate, polypropylene, polyalkylene oxalate, polyvinyl chloride, polyurethane, polysiloxane, nylon, poly(dimethylsiloxane), polycyanoacrylate, polyphosphazene, poly(amino acids), ethylene glycol I dimethacrylate, poly(methyl methacrylate), poly(2-hydroxyethyl methacrylate), polytetrafluoroethylene poly(HEMA), polyhydroxyalkanoate, polytetrafluoroethylene, polycarbonate, poly(glycolide-lactide) copolymer, polylactic acid, poly(γ-caprolactone), poly(γ-hydroxybutyrate), polydioxanone, poly(γ-ethylglutamate), polyiminocarbonate, poly(orthoesters), polyanhydrides, alginate, dextran, chitin, cotton, polyglycolic acid, polyurethane, gelatin, collagen, or derivatives thereof.
[0159] In some embodiments, the conduit comprises one or more of Li, Be, B, Na, Mg, Al, Si, K, Ca, Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Rb, Sr, Y, Zr, Nb, Mo, Ru, Rh, Pd, Ag, Cd, In, Sn, Sb, Cs, Ba, Hf, Ta, W, Re, Os, Ir, Pt, Au, Ti, Pb, Bi, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, and oxides thereof.
[0160] According to some embodiments, a system includes a tympanic membrane puncture or ventilation device having a catheter configured to be positioned in an ear, the catheter comprising: an input port configured to be received in the ear canal, the input port configured to receive a first liquid; an output port configured to be received in the middle ear, the output port configured to output the first liquid received in the input port; an inner surface extending from the input port to the output port, at least a portion of the inner surface comprising a conical or curved geometry that extends at least partially between the input port and the output port to allow the first liquid to be transported between the ports.
[0161] In some embodiments, the first liquid is a therapeutic agent.
[0162] In some embodiments, the conical or curved geometry is selected to allow a first liquid to pass from the input port to the output port and to prevent a second liquid from passing from the input port to the output port.
[0163] In some embodiments, the second liquid is selected from at least one of water, aqueous solutions, foams and emulsions, ototoxic agents, soap, pool water, fresh water, saline water, or sediment, foams and emulsions, ototoxic agents, and combinations thereof.
[0164] In some embodiments, a lubricating fluid layer is disposed on at least a portion of the inner surface, the lubricating fluid layer comprising a lubricating fluid that wets and adheres to at least a portion of the inner surface to form a slippery surface on at least a portion of the inner surface.
[0165] In some embodiments, the lubricating fluid and the conical or curved geometry are selected to allow a first fluid to pass from the input port to the output port and to prevent a second fluid from passing from the input port to the output port.
[0166] In some embodiments, the pattern is on at least a portion of the interior surface.
[0167] In some embodiments, the pattern comprises a wicking layer configured to transport a fluid along the wicking layer.
[0168] In some embodiments, the pattern comprises a difference in surface properties of at least a portion of the interior surface.
[0169] In some embodiments, the surface property of at least a portion of the interior surface changes from hydrophobic at the input port to less hydrophobic or hydrophilic at the output port.
[0170] In some embodiments, the pattern is selected from the group consisting of: geometrically patterned channels, macroporous channels, microporous channels, a three-dimensional periodic network of pores, a sponge-like network of pores, surface roughness, grooves, ridges, indentations, micropillars, and microridges.
[0171] In some embodiments, the lubricating fluid, pattern, and profile are selected to allow a first fluid to pass from the input port to the output port and prevent a second fluid from passing from the input port to the output port.
[0172] In some embodiments, the lubricating fluid layer reduces the adhesion of microorganisms and cells.
[0173] In some embodiments, otitis media, pus, mucus can enter the outlet port of the middle ear, be transported through the tube, and exit at the inner port into the ear canal.
[0174] In some embodiments, at least one of the input ports further comprises an input port flange configured to facilitate entry of the first material into the input port, and the output port further comprises an output port flange configured to facilitate entry of a third material into the output port.
[0175] In some embodiments, the third material is selected from the group consisting of: effusion, pus, blood, plasma, tears, breast milk, amniotic fluid, serum, synovial fluid, cerebrospinal fluid, urine, saliva, sputum, sweat, other body fluids, water, water containing surfactant, perilymph, endolymph, mucus, and any combination thereof.
[0176] In some embodiments, the catheter comprises a shape configured to change in response to a stimulus.
[0177] In some embodiments, the shape change is selected from one of closure of an input port, closure of an output port, closure of an interior surface between an input port or an output port, and combinations thereof.
[0178] In some embodiments, the shape change comprises one of: increasing the size of the output port, increasing the size of the input port, increasing the size of the catheter, expansion of a flange at the input port, expansion of a flange at the output port, actuation of an actuator on the outer surface of the catheter, or a combination thereof.
[0179] In some embodiments, the shape change comprises one of: reducing the size of the output port, reducing the size of the input port, reducing the size of the catheter, contraction of a flange at the input port, contraction of a flange at the output port, actuation of an external actuator on the catheter, or a combination thereof.
[0180] After reviewing the description and embodiments provided herein, those skilled in the art will appreciate that modifications and equivalent substitutions may be made when implementing the present invention without departing from the essence of the present invention. Therefore, the present invention is not meant to be limited by the embodiments described below.
[0181] Details
[0182] I. Problems with tympanostomy tubes and catheters
[0183] Problems with tubes such as tympanostomy tubes and subanal ventilation tubes are common.
[0184] For example, to place a tympanostomy tube, a small, typically cylindrical grommet is inserted into a small perforation of the tympanic membrane. Tympanostomy tubes can be made of silicone or fluoroplastic, although variants are made of titanium and stainless steel. They come in a variety of shapes and sizes, and the surgeon's choice of tube is based on pathophysiology, the patient's age, the number of previous collections of tubes, the surgeon's preferences, and the duration of placement. Tubes for short-term use are smaller and typically stay in place for 2 to 18 months before falling off on their own. Tubes for long-term use are larger, have flanges that ensure they remain in place for up to three years, and typically need to be removed by an otolaryngologist.
[0185] In addition to direct placement in the hole in the tympanic membrane, another option is subannular placement through a channel located beneath the skin of the external auditory canal and annulus (which is a bony ring surrounding the tympanic membrane). This technique can be used for atrophic and retracted tympanic membranes where there is not enough fibrous tissue to retain a standard tympanostomy tube. It may also be beneficial for patients who have undergone myringoplasty or tympanic membrane tissue replacement. The materials and design of subannular ventilation tubes are similar to those of tympanostomy tubes. For both types of tubes, antibiotic drops are generally recommended to allow local delivery and treat recurrent infections.
[0186] A. Blockage of the tube
[0187] An estimated 7% to 37% of implanted tympanostomy tubes fail due to blockage. Blockages can be caused by mucus, blood, keratinocytes, cerumen, or bacteria, which prevent fluid from flowing through the tubes, rendering them ineffective. Many tube materials, including silicones and fluoroplastics, while wettable to a low degree, do not resist adhesion by cells and require a high sliding angle for water and mucus droplets to slide off the surface. When a tube becomes blocked, ear drops may be prescribed to help relieve the blockage. When possible, an otolaryngologist can attempt to clear the blockage. Sometimes, patients must undergo painful surgery to remove the blocked tube. In addition to incurring additional medical expenses and increasing the risk of scarring, replacing the tube requires additional surgeon and patient time.
[0188] B. Premature extrusion of the tube
[0189] Keratinocytes are a type of basal epithelial cell that forms a layer on the outside of the tympanic membrane. When a tympanostomy tube is placed on or in the tympanic membrane, the squamous layer of the tympanic membrane keratinizes on the outer flange, pushing the tube from behind and below and causing the tympanostomy tube to be extruded relative to the insertion site. Premature extrusion of the tympanostomy tube can occur, requiring the patient to undergo another tympanostomy tube placement procedure.
[0190] C. The tube cannot self-extrude and migrate inward
[0191] One of the most serious problems associated with tympanostomy tubes is persistent tympanic membrane perforation. Perforations may require surgical closure with myringoplasty / tympanoplasty. When tympanostomy tubes remain in the tympanic membrane for more than 2 years, patients experience higher rates of complications such as persistent otorrhea, granulation tissue formation, or impending cholesteatoma. The incidence of tympanic membrane perforation has been reported to be more common at the time of tube removal (14.3%) than with spontaneous extrusion (4.0%). Long-term use T-tubes with two long flanges often remain in the tympanic membrane for 24 months or longer and are associated with a higher rate of persistent tympanic membrane perforation.
[0192] Another rare complication is medial migration of the myringotomy, in which the tube moves behind the intact tympanic membrane rather than following the natural extrusion path toward the ear canal. Some hypotheses link this complication to biofilm formation on the outer surface of the tube and Eustachian tube dysfunction.
[0193] D. Biofilm formation on the tube
[0194] Ventilation tubes can become sites of bacterial adhesion and biofilm formation. Bacterial biofilms are colonies of glycoprotein bacteria that resist penetration by antibiotics. In addition to blockage, this can cause other infections within the middle ear space. Otorrhea is the most common complication following middle ear ventilation tube insertion. Otorrhea can develop due to the presence of a biofilm in the middle ear, which acts as a reservoir of bacteria that is continually released into the middle ear. Postoperative otorrhea requires antibiotics and aggressive treatment, and often requires removal due to permanent contamination of the tube. Therefore, bacterial adhesion to tympanostomy tube materials has been a focus of research for over 30 years. In vitro studies have shown that more inert tympanostomy tube materials and smooth surfaces can inhibit the adsorption of key bacterial binding proteins, such as fibronectin. Biofilm forms on every type of tympanostomy tube currently available on the market.
[0195] E. Delivery of therapeutic droplets through tubes
[0196] To prevent the adverse side effects of systemic antibiotic use, targeted therapeutic delivery to the site of infection would be an ideal option for addressing recurrent OM. However, it is impossible for most droplet formulations to reach the middle ear space by themselves through the keratinized tissue of the tympanic membrane. Therefore, ventilation tubes can be used to deliver antibiotic droplets directly to the middle ear. However, delivering a single droplet through these small holes can be challenging. The current materials and geometries of these tubes (including metals and various plastics) do not address these issues because the advancing contact angles of these materials with water and other fluids produce very high pressures that prevent droplets from entering the tube. The researchers found that Cortisporin, TobraDex, and Cipro drops could not always pass through the tympanic membrane puncture tube without the use of gentle tragus pressure.
[0197] Currently, for diseases such as idiopathic sudden sensorineural hearing loss, clinicians inject steroids (via needle) into the middle ear, where they ideally will diffuse through the circular or oval window into the inner ear. Although placement of a tube and use of steroid-based ear drops are an option, most clinicians intuitively understand that based on current tube design and fluid dynamics, the steroid concentration of the drug will not be consistently or reliably high enough to treat hearing loss. According to certain embodiments, the creation of tubes that allow high flow rates will allow for minimally invasive drug delivery and the development of optimized formulations of topical drugs.
[0198] F. Ambient water enters the middle ear space
[0199] Ambient water encountered during swimming and bathing, especially soapy water containing surfactants, can enter the middle ear space and cause pain and other infections.
[0200] G. Invasive insertion and scarring
[0201] Many tympanostomy tubes require a relatively large incision due to their bulky flange and surgical placement through the narrow and long ear canal. These large incisions can cause scarring, called tympanosclerosis, and lead to incomplete healing of the perforation in approximately 5% of cases. Small perforations cannot adequately capture and conduct sound, and scar tissue on the eardrum thickens the sound and impedes movement.
[0202] H. Reduced fluid flow through small radius tubes
[0203] Movement of fluids through small tubes such as tympanostomy tubes can be challenging. The advancing contact angle of the tube material with water or other fluids results in extremely high pressures that prevent fluids from entering and flowing along the length of the tube. Although tubes with a small radius are desirable, the high pressures encountered place a lower limit on the tube diameter. Additionally, the high pressures limit the use of tympanostomy tubes for delivering medications to the middle ear.
[0204] II. Design Principles for Controlled Fluid Transport
[0205] According to certain embodiments, disclosed herein are improved catheters for various applications. According to certain embodiments, disclosed herein are tympanostomy tubes and / or subannular ventilation catheters. The geometry and / or surface properties of these tubes or catheters have been optimized for controlling the transport of various fluids. These catheters can provide any desired shape, such as flat, curved, wavy, circular, tubular, cylindrical, conical, sharp, beveled, isotropic and anisotropic, reticular, membranous, catheter-like, flower-like, linear. The catheter can be all smooth or rough, solid or porous, single-layer or multi-layer, soft or hard, hollow or filled with one or more other functional materials or therapeutic agents. The catheter can include a fully or partially biodegradable portion. The catheter can have a chemically or structurally patterned surface. The catheter can have one or more soft or hard flanges. The catheter may have one or more of the properties described in FIG. 1 : A) anti-fouling properties, B) guided fluid transport, C) minimal invasiveness, and D) programmable "on-demand" shape and chemical switching.
[0206] Some of the exemplary design principles discussed in this application include reducing and / or preventing obstruction of the catheter lumen, reducing biofilm adhesion to the inner and outer surfaces of the catheter, enhancing the guided flow of biofluids and antibiotic droplets, reducing and / or preventing premature extrusion of the catheter, making the inner and outer surfaces of the tube smooth by adding a slippery layer or lubricating layer, inducing a coating on biofluids, antibiotic droplets, cells and bacteria, on-demand replenishment of lubricating layers, minimizing invasiveness, avoiding hearing loss and formation of scar tissue in the tympanic membrane, patient-specific customization of the tube, patient-specific customization of drugs, on-demand changes in the geometry and surface chemistry of the tube, controlled capture and release of biomarkers in the middle and outer ear, patterning of the tube to improve fluid transport and bioadhesion, and remote monitoring of the middle ear condition through built-in sensors.
[0207] Although certain embodiments of the present disclosure discuss tympanostomy catheters, and other embodiments discuss subannular ventilation catheters, it should be understood that the tympanostomy catheter designs and principles herein can be used for subannular ventilation catheters, and the subannular ventilation catheter designs herein can be used for tympanostomy catheters. In addition, the catheter designs herein can be used for other medical and biological purposes outside the middle ear. Non-limiting examples include inner ear catheters, prostate and biliary stents, sinus cavities, stents for sinus cavities, and abdominal-based drainage, such as drainage of the gallbladder, pancreas, and intestines.
[0208] Other non-limiting examples include eye tubes, such as glaucoma shunts or tear ducts. According to a 2002 study by the Worth Health Organization, glaucoma is the second leading cause of blindness. Glaucoma patients who require surgical treatment often use glaucoma drainage devices, such as Ahmed Glaucoma Valve (AGV), Baerveldt or Molteno. Glaucoma drainage devices are designed to transfer aqueous humor (fluid in the eye) from the anterior chamber to an external reservoir. Glaucoma drainage devices allow control of intraocular pressure (IOP) in eyes that have undergone previously failed trabeculectomies and eyes with insufficient conjunctiva due to scarring from previous surgical procedures or losses. Glaucoma drainage devices with or without IOP regulating valves of different sizes, materials and designs are available, but they often face many postoperative complications, such as low pressure, due to poor drainage regulation, occlusion, corneal scarring and other reasons. All of these complications require more surgery and treatment, which may lead to unforeseen complications and patients who cannot undergo surgery; and untreated postoperative low pressure can lead to blindness. Therefore, minimizing repetitive surgical procedures by improving fluid flow regulation is a constant goal of certain embodiments.
[0209] In certain embodiments, the catheter solves the problem of blocked tear ducts. Tear duct obstruction is caused by obstruction of the tear drainage system and may cause reactions such as infection, swelling, allergic reactions, tumors, or injuries. In the United States, tear duct obstruction affects up to 5% of infants. Currently, there are many methods for treating blocked tear ducts, depending on the cause and severity. One treatment method is to insert a tear duct stent (or canalicular stent). The two main classifications of stents are double canalicular versus single canalicular. The placement of nasolacrimal stents can also sometimes lead to obstruction and infection associated with the production of biofilms from organisms such as nontuberculous mycobacteria.
[0210] A particular advantage of the embodiments of the present invention is that they can reduce the need for revision surgery and can be customized and optimized for a variety of specific clinical indications. As shown in Table 1, the design tympanostomy catheter discussed in the embodiments of the present disclosure can meet the customized needs of patients, including important needs such as Eustachian tube dysfunction and sensorineural hearing loss in a minimally invasive manner. Figure 1C One or two of the benefits or synergies of multiple benefits shown in the may be useful and may be achieved through the materials and geometric factors disclosed in the embodiments of the present invention. Advantages of certain embodiments include size reduction, improved fluid transport, and reduced bacterial and cell adhesion compared to other catheter material designs. According to certain embodiments, a combination of material designs for the tubes described in this application may be utilized to achieve a synergistic effect of the benefits of a tympanostomy catheter. In some embodiments, only by synergistically utilizing Figure 1BSeveral features of the design shown in the tympanostomy tube kit can achieve certain benefits.
[0211] Table 1. Designer tympanostomy tubes for specific clinical indications in certain embodiments.
[0212]
[0213] The number of * indicates higher importance.
[0214] In certain embodiments, the surface properties and shape of the tube are selected to meet the needs of certain patients. For patients with chronic serous otitis media (children and adults), ventilation is a major problem due to poor Eustachian tube function, so the tube needs to remain unobstructed and have a low-adhesion surface and remain in the tympanic membrane for the required time. In pediatric patients, it is important to avoid water, so selective permeability is important. For recurrent acute otitis media, the ability to apply antibiotic ear drops (drug transport) is crucial, so the tube can be optimized for bidirectional flow: inflow and outflow of the middle ear. For Eustachian tube dysfunction in adults, ventilation is a major problem and requires long-term duration, so tubes with low adhesion are desired. For patients with inner ear diseases (adults with sensorineural hearing loss, Meniere's disease, autoimmune hearing loss, etc.), the main concern is the transportation of drugs. For short-term ventilation in adults, the on / off ability of the tube should be considered first, such as "open" when flying in an airplane and "closed" when barotrauma is not a concern.
[0215] A particular advantage of certain embodiments of the present invention is the ability to deliver drugs to infected areas.
[0216] Certain embodiments describe unique features of dynamically deformable tubes and uses thereof.
[0217] Other advantages of the present embodiments of the present invention will be readily apparent to those skilled in the art from the following detailed description, wherein only preferred embodiments of the present invention have been shown and described simply by way of illustration of one contemplated best mode of carrying out the present invention. It will be appreciated that the present invention is capable of other and different embodiments, and that its several details are capable of modification in various obvious respects, all without departing from the embodiments of the present invention. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not restrictive.
[0218] III. Antifouling properties
[0219] In certain embodiments, medical catheters such as tympanic membrane puncture catheters and / or subannular ventilation catheters can be made of anti-fouling materials on the inside of the catheter to reduce and / or prevent obstruction and / or on the outside of the catheter to reduce and / or prevent premature rejection, minimize the prevalence of infection, reduce inflammation, improve the smoothness of the tube and provide a protective coating (e.g., in the form of a wrap layer) against impinging biological fluids, microorganisms, waxes and dust. Although the following description contains certain embodiments related to tympanic membrane puncture catheters and / or subannular ventilation catheters, the design can be used for other medical applications (catheters, inflatable balls, stents, drainage tubes, etc.) or non-medical applications, such as microfluidics, membranes, bioreactors, transport of coolants and other chemicals by machinery, discharge of reaction waste, sensors, printing nozzles, food and beverage industries, cosmetics and perfumes, and other applications.
[0220] In certain embodiments, the materials used in the design of tympanostomy tube 201 utilize a fixed liquid interface that can facilitate low cell adhesion and high liquid mobility on a swellable or non-swellable solid substrate, such as Figure 2 (View b). When the tympanostomy tube is inserted into the tympanic membrane 205 or other physiological membrane, a stable or partially stable or temporarily stable lubricating layer 202 covers the solid surface of the tube and creates a smooth self-healing surface and resists or reduces the adhesion of cells 203 and immiscible liquids 204 (see Figures 4-6). The lubricating liquid can be stabilized on the outer surface 207 of the tube, the inner surface 208 of the tube, or both the inner and outer surfaces of the tube. The lubricating liquid on the inner surface facing the air or effluent 209 can prevent the obstruction of the inner cavity 206 by preventing the adhesion of cells and immiscible liquids. The lubricating liquid on the outer surface of the tube can prevent the formation of biofilms by preventing the adhesion of cells and immiscible liquids.
[0221] A detailed discussion of slippery surfaces infused with liquids can be found in the following patents: U.S. Patent 9,683,197, entitled “Dynamic and switchable slippery surfaces,” issued on June 20, 2017, U.S. Patent 9,121,306, entitled “Slippery surfaces with high pressure stability, optical transparency, and self-healing characteristic,” issued on September 1, 2015, U.S. Patent 9,630,224, entitled “Slippery liquid-infused porous surfaces having improved stability,” issued on April 25, 2017, U.S. Patent Application Publication No. 2015 / 0152270, entitled “Slippery self-lubricating polymer surfaces,” published on June 4, 2015, and U.S. Patent Application Publication No. 2015 / 0152270, entitled “Slippery Liquid-infused Porous Surfaces and Biological Applications,” published on July 3, 2014. and U.S. Patent Application Publication No. 2012 / 021929, entitled “SLIPS Surface Based on Metal-Containing Compound”, U.S. Patent Application Publication No. 2015 / 0175814, entitled “Solidifiable composition for preparation of liquid-infused slippery surfaces and methods of applying”, published on February 4, 2016, U.S. Patent Application Publication No. 2014 / 0342954, entitled “Modification of surfaces for fluid and solid repellency”, published on November 20, 2014, and U.S. Patent Application Publication No. 2015 / 0173883, entitled “Modification of surfaces for simultaneous repellency and targeted binding of desired moieties”, published on June 25, 2015, the contents of which are incorporated herein by reference in their entirety.In certain embodiments, the lubricating layer on the solid surface can be fully, partially or temporarily stabilized by a number of different effects, including capillary forces caused by micro / nanoscale topography (10nm-1000μm), molecular porosity, surface chemistry, van der Waals interactions, and combinations thereof. Thus, the underlying solid can be smooth, have roughness / porosity, and / or be able to swell with the lubricating phase. In addition, in certain embodiments, the lubricant can be dynamically stabilized by liquid flow. In certain embodiments, surfaces with partially stabilized lubricating layers or lubricating layers that are only stable under flow also have improved performance. In certain embodiments, molecules that are easily reconstructed with highly flexible long chains and low energy barriers for internal rotation (e.g., long polydimethylsiloxane polymers or other types of polymers and copolymers, including random or block silicone copolymers with other siloxane comonomers characterized by alkyl, aryl, aralkyl substituents on silicon atoms) can be grafted to solid surfaces and continue to exhibit liquid-like behavior, thereby providing some benefits to surfaces with stable lubricating layers.
[0222] In certain embodiments, such as Figure 3A-3B As shown, the catheter can be designed to have a texture or pattern morphology (e.g., grooves, pillars, and other geometric shapes with a size between 0.01-1 μm or 1-1000 μm or 1000-10000 μm), which helps Figure 3A-3B As shown, the lubricant or lubricating fluid 301 is retained over a longer period of time and during times of high volume transport of fluid on the surface 302. For example, the micron-sized grooves can increase the life of the fixed oil interface by retaining the lubricating fluid. In certain embodiments, the lubricating fluid layer 301 is filled in the grooves 303 and ridges with a roughness RMS between 10 nm and 1000 μm, thereby effectively smoothing any adhesion and pinning sites that lead to clogging, biofilm formation, and ineffective flow through the conduit 304, as shown. Figure 3CAs shown. The ultra-smooth surface of the lubricating fluid layer 301 is able to recover its original shape when externally deformed. As used herein, an "ultra-smooth" surface refers to a surface having a roughness coefficient equal to or close to 1, where the roughness coefficient (R) is defined by the ratio of the actual surface area to the projected surface area. Because the roughness coefficient of the fluid surface is generally 1, and the top surface of the smooth surface is a lubricating fluid that can completely cover the substrate above its hills, a surface such as a lubricant-coated catheter can be referred to as an ultra-smooth surface. In certain embodiments, the ultra-smooth surface may have an average surface roughness of about or less than about 1 nm. In certain embodiments, "ultra-smooth" may refer to a surface that is substantially molecularly or even atomically flat. The absence of any defects or roughness on such a surface can assist in minimizing the pinning points of the sliding fluid, thereby reducing the contact angle hysteresis, making it almost frictionless and smooth. A detailed discussion of SLIPS can be found in U.S. Patent No. 9,932,484, filed on January 19, 2012, entitled “Slippery Liquid-infused Porous Surfaces and Biological Applications Thereof,” the contents of which are incorporated herein by reference in their entirety.
[0223] In certain embodiments, such as Figure 3D As shown, the enhanced wrapping effect of the lubricant 301 around the contact fluid 305 will allow for the promotion of easy removal of bacteria and cells, wax, mucus and blood from the surface 302. Advantageously, in some embodiments, the wrapping layer 306 can be promoted by applying a lower viscosity oil or other lubricating layer on the surface to enhance the mobility of the impinging biological fluid or microorganisms on the fluid surface and reduce the incidence of postoperative otorrhea compared to tympanostomy tubes without a lubricating layer. In certain embodiments, the lubricating layer will allow for reduced clotting of blood. The life of the lubricated rough surface can be modified by selecting a lubricant with a low evaporation rate or high viscosity, low miscibility, and reduced wrapping of the lubricant around the contact fluid. In other embodiments, the lubricant can be one or more of an oleophobic lubricant, an oleophilic lubricant, a hydrophobic lubricant and / or a hydrophilic lubricant and / or an omniphobic lubricant. The lubricating layer can remove a large number of bacterial strains, including clinical isolates associated with or not associated with otitis media, Staphylococcus aureus, Haemophilus influenzae (H.influenzae), Moraxella catarrhalis, Streptococcus pneumoniae and Pseudomonas aeruginosa (P.aeruginosa), Branhamella catarrhalis (B.catarrhalis), Staphylococcus epidermidis (S.epidermidis), etc.
[0224] Can be used with Figure 1BOther advantages of the design space of the catheter are to synergistically utilize multiple properties, such as changes in shape and size. In some embodiments, relubrication or addition of a different lubricant with a lower viscosity can increase the expansion of the catheter material and thus change the shape and size of the catheter. In certain embodiments, adding a different lubricant with a lower viscosity helps remove cells or biofilms and triggers the release of biofilms from the surface. In addition, changing the geometry to a more curved geometry can eliminate pinning sites caused by angles, improve fluid performance, and reduce adhesion of unwanted surface contamination.
[0225] In certain embodiments, further modification of the surface of the tube by adding chemicals (or structures) will improve the benefits of adding one or more benefit mechanisms from the designer's toolbox ( Figure 1B ). Those skilled in the art will recognize that there are many chemical functionalizing agents and methods that will provide the desired surface chemistry (hydrophobic, hydrophilic, oleophobic, oleophilic, superphobic) for the catheter. In certain embodiments, the functionalization method may include liquid or gas phase reactions or depositions. In certain embodiments, the functionalization may include the deposition of a bottom coating and a top coating, pre-treated with plasma or reactive chemicals, which will make the surface susceptible to further functionalization, resulting in the installation of moieties with the desired surface energy and the ability to attract or repel certain fluids, liquids, complex liquids, heterogeneous emulsions and suspensions, and complex biological substances. Non-limiting examples of hydrophobic moieties are long chain hydrocarbons of linear and / or branched structures. Non-limiting examples of hydrophilic moieties are polyethylene glycol chains and analogs of different molecular structures thereof. Non-limiting examples of superphobic moieties are polyfluorinated linear and branched (hydrocarbon) carbon chains with or without heteroatoms in the chain. Those skilled in the art will recognize that these examples illustrate general methods of chemical modification and are not limited to any specific deposition method or type of chemical reaction used to functionalize the catheter surface. These examples are non-limiting and merely illustrate various methods that may be used to render the surface of a catheter attractive or repulsive to an object or medium of interest.
[0226] Other non-limiting examples of surface modifications include reconfigurable molecules with highly flexible long chains (with low energy barriers for internal rotation) (e.g., long polydimethylsiloxane polymers or other types of polymers and copolymers, including random or block silicone copolymers with other siloxane co-monomers characterized by alkyl, aryl, aralkyl substituents on the silicon atoms) that can be grafted to solid surfaces and continue to exhibit liquid-like behavior, thereby providing some benefits to surfaces with stable lubricating fluid layers. Other non-limiting examples include photolithography, micropatterning, 3D printing, etching or plasma treatment, conjugation of proteins or short polymer chains, ionic bonding of small molecules, addition of hydrogen bonding moieties or infusion and etching of other liquids or gases.
[0227] Figure 4A Depicted are bar graphs showing the average positive and negative standard deviations of the sliding angles of water (left bar) and mucus (right bar) on different surfaces (including commercial silicone, commercial fluoroplastic (Teflon), uninfused PDMS SE1700 plates, and PDMS SE1700 plates infused in 10 cSt, 20 cSt, and 50 cSt silicone oils), measured by the goniometric setup shown in the inset. Using the goniometric setup, a surface 401 is placed on a sample stage 402, and a fluid 403 is placed on the surface. The sample stage is tilted until the sample stage meets the sliding angle 404 at which the fluid slides off the surface. Figure 4B Depicted is a bar graph showing the average sliding angles (± standard deviation) of medical grade silicone infused in medical grade silicone oil 50 cP, 100 cP, and 350 cP, and their corresponding contact angle hysteresis (difference in advancing and receding contact angles) according to certain embodiments. The sharp decrease in the sliding angle of the silicone sheet infused with oil indicates the application of the immobilized liquid interface as an antifouling coating for tympanostomy tubes and subcircuitary catheters according to certain embodiments.
[0228] Figure 5A Depicted is a comparative study of human primary epidermal keratinocyte adhesion to commercial silicone, commercial fluoroplastic, uninfused PDMS SE1700 plates, and PDMS SE1700 plates infused in 10 cSt and 50 cSt silicone oils, demonstrating very low adhesion of cells to liquid-infused silicone sheets, as shown in bright field images ( Figure 5A View a and view b) and fluorescence microscopy images ( Figure 5A As shown in view c). Figure 5A This showed very low adhesion of cells to the liquid-perfused silicone sheet. Figure 5B Depicted are enhanced green fluorescent protein (EGFP, λ ex Comparative study of the adhesion of human neonatal dermal fibroblasts (HNDF) modified with α = 488 nm to medical grade silicone infused in medical grade silicone oil at different time points. For confocal imaging, HNDF were plated in 6-well plates at 50,000 cells cm -2 The cells were then inoculated onto silicone discs at a density of 1:1 for 12, 24, 36, and 48 hours. The cells were then incubated at 37°C with 5% CO 2 Incubate under 4% CO atmosphere until imaging. Cell adhesion was assessed by quantifying cell coverage recorded by confocal scanning laser microscopy. Confocal z-stacks over the entire surface of the sample were taken at 5x magnification and stitched together. Figure 5B The low adhesion of HNDF to silicone-infused silicone sheets was demonstrated. Figure 5B c and d) compared to the uninjected surface ( Figure 5BThe fluorescence corresponding to attached cells is higher in view b) of FIG. 1 . Thus, the number of human cells is lower on the perfused surfaces than on the non-perfused surfaces, which means that these cell lines adhere to these surfaces in lower amounts. Therefore, tympanostomy tubes made of these materials will have a lower rate of clogging caused by granulation tissue and / or premature extrusion from the eardrum caused by the growth of a keratinocyte layer onto the outer flange of the tube.
[0229] Figure 5C Depicted is a comparative study of the adhesion of HNDF to medical grade silicone infused in medical grade silicone oil, measured at 37°C using lateral pulling by an atomic force microscope (NanoWizard 4a, JPK Instruments) with a silicon AFM probe (All-In-One-Al, BudgetSensors). Cells were pulled laterally from the surface by engaging the tip on one side of the cell and pulling it over with the AFM in constant height mode. The resulting peak deflection was converted to lateral force. This study also demonstrated that 48 hours after inoculation, the adhesion of HNDF on the surface infused with oil was significantly lower compared to the non-infused surface, according to certain embodiments.
[0230] Figure 6 Figure 2 shows the quantification of human epidermal keratinocytes cultured on commercial silicone, commercial fluoroplastic, uninfused PDMS SE1700 plates, and PDMS SE1700 plates infused in 100 cSt and 50 cSt silicone oils by lactate dehydrogenase (LDH) fluorometry. Figure 6 View of a) and human dermal fibroblasts ( Figure 6 b) Comparative study of cytotoxicity of PDMS plates perfused with oil demonstrates low toxicity. In certain embodiments, the type of lubricant is selected based on criteria including longevity, uptake of the material, dissipation to surrounding tissue, and adhesion of cells and biofilms over time.
[0231] Fig. 7A (View a) depicts a comparative study of the adhesion of some exemplary clinical isolates of methicillin-resistant Staphylococcus aureus (SA) recovered from patients with chronic otitis media seen at the Massachusetts Eye and Ear Infirmary (MEEI) to uninfused medical grade silicone and medical grade silicone infused in medical grade silicone oil (100 cP), demonstrating extremely low adhesion of bacteria to the liquid-infused silicone sheets ( Fig. 7A The samples were then stained with 0.5 w / v% crystal violet for 10 minutes and then rinsed with PBS. The remaining dye of the stained samples was then resuspended in 7% glacial acetic acid. The absorbance of the suspension solution was measured at 570 nm ( Fig. 7AView a). Larger optical density (OD) values correspond to larger numbers of bacteria and biofilm found on the sample surface. Fig. 7A (View c) shows confocal microscopy images of bacterial adhesion on uninfused silicone samples and silicone samples (MED 4960) infused with medical grade silicone oil (100 cP MED361) after 24 hours of immersion in bacterial broth. The uninfused silicone samples showed a higher density of live bacteria and the formation of an extracellular matrix. The infused silicone samples showed a lower bacterial density with no signs of a biofilm matrix.
[0232] Figure 7B (View a) depicts a comparative study of the adhesion of some exemplary clinical isolates of Moraxella catarrhalis (MC) and Streptococcus pneumoniae (SP) recovered from patients with chronic otitis media seen at the Massachusetts Eye and Ear Infirmary (MEEI) to non-infused medical grade silicone and medical grade silicone infused in medical grade silicone oil (100 cP). As shown in the absorbance images, the bacteria exhibited very low adhesion to the liquid-infused silicone sheet ( Figure 7B View ab). Figure 7B OD readings measured using crystal violet staining on non-perfused (MED 4960) and perfused samples (100 cP MED 361) were compared. The perfused silicone samples showed much lower bacterial density with no evidence of a biofilm matrix.
[0233] In certain embodiments, other types of antifouling coatings may include hydrophobic and hydrophilic materials, some of which are discussed below with respect to directed fluid transport.
[0234] IV. Guided Fluid Transport
[0235] In certain embodiments, directed fluid transport can be designed to occur in multiple directions through a catheter (e.g., a tympanostomy catheter), such as Fig. 8A As shown, many optimized designs can allow certain fluids to be selectively transported through the catheter while other fluids are hindered. Although certain embodiments describe selective transport through a tympanic membrane puncture catheter, it should be understood that other embodiments can use the catheter in other applications. When certain embodiments describe a catheter across the tympanic membrane, it should be understood that the catheter can cross other membranes or tissue barriers in the body. When certain embodiments describe a catheter with a distal end in the middle ear and a proximal end in the outer ear, it should be understood that the catheter can have its distal end in other internal compartments of the body and its proximal end in other external spaces or compartments.
[0236] In certain embodiments, such as Fig. 8AAs shown, conduit 800 has a distal end 802 or tube inlet and a proximal end 801 or tube outlet. In the embodiment where the conduit is a tympanostomy tube, the tube spans the tympanic membrane 803, the distal end is located in the middle ear 804, and the proximal end is located in the external ear 805. In certain embodiments, the distal radius and the proximal radius can be selected to control the flow of fluid through the conduit. In certain embodiments, the flow of fluid through the tube can be controlled by the curvature or angle of the inner surface of the conduit. For example, the inner surface can form a proximal angle at the proximal end, and a distal angle at the distal end. In certain embodiments, the surface properties of the inner surface can be selected to control fluid flow. For example, the proximal end or the distal end can have a surface property, such as hydrophobicity or hydrophilicity, to control the flow of fluid in one or two directions.
[0237] In certain embodiments, it is desirable to transport certain fluids from the distal end to the proximal end. In these embodiments, the distal end is the inlet for the material and the proximal end is the outlet for the material. In other embodiments, it is desirable to transport other fluids from the proximal end to the distal end. In these embodiments, the proximal end is the inlet for the material and the distal end is the outlet for the material. In certain embodiments, it is desirable to prevent other fluids from entering the conduit.
[0238] In some embodiments, the surface properties and shape of the catheter can be controlled so that the first material can leave the middle ear and be transported from the distal end to the proximal end of the catheter without pinning, and leave the catheter but not enter the middle ear and be transported from the proximal end to the distal end of the catheter. Fig. 8A As shown, the surface characteristics and shape of the catheter 800 are selected to allow the first material 810 to more easily enter the distal end 802 of the catheter 800, be transported through the catheter 800 toward the proximal end 801, and exit the proximal end 801 of the catheter 800 than the first material 810 enters the proximal end 801 of the catheter 800, is transported through the catheter 800 toward the proximal end 802, and exits the proximal end 801 of the catheter 800. In certain embodiments, the surface characteristics and shape of the catheter can be controlled so that the second material cannot enter the middle ear. In this embodiment, the surface characteristics and shape of the catheter 800 are selected to prevent the second material 820 from entering the proximal end 801 of the catheter 800. In this embodiment, it may be desirable to remove body fluids from a compartment of the body, such as the middle ear, and to prevent other fluids from entering the compartment. The first material 810 can be, for example, effusion, pus, blood, perilymph, endolymph, plasma, tears, breast milk, amniotic fluid, serum, synovial fluid, perilymph, endolymph, urine, saliva, sputum, sweat, any other body fluid, water, water containing surfactants, mucus, and any combination thereof. The second material 820 can be, for example, water, aqueous solutions, foams and emulsions, ototoxic agents, soap, pool water, fresh water, saline water or sediment, foams and emulsions, or ototoxic agents.
[0239] In some embodiments, the surface properties and shape of the catheter can be controlled so that the third material can enter the catheter at the proximal end but cannot enter the middle ear. Figure 8B As shown in , the surface properties and shape of the catheter 800 are selected to allow the third material 830 to more easily enter the proximal end 801 of the catheter 800 and be transported through the catheter 800 toward the distal end 802, compared to the third material 830 that can enter the distal end 802 of the catheter 800 and be transported through the catheter 800 toward the proximal end 801 and prevent the third material 830 from leaving the distal end 802. In this embodiment, it is desired that the material enters the catheter 800, for example, to change the surface properties, shape or texture of the catheter 800 or to supplement the lubricating layer, but it is not desired that the material enters a compartment of the body such as the middle ear. The third material can be, for example, a lubricating fluid, a cross-linking agent, or other chemical components that act as a stimulus. In certain embodiments, the third material is a drug that is eluted on the surface of the tympanic membrane through the tube, but does not enter the middle ear space.
[0240] In some embodiments, the surface properties and shape of the catheter can be selected so that the fourth material can be delivered to the middle ear by entering the proximal end and exiting the distal end. Figure 8C As shown, the surface properties and shape of the catheter 800 are selected to allow a fourth material 840 to more easily enter the proximal end 801 of the catheter 800, be transported through the catheter 800 toward the distal end 802, and exit the distal end 802 of the catheter 800 than a fourth material 840 can enter the distal end 802 of the catheter 800, be transported through the catheter 800 toward the proximal end 801, and exit the proximal end 801 of the catheter 800. It is desirable for the material to enter the catheter 800 and exit into a compartment of the body, such as the middle ear, for example, to deliver a therapeutic agent. The fourth material 840 can be, for example, oil-based, water-based, and other solvent-based therapeutic agents comprising at least one of the following: antibiotics, preservatives, antivirals, anti-inflammatory agents, water-based or oil-based solutions, small molecules, immunotherapies, nanoparticles, genetic therapies including viral-based and lipid-based therapies, chemotherapy, stem cells, cell therapies, growth factors, proteins, radioactive materials, other liquid or gas-based pharmaceutical compounds, cerumen dissolving agents such as squalene, chlorhexidine and EDTA, deferoxamine, dihydroxybenzoic acid, glutathione, D-methionine and N-acetylcysteine, also in the form of foams and emulsions, and combinations thereof.
[0241] In certain embodiments, such as Fig.8DAs shown, conduit 800 has flange 803 at the distal end 802 of conduit 800. In other embodiments, conduit has flange at the proximal end of conduit. In some embodiments, flange 803 is configured to keep conduit 800 in the proper position in the tympanic membrane. In certain embodiments, flange is configured to guide fluid. In certain embodiments, flange is configured to keep conduit 800 in the proper position and guide fluid. In certain embodiments, flange 803 is flat, angled or arched.
[0242] Fig. 8E An exemplary embodiment is shown in which the catheter is secured to the tympanic membrane 803 with the distal end 802 at the middle ear 804 and the proximal end 801 at the external ear. According to this exemplary embodiment, the first material 810 discussed above is effusion or pus, the second material 820 discussed above is water, and the fourth material 840 discussed above is a therapeutic agent, such as therapeutic drops.
[0243] Fig.9A (View a) shows a symmetrical catheter 901 having a distal end 903 and a proximal end 902 having the same diameter, according to certain embodiments. Fig.9A (View b) shows a symmetrical catheter 901 having a lubricating layer (oil) 904 on the inner and outer surfaces of the catheter. In this embodiment, the lubricating layer on the outer surface is in contact with the tympanic membrane 905, and the lubricating layer on the inner surface is in contact with the air or effluent 906. In certain embodiments, anisotropy in the design of catheter 901 can achieve preferential transport of a given liquid in one direction while preventing transport of the liquid in the opposite direction. Anisotropy can arise from macroscopic catheter geometry, such as Fig.9A (View c) shown. Fig.9A(View c) shows an asymmetric catheter according to certain embodiments, which includes a distal end 903 having a first diameter and a proximal end 902 having a second larger diameter. In this embodiment, the fluid can preferentially flow into the distal end and out of the proximal end. In certain embodiments, anisotropy can be derived from directional micro / nano morphology or porosity, gradient chemical patterning and / or dynamic characteristics. In certain embodiments, the catheter can have a certain morphology or porosity at the distal or proximal end of the catheter. In other embodiments, the characteristic size of the morphology or porosity can be different at the distal and proximal ends. In certain embodiments, the catheter can have a chemical or geometric pattern at the distal or proximal end. In certain embodiments, the catheter may have a chemical gradient that increases or decreases from the distal end to the proximal end. In certain embodiments, a chemical gradient is set at the stage of surface functionalization or at the stage of catheter manufacturing by controlled polymerization, 3D printing, molding and other manufacturing methods (by utilizing the gradient in the prepolymer composition, the amount and properties of the cross-linking agent, the irradiation intensity, the amount of the free radical initiator, etc.). This list of methods is by no means exhaustive, but rather illustrates the modularity of designs and tools that can be used to achieve desired transport effects. In other embodiments, various regions of the tube surface can carry different chemicals to promote anisotropic flow. Non-limiting examples may include differences in hydrophobicity and hydrophilicity, which can locally change liquid contact angles and whether liquids are pinned or transported through the tube.
[0244] In certain embodiments, such as Fig. 9B As shown in the example of , anisotropic and directional fluid transport can result from a multi-component assembly with functional add-ons / inserts 904. Fig. 9B (Views ac) show certain embodiments of the insert that allow a droplet placed on the surface of the insert to spontaneously begin to spread in the direction of increasing insert radius. In certain embodiments, the flow is determined by capillary forces. At the same time, this anisotropy can allow different liquids to be transported through the conduit in opposite directions. Fig. 9B (View a) shows an insert allowing flow out of the catheter 901 through the distal end 903. Fig. 9B (View b) shows an insert allowing flow into and out of the catheter through the distal end 903. Fig. 9B (View c) shows two inserts at the proximal end 902 and the distal end 903, which allow flow into and out of the catheter through the proximal and distal ends.
[0245] Although the following description contains certain embodiments related to tympanostomy catheters and / or subannular ventilation catheters, these designs can also be used in other medical or non-medical applications, such as microfluidics, membranes, bioreactors, transport of coolants and other chemicals through machinery, discharge of reaction waste, sensors, additive manufacturing nozzles, funnels, food and beverage industries, cosmetics and perfumes, and other applications.
[0246] In certain embodiments, directional features designed into tympanostomy catheters can allow (1) mucus from the middle ear cavity (formed by otitis media) to pass through the catheters into the external auditory canal, and (2) oil or water-based antibiotic drops delivered through the external auditory canal to pass through these catheters into the middle ear cavity, where they can treat otitis media infection; and (3) blood drainage after myringotomy. Many other fluids can be administered to pass through the catheter in a desired direction. In certain embodiments, directional features can cause dynamic reversible or irreversible, local or global changes in tube geometry, surface structure, chemistry, or dimensions that can be used for local delivery of drugs, drainage of body fluids, improved device placement, or structural reconfiguration of the device to assist in its stabilization or extrusion at a desired time.
[0247] In some embodiments, drops applied from one side can temporarily close the tube to temporarily prevent any liquid from being transported through the catheter. In certain embodiments, drops can block the tympanostomy tube before swimming / bathing to prevent ambient water from entering the middle ear. In certain embodiments, other stimuli such as light, temperature, electric or magnetic fields, pH changes, pressure gradients, and other stimuli cause physical or chemical transformations of the tube to achieve the desired purpose. Exemplary scenarios are described throughout the disclosure.
[0248] Fig.10 Parameters of catheters and test liquids according to certain embodiments are highlighted, which constitute exemplary design principles for enhanced flow of ambient water, oil-based ear drops, and effusion / mucus / pus in the middle ear directed through a tympanostomy catheter. In certain embodiments, design principles for optimizing bidirectional flow in the catheter include the size and shape of the flange, the radius and length of the catheter lumen, the curvature of the catheter, the chemical properties of the surface and the surface tension of the liquid, and the integration of multiple catheter paths with different properties, each with a specific directional transport function.
[0249] In certain embodiments, geometric patterns can be used for preferential flow. In certain embodiments, geometric patterns increase the advancing angle and contact angle hysteresis of the liquid entering the conduit, and in other embodiments, geometric patterns reduce the advancing angle and contact angle hysteresis of the liquid entering the conduit. In certain embodiments, geometric patterns can induce Casey-Baxter, Young-Laplace or Wenzel state or other intermediate states. In certain embodiments, geometric patterns are arranged on the outer surface or inner surface of the conduit. In certain embodiments, geometric patterns are produced by surface topography such as surface roughness, grooves, ridges, indentations, micro-pillars, micro-ridges or holes and other 3D mosaics.
[0250] In certain embodiments, various parameters of the catheter, such as the radius, angle of the flange (horizontal piece at the distal or proximal end) or angle of the lumen wall, surface tension, and lubricant, can be adjusted to promote fluid flow into and out of the proximal end or to restrict fluid flow, wherein fluid is trapped in the lumen and cannot exit the distal end or enter the proximal end.
[0251] A. Prevent fluid from entering the proximal end of the catheter
[0252] In certain embodiments, the surface of the conduit can be surface functionalized by chemical methods such as, but not limited to, silanization, fluorination, hydroxylation, carboxylation, and esterification, wherein the resulting surface is hydrophobic or hydrophilic. By using these surface functionalizations, the entry of fluids of hydrophilic or hydrophobic nature can be inhibited at lower Young-Laplace pressures. In certain embodiments, the use of surface active fluorinated conduits will significantly increase the Young-Laplace pressure of water entering the conduit compared to non-polar, low surface tension liquids.
[0253] In some embodiments, the radius of the proximal end can be much smaller than the distal end to prevent fluid from entering the catheter from the proximal end. In some embodiments, the proximal end and the distal end are separated by a membrane such as a tympanic membrane, anterior chamber, etc. In some embodiments, this geometry prevents fluid from entering the proximal end and preferably minimizes the volume flow rate.
[0254] In certain embodiments, pinning of the liquid can be observed proximally by irregularities in the inlet geometry and tip within the catheter. The sharp tip of the geometry at the inlet will cause higher Young-Laplace pressures and create potential pinning points.
[0255] B. Prevent fluid from flowing out of the distal end of the catheter
[0256] In certain embodiments, the lumen angle at the distal end can be changed to cause a sudden increase in Young-Laplace pressure for fluid to exit. For example, in the case of a "collar button" geometry, the lumen angle is maintained at 0° to the vertical, so the fluid must experience a sudden change in contact angle, the fluid must change its contact angle at the distal end from its equilibrium contact angle to 180° with the lumen wall. In this embodiment, the angle change caused by the discontinuity causes a sudden rise in Young-Laplace pressure at the outlet. Thus, in this embodiment, the fluid is inside the conduit, but the barrier cannot leave due to this sudden pressure.
[0257] In certain embodiments, the use of a ciliary structure can be used as a pinning point in the lumen. Pinning is the phenomenon of discontinuous motion of a meniscus. Pinning is usually caused by the discontinuity of the geometry contacted by the meniscus (e.g., by roughness or a ciliary structure). The direction of the structure determines the preferred direction of flow, so the direction of the structure can be strongly directed toward the proximal end to prevent fluid from flowing out of the distal end. The ciliary structure can be used in combination with radial changes through the lumen to prevent fluid from flowing out from either end. In certain embodiments, a gradient of surface tension can be applied to the catheter, wherein when the fluid travels through the catheter to reach the distal end, the fluid encounters a higher energy barrier therein. In certain embodiments, this increase in Gibbs free energy prevents or increases the barrier of fluid from leaving the distal end. In certain embodiments, this can be achieved by a gradient of lubricant coating thickness, surface tension, density, Young's modulus, or heterogeneity of the material.
[0258] C. Adjust the catheter to induce optimal fluid flow
[0259] In certain embodiments, the catheter lumen wall is continuously curved from the proximal end to the distal end to minimize the sudden pressure jump experienced by the fluid to leave the catheter. In certain embodiments, the sum of the advancement angle at the distal end and the lumen flange angle will be 180 °, so that there is no discontinuity in pressure, thus avoiding any pinning of the fluid.
[0260] In certain embodiments, a lubricant (or other low surface tension fluid) is perfused in the lumen of the catheter, wherein the sheath assists the fluid flow through the catheter and out the distal end. In certain embodiments, the sheath minimizes surface interactions between high surface tension liquids and air. In certain embodiments, the sheath reduces pinning, thereby reducing the Young-Laplace pressure at the outlet.
[0261] In certain embodiments, conduit is surface functionalized according to the hydrophilicity or hydrophobicity of fluid.In certain embodiments, fluid is water, and by modifying the inner cavity wall with metal elements, the surface is modified.In certain embodiments, fluid preferentially wets the inner cavity wall without pressure gradient.In this embodiment, by adjusting this surface modification relative to the fluid to be transported, the Young-Laplace pressure leaving the far-end can be minimized.In other embodiments, the length of conduit is adjusted to the capillary height of the fluid that makes the inner cavity wall moistening, and the radius is lower than the capillary length of fluid, thereby allowing fluid to spontaneously wet and overcome gravity and approach the far-end.In certain embodiments, fluid can optimally flow through conduit and leave the far-end without increasing the pressure gradient applied.
[0262] D. Tympanostomy catheter with optimized structure and surface chemistry
[0263] In certain embodiments, to optimize flow transport through a conduit, the shape and surface chemistry of the proximal and distal ends of the conduit are considered in order to induce or prevent liquid pinning in the conduit, thereby enabling or preventing liquid passage. The ability of a liquid to be pinned or transported within a conduit can be most effectively described in terms of the capillary pressure ΔP maintained at the interface between two static fluids in the conduit (e.g., water and air or oil and air, or mucus and air). The pressure can be determined by using the Young-Laplace equation To describe, where γ eff is the effective surface tension of the liquid entering the catheter, r int is the inner radius of the conduit, and θ adv It is the advancing contact angle of liquid, which is the feature of wettability or chemical property on the surface.The transportation by conduit is subject to the constraint of the highest pressure barrier in the system, and this highest pressure barrier may occur in the different regions of conduit, specifically depending on the design of conduit (i.e., along the local geometry and local advancing contact angle of conduit), the direction of liquid transportation, shape and curvature of conduit and flange and the characteristic of material.When high pressure barrier appears in some areas, liquid will be pinned at these positions, and can't move or leave conduit in conduit.In certain embodiments, by making conduit substantially without obvious pressure jump, as described in the following non-limiting examples, liquid pinning can be avoided and can realize the transportation by pipe.As described below, in certain embodiments, such pressure jump can occur at the inlet or outlet of pipe, for example, when fluid enters and leaves pipe.In certain embodiments, the breakthrough pressure of conduit end is optimized and reduced by the local change of the chemistry or geometry of conduit or flange.Some non-limiting examples are shown in AD of Figure 11. Fig.11A The optimization for cylindrical ( Fig.11A View a), cone ( Fig.11A b) or curved ( Fig.11A c) The parameters of the pressure barrier of the transport of the catheter, such as the initial radius (R t ), initial flange angle (θ f ), lumen length (h), and lubricant used. In certain embodiments, by carefully designing the geometry and chemistry of the tube using the above parameters, transport of certain liquids can be facilitated. In certain embodiments, pinning can be induced for other liquids. In other embodiments, one liquid is transported anisotropically in one direction and another liquid is transported anisotropically in the opposite direction.
[0264] 1. Surface characteristics, size and shape of the duct and flange
[0265] In certain embodiments, such as in Fig. 11BAs can be seen in FIG. 1 , the surface properties of the conduit material play a role in driving the liquid into the inlet or proximal end 1101 of the conduit 1102. If the advancing angle θ of the liquid 1103 on the surface at the inlet adv At less than 90 degrees, the liquid can be driven into the catheter ( Fig. 11B view b), and if θ adv >90 degrees, there will be resistance to liquid entry ( Fig. 11B ). In various embodiments, the slippery surface improves transport by reducing physical pinning and changing the interfacial properties of the material to reduce the advancing contact angle. For surfaces impregnated with lubricants, the contact angle of the liquid with the surface can be further reduced by physically wrapping the lubricant around the impinging fluid and reducing its surface energy. According to certain embodiments, the type of lubricating fluid can be tailored for a customized tube design depending on the application. In certain embodiments, the lubricating layer can also be used as a means to elevate the fluid from the surface so that flow occurs at the droplet-lubricant interface rather than the droplet-substrate interface, as dictated by diffusion coefficient theory and minimization of surface free energy.
[0266] Fig. 11C It is shown that in certain embodiments, changing the shape of the outlet or distal end 1104 of the hydrophobic conduit can facilitate guided fluid transport. In certain embodiments, positioning the flange at an angle to the hydrophobic conduit allows for a lower pressure differential across the fluid interface. In certain embodiments, the conduit can have a flat flange 1105, an angled flange 1106, or a curved flange 1107. In certain embodiments, the size of the outlet flange is selected to reduce the pressure barrier for droplets to leave the conduit by integrating the curvature (see Fig. 11C The arched flange in the int Hours, θ 凸缘 low, and with r int In this case, in And by ensuring The exact shape is numerically optimized to minimize the maximum breakthrough pressure for a given liquid. In certain embodiments, for a flat flange, And the breakthrough pressure depends only on the radius of the tube and the effective surface tension. In certain embodiments, when for curved or angled flanges, θ adv +θ 凸缘 When ≥180°, the pressure barrier becomes In this embodiment, due to the angled flange, r int (z) is greater than the radius of the lumen, thereby reducing the pressure barrier compared to a sharp flange angle. For hydrophilic catheters, certain embodiments should consider a first breakthrough pressure and a second breakthrough pressure. Fig.11DAs shown, the first breakthrough pressure is the pressure at which the fluid leaves the conduit and the second breakthrough pressure is the pressure at which the liquid wets the entire area of the flange.
[0267] As described herein, the size and shape of the tube, flanges, and surface characteristics of the conduit material play an important role in directing or inhibiting liquid flow.
[0268] In certain embodiments, the pore size (r) will range from hundreds of nanometers to tens of micrometers. 孔 ) membrane is incorporated into the tympanostomy catheter to increase the pressure barrier associated with fluid transport. int =r 孔 , and only highly wetting liquids can penetrate the ear canal. This effect can be advantageous for allowing, for example, silicone oil carrying drugs to be transported while reducing and / or preventing the transport of aqueous liquids into the inner ear cavity.
[0269] In certain embodiments, the hole can be opened and closed quickly and repeatedly, enabling precise and dynamic regulation of gas / liquid sorting and controllably separating three-phase systems of air / water / oil mixtures, complex solutions and suspensions such as proteins and blood. In certain embodiments, according to US 2018 / 0023728, published on January 25, 2018 (the contents of which are incorporated herein by reference), liquid-filled holes can provide a gating strategy that provides a unique combination of dynamic and interfacial behavior. According to certain embodiments, these embodiments can be used to design gated transport systems starting from various pore sizes, geometries and surface chemistry and gating liquids. In certain embodiments, the substrate may include holes having a size of an average of about 10 nm to about 3,000 microns or any combination of sizes therebetween (e.g., 20 nm to 2 microns, 100 nm to 10 microns, 100 nm to 1.2 microns, 80 nm to 1 micron, 200 nm to 5 microns, 10 nm to 10 microns and 100 nm to 50 microns).
[0270] In certain embodiments, the geometry and chemistry of a device made of a dynamic, environmentally sensitive material can be temporarily altered by applying an external stimulus such as light, temperature, or chemical environment to allow temporary transport or delivery through a tube according to certain embodiments and as discussed in more detail throughout this disclosure.
[0271] 2. Surface tension of lubricating fluid
[0272] In certain embodiments, the lubricating fluid can change the surface tension of the catheter surface. In certain embodiments, the catheter low surface tension lubricating fluid (about 19mN / m) forms an advancing contact angle of 0 degrees on the tympanic membrane puncture catheter to allow essentially unimpeded transport of oil droplets through the catheter. Depending on the presence of the lubricating fluid coating, water droplets have a much greater surface tension (60mN / m with a coating and 72mN / m without a coating), and a high advancing angle. Therefore, in certain embodiments, driving water through the catheter may be more challenging. Therefore, in this embodiment, mucus with a surface tension of about 50mN / m is easier to transport through the catheter than water. The fixed liquid interface helps water enter the ear through a catheter of a certain size (<1mm ID). According to certain embodiments, the choice of lubricant can be optimized to reduce the effective surface energy and reduce the contact angle of a certain fluid to promote transportation, or conversely, increase the contact angle and inhibit transportation. According to certain embodiments, the introduction of surfactants into water also changes the fluid transport through the catheter.
[0273] 3. Geometry optimization for enhanced preferential flow
[0274] In certain embodiments, optimization of the conduit geometry may be performed to allow selective preferential flow of one or more liquids. The parameters for such optimization are provided by the Young-Laplace equation governing the maximum pressure of the fluid: where ΔP is the pressure difference across the meniscus of the fluid. It can be modified as follows: a) The effective surface tension of the phase in contact with air (γ eff ), b) the radius of the tube (r), c) the advancing angle of the three-phase front, d) the inclination angle of the inner cavity wall and θ 凸缘 , e) the surface characteristics of the tube, and f) the bevel angle of the tube and flange. The effective surface tension depends on the diffusion coefficient of the lubricant on the fluid: S LD =γ DV -γ DL -γ LV , where S LD is the diffusion coefficient of the lubricant on the droplet, and γ DV , γ DL and γ LV are the interfacial tensions of droplet-vapor, droplet-lubricant, and lubricant-vapor, respectively. When the expansion coefficient is greater than 0, the formation of a wrapping layer is favored due to energy minimization. The effective surface tension is γ DV and γ DL +γ LV According to certain embodiments, this optimization can be performed for various materials that are smoothed, chemically patterned, or morphologically textured on the tube.
[0275] In some embodiments, preferential flow is preferential unidirectional flow of one material over another. In some embodiments, preferential flow is preferential unidirectional flow of therapeutic droplets over ambient water. One approach to optimization can be performed numerically by maintaining a constant Young-Laplace pressure of the antibiotic solution over the entire length of the lumen. In some embodiments, the angle of the inner surface of the catheter can be changed to maintain a constant Young-Laplace pressure. By adjusting the Young-Laplace pressure in infinitesimal increments (dr and dθ) to maintain a constant Young-Laplace pressure, the Young-Laplace pressure can be increased by 1.5 times the Young-Laplace pressure. 凸缘 ) By continuously changing the flange angle (e.g., the distal angle of the distal flange or the proximal angle of the proximal flange) and the radius, an azimuthally symmetric or axisymmetric geometry with an optimal curvature can be achieved, which maintains a constant Young-Laplace fluid pressure: The same pressure can be achieved through the lumen of the catheter, where θ adv +θ 凸缘,最终的 =180°. In certain embodiments, the final flange angle can be adjusted by adjusting the material properties. In certain embodiments, catheters with improved performance incorporating right angle or curved flanges can be achieved by allowing the pressure in the flange to vary by up to ±1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or any intermediate value. In certain embodiments, these shapes are determined by considering the initial pressure in the flange: Over the entire flange length z, the condition can be applied for all z Until the end of the flange, where x = 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and x is the allowable pressure change in the flange. Fig. 12A A comparison of the maximum pressure difference of antibiotic droplets flowing through an optimized conduit and a cylindrical or conical conduit, normalized by the maximum pressure of a cylindrical or conical conduit, respectively, is shown to show that the deviation of the pressure in the optimized tube can be within about 80%. The flange can be curved or straight, or can be composed of many right-angled sections. The pressure can also be optimized to reduce the pressure compared to existing similar devices (where ΔP = f(z), where f(z) is a selected function that controls the pressure difference along the tube).
[0276] In some embodiments, the Young-Laplace pressure of the material does not change along the tube or conduit. In some embodiments, the Young-Laplace pressure of the material changes only 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 10% or less, 5% or less, 2% or less or 1% or less. In some embodiments, the material can be a first material that travels from the distal end to the proximal end. In some embodiments, the material can be a fourth material that travels from the proximal end to the distal end.
[0277] The flow model can be optimized by the interaction of various parameters: Young-Laplace fluid pressure (ΔP), initial radius (r), initial flange angle (θ 凸缘,初始 ) (e.g., the distal angle of the distal flange or the proximal angle of the proximal flange) and the lumen length (L). These degrees of freedom can be scanned and optimized to (1) maximize the Young-Laplace pressure of water; (2) minimize the Young-Laplace pressure of the drug solution; and (3) minimize the deviation from the specified tube length. As shown in certain embodiments, Fig. 12A In the study, the difference between antibiotic pressure and water pressure was greater in the curved catheter compared to the collar and conical catheters. An example of such an optimized curved tube is shown in Fig. 12B , where the length of the tube is limited to 2 mm, and an exemplary radius is chosen to be 0.275 mm at the proximal end 1201. The shape indicates a constant antibiotic pressure of 74.7 Pa throughout the tube from the proximal end to the distal end 1202.
[0278] In certain embodiments, the radius is in the range of 10 nm to 1500 μm (capillary length of water). In certain embodiments, the radius is 10 nm, 50 nm, 100 nm, 200 nm, 300 nm, 400 nm, 500 nm, 600 nm, 800 nm, 1 μm, 10 μm, 50 μm, 100 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, 1000 μm, 1100 μm, 1200 μm, 1300 μm, 1500 μm, or any value therebetween. In certain embodiments, the radius is 1 mm, 2 mm, 3 mm, or any value therebetween.
[0279] Advantageously, the tubes with the optimized design have significantly smaller (1.5-10 times) radii than any control cylindrical or conical tubes having larger radii independent of their shape, but have similar or much lower maximum antibiotic Young-Laplace pressures and higher Salicyl Laplace pressures, such as Fig.13 As shown. Thus, the tube can be smaller, less invasive, and less disruptive, but still obtain the benefits of, for example, passing antibiotics through the inner ear without allowing water to pass through. In addition, a tube with a bend, optimized design based on the interaction of tuning Young-Laplace equation parameters provides excellent selectivity for a desired fluid. For example, in some embodiments, a tube with an optimized bend design (e.g., Fig.13 (View a) shows the largest difference between the pressure of the water and antibiotic droplets with radii of 0.058 mm and 0.144 mm. Note that compared to the larger cone ( Fig.13b) (e.g. Baxter bevel shape, r = 0.107 mm, r = 0.279 mm) and a much larger cylindrical shape ( Fig.13 Compared to the view c) (e.g., collar button shape, r = 0.380 mm, r = 0.750 mm), the antibiotic pressure remains constant throughout the entire tube length from the proximal end 1301 to the distal end 1302, and no pressure jump is shown. In certain embodiments, Fig.14A and Fig. 14B The highest selectivity for the optimized curved tube can also be seen in the , where the strongest pressure difference is seen for the curved geometry compared to the conical and cylindrical shapes with the same tube outlet radius, and the smallest inlet radius is also seen for the curved tube (again showing that the optimized tube can be much smaller in size while retaining all the benefits of a commercial tube).
[0280] Similarly, in some embodiments, the tubes can be optimized for various liquids, such as water and antibiotics. Fig.14A and Fig. 14B The interfacial tension (IFT) of the fluid is measured using the pendant drop method using a goniometer. The IFT of water is γ DV =72.3mN m -1 and γ DL =44.5mN m -1 ; IFT of antibiotic droplets is γ DV =41.43mN m -1 and γ DL =25.00mN m -1 ; Lubricant-vapor IFT(γ LV ) is 18.8 mN m -1 For simulation purposes, the advancing angles of the three-phase fronts are obtained from Young's equations:
[0281] In certain embodiments, such as Fig.14A As shown, by design, antibiotics ( Fig.14A View ac) The maximum Young-Laplace droplet can be adjusted to be the same (75 Pa) for all oil-filled tubes: collar or cylindrical ( Fig.14A Views c and f), cone ( Fig.14A Views b and e) and curved ( Fig.14A The simulations show that for curved geometries, the corresponding pressure of the water ( Fig.14AAccording to certain embodiments, this indicates that the greatest pressure difference is seen for the curved geometry compared to the conical and cylindrical tubes with the same catheter outlet radius 1402 (with different inlet radii 1401). In certain embodiments, the inlet radius 1401 is at the proximal end of the catheter, and the outlet radius 1402 is at the distal end of the catheter to prevent water from entering the inner ear, but allow antibiotics to pass through the catheter.
[0282] In certain embodiments, such as Fig. 14B As shown, for all shapes: curved ( Fig. 14B Views a and d), cone ( Fig. 14B b and e), or cylindrical or button-shaped ( Fig. 14B In views a and d), the entrance radius 1401 can be chosen to be the same (the exit radius remains constant). Fig. 14B Mapping of antibiotics along the length of catheters of various geometries ( Fig. 14B View of ac) and water ( Fig. 14B The simulations show that the optimized catheters with the same catheter inlet radius as the control tubes of various shapes (e.g., Baxter bevel and collar button) show higher fluid selectivity at the maximum pressure point within the lumen, as shown in Figure 2. Fig. 14B The fluid selectivity is determined by the normalized Young-Laplace pressure difference between the transported fluids. For unidirectional transport, the therapeutic droplets flow preferentially compared to water, and the optimized curved tube design has a higher fluid selectivity of 3.1 compared to 2.5 for the conical and 1.5 for the cylindrical. Fig. 14C Certain embodiments are shown where the selectivity (ratio of maximum water pressure to maximum antibiotic pressure) for the optimized curved design is in a non-limiting range of 3-4, compared to the lower selectivity of cylindrical and conical conduits. In certain embodiments, the selectivity can be further optimized for other specific fluid examples to achieve a selectivity between 0.0001 and 10. In certain embodiments, the selectivity is between 5 and 6.
[0283] In certain embodiments, the selectivity between materials, such as the first and second material, is in the range of 1 to 1.2, 1.2 to 1.5, 1.5 to 1.7, 1.7 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 8, 8 to 10, 1 to 10, 1.2 to 10, 1.5 to 10, 1.7 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 1 to 10, 1.2 to 8, 1.5 to 6, 1.7 to 5, and 2 to 4.
[0284] In some embodiments, the difference between the Young-Laplace pressures of two materials (e.g., the difference between the first, third, or fourth material and the second material) is greater than 1 Pa, greater than 5 Pa, greater than 10 Pa, greater than 25 Pa, greater than 50 Pa, greater than 100 Pa, or within the range of 1 MPa to 1000 MPa, 5 MPa to 1000 MPa, 10 MPa to 1000 MPa, 25 MPa to 1000 MPa, 50 MPa to 1000 MPa, 100 MPa to 1000 MPa, or 500 MPa to 1000 MPa.
[0285] Fig.15A An additive manufacturing and injection molding manufacturing method for making a tympanic membrane puncture catheter having a cylindrical "collar button" shape according to certain embodiments is shown. In certain embodiments, the tube can be redesigned after molding to have a desired surface modification, such as a lubricating coating for enhanced antifouling properties and enhanced fluid flow on the catheter surface, improved smoothness and reduced pinning, or different single or multi-layer functional coatings, or structural modifications, such as patterned morphologies according to certain embodiments described below. Fig.15A (View a, including views a1-a5) is a schematic diagram of the injection molding manufacture of a tube having a cylindrical shape. The mold 1501 design consists of four 3D printed parts: two side parts 1502a, 1502b, which have concave surfaces designed to fit tightly around a custom pin 1505 of the desired diameter (which forms the inner cavity of the catheter); two "top" 1503 and "bottom" 1504 parts with rectangular holes, which accommodate flat polydimethylsiloxane blocks 1506 (PDMS, Sylgard184, Dow Corning). The two PDMS blocks (5:1 = substrate to cross-linker ratio) hold the pin in place and provide a tight seal between the pin and the surrounding parts. In some embodiments, such as Fig.15A As shown in (view a1), the bottom part of the mold is filled with a curable polymer 1507, such as PDMS. A PDMS block ( Fig.15A , view a2) to hold the pin in place ( Fig.15A , view a3). A first side member is added to define the outer surface of the conduit, and then a second side member and a top member are added. In some embodiments, the curable polymer is cured by exposure to heat, light, or a cross-linking agent. Fig.15A (View b) shows a three-dimensional schematic diagram of a catheter according to certain embodiments. Fig.15A (Views c1 and c2) show a side view of a catheter and a cross section thereof according to certain embodiments.
[0286] Fig. 15BThe fabrication of an exemplary embodiment of a tympanostomy catheter having an anisotropic curved shape is shown. Fig. 15B (View a) is a schematic diagram of the injection molding manufacture of a tube having a curved shape, which uses the same method for similar components. Fig.15A Similar reference numerals. The mold is manufactured by additive manufacturing. Fig. 15B (Views bl and b2) show schematic three-dimensional views of a catheter according to certain embodiments. Fig. 15B (Views c1 and c2) show a side view of a catheter and a cross section thereof according to certain embodiments.
[0287] The following examples further describe and illustrate embodiments within the scope of the present invention. These examples are given for illustrative purposes only and should not be construed as limitations of the present invention, as many changes can be made without departing from the spirit and scope of the present invention.
[0288] In some embodiments, experimental results with tubes having approximately the same inner radius of 0.275 mm and length of 2 mm showed that the Young-Laplace pressure for fluid transport of antibiotic droplet simulation solutions was significantly lower than water for the curved perfused tubes compared to the "collar button" unperfused tubes, as shown using Fig.16 The device shown is measured. Fig.16 As shown, the device consists of an acrylic chamber 1601, a polyethylene terephthalate-based membrane 1602 and a rubber hybrid gasket 1603 holding two magnetic rings 1605 for measuring Young-Laplace pressure. Before each experiment, the device was washed with isopropyl alcohol and dried with compressed air. A tube 1604 was inserted into the rubber gasket through a circular hole with a diameter of 0.20-0.75 mm to prevent leakage of the test fluid. A tight seal between the gasket and the membrane was ensured by two annular magnetic rings 1605. The membrane with the gasket was then placed on the chamber and fixed with two rubber O-rings 1606 on both sides of the membrane for a tight seal. A needle 1607 was placed in a rubber stopper to pump the fluid into the chamber. A syringe pump (Harvard Apparatus PHD UltraTM) was used to dispense the fluid, thereby 1000 μLmin -1 The initial 3 mL of fluid was delivered at a rate of 500 μL min -1 An additional 3 mL was delivered at a rate of 250 μL min -1 The water level was captured using a camera. ImageJ was then used to determine the height (h) of the fluid on the image as it left the tube, and by using h, the static pressure (P) of the fluid was calculated using P = ρgh, where ρ is the density of the fluid and g is the acceleration due to gravity.
[0289] According to certain embodiments, the pressure drop from the unfilled collar tube to the optimal curved tube filled with the antibiotic droplet simulation solution is 77%, such as Fig.17 Thus, even at the same radius value, the fluid selective transport properties of the curved design according to certain embodiments will still be maintained. Fig.17 The pressure of the unperfused and perfused curved samples was shown to be dramatically reduced by 70% and 77%, respectively, compared to the unperfused collared cylindrical tube, as indicated by the arrows. The oil-perfused collared tube showed a 13% reduction in pressure compared to the unperfused collared tube, indicating that, in certain embodiments, the addition of a lubricating layer also reduces pressure by changing the effective surface tension of the liquid and preventing pinning. In certain embodiments, catheters can have reduced pressure and guided fluid flow based on geometry without the need for lubricating fluids.
[0290] In certain embodiments, such as Fig.18 As shown, a bidirectional design is desired and the catheter may be constructed, for example, from the joining of a proximal curved segment 1801 and a distal curved segment 1802. Each segment is optimized for fluid transport of a specific fluid group. Fig.18 This "hourglass" geometry and its side faces are shown ( Fig.18 A) and a cross section ( Fig.18 The length of the inlet section is optimized for administering antibiotic ear drops and minimizing the entry of water from the middle ear 1803, while the length of the outlet section is optimized for draining the middle ear 1804 fluid.
[0291] Such properties may enable local administration of drugs such as antibiotics (which currently cannot be effectively delivered with existing devices because they cannot pass from the proximal end of the tube through the distal end to the inner ear).
[0292] In certain embodiments, the catheter provides controlled flow of aqueous humor of the eye from the anterior chamber to the subconjunctival space to lower intraocular pressure (IOP) in a controlled manner and reduce the need for further treatment of glaucoma patients.
[0293] In certain embodiments, the use of a curved geometry for a catheter that transports the aqueous humor of the eye will reduce the minimum pressure gradient across the anterior chamber and subconjunctival space required for flow. In certain embodiments, this reduction in pressure gradient allows for a smaller difference in opening and closing pressures of the AGV shunt and a reduced opening pressure. Higher opening pressures can result in insufficient control of IOP with long-term placement and can be exacerbated by increased flow resistance of the tissue surrounding the glaucoma drainage device.
[0294] In certain embodiments, the catheter has a switchable slippery surface. In these embodiments, the catheter can be switched between a slippery state and a non-slippery state to limit excess flow of aqueous humor, thereby preventing postoperative hypotension.
[0295] In some embodiments, the catheter has a switchable pinning sight for controlled fluid flow. In some embodiments, the pinning sight is deactivated when the intraocular pressure is within the normal range of 12-20 mmHg. In some embodiments, when the intraocular pressure drops below 12 mmHg, the flow of aqueous humor is inhibited by stimulation that increases the effect of the pinning sight and naturally allows the intraocular pressure to equalize to within the normal range.
[0296] In certain embodiments, the catheter has a surface-modified lumen in which flow is reduced or completely restricted by stimulation to prevent post-operative hypotension.
[0297] 4. Chemical and geometric patterns for enhanced preferential flow
[0298] In some embodiments, the tympanostomy catheter or subannular ventilation catheter includes a wicking material or chemical gradient on the flange of the catheter to direct or enhance the flow of fluid. In some embodiments, the chemical gradient increases the effective surface tension of the catheter, and in other embodiments, the chemical gradient decreases the effective surface tension of the catheter. In some embodiments, multi-material printing or other manufacturing methods can allow two or more materials (shown in different shades of gray) to be patterned into the same device for collecting or wicking liquids, such as Fig.19 (Views ae) are shown in the designs. In some embodiments, the catheter comprises non-swellable and swellable hydrophilic materials and non-swellable and swellable hydrophobic materials. Typically, the flange at the end of the tympanostomy catheter is primarily used to secure the catheter to the hole formed in the tympanic membrane. In addition to surface chemistry, the physical structure of the tympanostomy catheter can also be modified to combine the flange with these specific chemical components to direct the fluid flow toward the other side of the catheter. In certain embodiments, the directed flow utilizes a funnel, a flange, a flange with different chemical properties, or a flange with a gradient in surface chemical properties that moves toward the hole in the tube. In certain embodiments, such a gradient can also be included on the inner surface of the catheter, such as Fig. 20As shown. In some embodiments, the chemical pattern 2001 may include a chemical gradient, wherein the first density of the chemical substance is at the distal end 2002 of the catheter and the second density of the chemical substance is at the proximal end 2003 of the catheter to enhance the flow along the length of the catheter. In other embodiments, the chemical pattern may have a shape that enhances the flow through the catheter. For example, the width of the chemical pattern may increase from the proximal end to the distal end. A second chemical pattern may also be included, which has a change in shape, density or other parameters from the distal end 2002 to the proximal end 2003. In certain embodiments, the first chemical pattern may be hydrophobic and the second chemical pattern may be hydrophilic. In certain embodiments, the distal end 2002 is hydrophobic, while the proximal end 2003 is hydrophilic, and the transport of water from the proximal end to the distal end is enhanced. In certain embodiments, depending on the lipophilicity or surface tension of the hydrophobic proximal end, it can promote the transport of antibiotics from the distal end to the proximal end. Depending on the composition of the effusion, the flow is preferentially from the distal end to the proximal end. In other embodiments, the distal end is hydrophilic and the proximal end is hydrophobic.
[0299] Fig.19 is a schematic diagram of a chemically patterned tympanostomy catheter according to certain embodiments. In some embodiments, the chemical pattern may include a wicking layer 1901 on the inner surface of the catheter that is optimized for transport of fluids. In some embodiments, the wicking material is porous and the fluid moves through the wicking material by capillary action. Fig.19 (View a) depicts a single wicking layer. Fig.19 (View b) depicts multiple wicking layers. Fig.19 (View c) depicts a wicking flange material 1902 connected to the multiple wicking layers inside the catheter. Fig.19 (View d) depicts a wicking layer comprising a portion 1903 of a conduit, Fig.19 b (view e) depicts a wicking layer selectively placed on the inner or outer surface 1904 of the conduit. In certain embodiments, a chemical gradient may be placed on the central portion of the conduit.
[0300] Non-limiting examples of materials for the wicking layer include hydrophilic polymers or hydrogels, such as poly(ethylene glycol), poly(acrylic acid), poly(N-isopropylacrylamide) (PNIPAM), poly(vinyl pyrrolidone), poly(2-oxazoline), cellulose, or alginate. The material may also include a hydrophobic polymer, such as poly(dimethylsiloxane), polyurethane, acrylic acid, carbonate, polyester, polyether, or fluorocarbon, which may have a surface modification. The material may also be a protein, including collagen, gelatin, fibronectin, laminin, or any natural or synthetic material conjugated to RGD.
[0301] In certain embodiments, the solution includes a dual channel catheter with patterned chemistry, e.g. Fig.21A as shown, or with Fig.21B In some embodiments, each different channel is optimized with a different patterned chemical property for transporting a different fluid into or out of the ear. For example, Fig.21A As shown in (view a), the first channel 2101a has a surface chemistry and structure optimized to transport mucus out of the middle ear space 2102, while the second channel 2101b has a surface chemistry and structure optimized to transport certain antibiotic droplets into the middle ear space. In certain embodiments, these channels may or may not be combined with flanges 2104 that hold the catheters in place. In some embodiments, each catheter has its own flange, while in other embodiments, such as Fig.21A As shown in (view a), the dual channel conduit has a flange at each end. In certain embodiments, it may or may not have a conical geometry to specify flow in certain directions, such as Fig.21A (View c). The flange can also be specially designed to wick in or wick out the fluid of interest at the inlet or outlet. In addition, for example Fig.21B As shown, the catheter may include tubes 2101a-g, which may have a variety of different chemical properties to facilitate the selectively directed transport of a variety of different fluids into or outside the ear.
[0302] In certain embodiments, geometric patterns can be used for preferential flow. In certain embodiments, geometric patterns increase the advancing angle and contact angle hysteresis of the liquid entering the conduit, and in other embodiments, geometric patterns reduce the advancing angle and contact angle hysteresis of the liquid entering the conduit. In certain embodiments, geometric patterns increase the advancing angle and contact angle hysteresis of the liquid entering the conduit. In other embodiments, the pattern reduces the advancing angle and contact angle hysteresis of the liquid entering the conduit. In certain embodiments, geometric patterns can induce Casey-Baxter, Young-Laplace or Wenzel state or other intermediate states. In certain embodiments, geometric patterns are arranged on the outer surface or inner surface of the conduit. In certain embodiments, geometric patterns are produced by surface topography such as surface roughness, grooves, ridges, indentations, micro-pillars, micro-ridges, holes or other 3D mosaics.
[0303] In certain embodiments, for example, Fig. 21C As can be seen in the figure, the catheter comprises a porous material within the lumen 2105. In certain embodiments, the porous material can be an array of channels 2101a-g ( Fig. 21C A view of a) or the three-dimensional periodicity of pores with sizes from 0.01 to 1000 μm ( Fig. 21Cb) or a three-dimensional non-periodic (sponge-like) interconnected network that allows the propagation of air and fluids ( Fig. 21C c). In some embodiments, the channels are oriented parallel to the length of the channels, e.g. Fig. 21C . In some embodiments, the three-dimensional network of interconnected pores is isotropic. In other embodiments, the three-dimensional network of interconnected pores is anisotropic, so that the anisotropy allows the fluid to travel along the length of the lumen. For example, the pores can have higher connectivity on the axis along the length of the lumen. In other embodiments, the conduit can be composed of geometrically patterned channels, macroporous channels, and microporous channels.
[0304] 5. Using gravity for preferential flow
[0305] In certain embodiments, gravity plays a role in attempting to transport antibiotic droplets into the middle ear and mucus out of the ear, e.g. Fig. 22 As shown (and about Fig.18 In some embodiments, the first conduit 2201 is provided with a conical flange 2202 on the outside (external ear) 2203 of the tympanic membrane 2204, so that antibiotic droplets 2205 or other oil-based solutions or other therapeutic agents can only enter when the patient keeps the head level. In some embodiments, this design allows the droplets to enter while reducing and / or preventing the entry of ambient water in most bathing and swimming situations. At the other end, the second conduit 2206 connects the middle ear space 2207 to a hose-like structure 2208, which is drawn from the tympanic membrane to drain the effusion 2209 into the external auditory canal. In order to better remove this fluid, in some embodiments, the patient can be made to lie horizontally on their other side to promote the outflow of fluid into the middle ear space. In some embodiments, the opening or hose-like structure 2208 is bent to the side to reduce and / or prevent the re-entry or water entering the end through another conduit. In some embodiments, applying positive or negative pressure by introducing air, gas or liquid can be used to assist transportation. In certain embodiments, these designs may also have other gating mechanisms, as described below.
[0306] In certain embodiments, the Figure 1B The shape / size changes of the inner cavity can be used to achieve or enhance fluid properties, such as through muscle-like contraction / expansion of the inner cavity, or biomimetic approaches that mimic the shape-changing mechanisms of a butterfly proboscis, an insect ovipositor, or a water bird beak.
[0307] E. Tympanostomy catheter with pinning to reduce and / or prevent ingress of ambient water
[0308] In certain embodiments, the ingress of ambient water can be reduced and / or prevented by increasing the pinning area of a water droplet, e.g. Fig.23A -D. In some embodiments, the pinning site increases the surface tension at the inlet or conduit. In some embodiments, this can be achieved by creating an opening 2301 with many angles and different corners, such as a star-shaped lumen 2302 ( Fig.23A ) and / or a cage design 2306 surrounding the inner cavity ( Fig.23C ).exist Fig.23A An example of a catheter having a pinning site at the tip created by the shape of the lumen and located within this non-limiting segmented geometry is depicted in FIG. In certain embodiments, such pinning involves having small hair-like features 2303 that cover the flange and / or interior of the catheter. Ambient water droplets 2304 or oil droplets 2305 are pinned against these corners rather than traveling through the lumen into the middle ear space. Fig. 23B An example of a catheter having a pinning site created by modifying the lumen surface is depicted in . In other embodiments, a cage handle is added on the top of the catheter or within the lumen to reduce and / or prevent environmental fluids from entering the catheter. Fig.23C An example of a catheter with a pinning site formed by a cage-shaped handle on the catheter tip or in the lumen is shown in FIG. In certain embodiments, ear drops can be designed to overcome these pinning effects by using surfactants, organic solvents, or oil-based droplets. In some embodiments, surfactants, organic solvents, or oil-based droplets reduce the surface tension of the pinning site.
[0309] F. Refill and apply lubricant to the catheter
[0310] In certain embodiments, when the lubricating oil on the surface of the device is exhausted, drops of lubricant can be applied to replenish the reservoir and re-establish the antimicrobial and improved transport characteristics of the catheter. For tympanostomy catheters, replenishment can be performed, for example, by applying an ear oil-based formulation with a high or low chemical affinity for the catheter material to induce long or short life of the lubricating liquid on the catheter. The application of lubricating liquid can be directed to replenishment of a) only the outer surface or b) only the inner surface, c) only the proximal end or d) only the distal end of the catheter or e) only the flange or any combination thereof. The material of the tube can contain holes and channels that serve as a reservoir for replenishing the lubricating liquid.
[0311] In other embodiments, an excess of lubricating fluid may be applied that lubricates the flange or causes it to expand, swell, twist, roll, collapse, or cause a periodic or aperiodic array of features (wells, bumps, holes, etc.), or to achieve controlled extrusion of the tube at a desired point in time. In certain embodiments, controlled extrusion may be achieved by causing a size or shape transformation of the outer surface of the catheter or by stripping off an outer thin layer around the catheter. More details are in other parts of this disclosure.
[0312] V. Shape changes to minimize invasiveness and tissue damage
[0313] In certain embodiments, tympanic membrane puncture catheter and / or conduit under the ring can be designed to be minimally invasive and avoid tissue damage. Although the following description includes some embodiments related to tympanic membrane puncture catheter and / or ventilation conduit under the ring, these designs can also be used for other medical or non-medical applications, such as microfluids, films, bioreactors, by mechanical transport coolants and other chemicals, discharge reaction waste, sensors, printing nozzles, food and beverage industry, cosmetics and perfume and other applications. Non-invasive design can also be for example combined with anti-fouling, guided fluid transport, therapeutic delivery and other aspects that run through the present disclosure description. In certain embodiments, conduit comprises shape change or stimulus response portion, which promotes insertion, extrusion, guided transport or therapeutic delivery.
[0314] In certain embodiments, the shape-changing material changes its shape and / or size in response to one or more stimuli (effects of light, temperature, pressure, electric or magnetic fields, or chemical stimuli) influenced by an external source. In certain embodiments, the chemical stimuli are cross-linking agents or swelling agents. In certain embodiments, the swelling agent is a lubricating fluid. In certain embodiments, the catheter has a first configuration prior to exposure to the stimulus and has a second configuration after exposure to the stimulus.
[0315] A. Tympanostomy catheter with shape-changing features
[0316] In certain embodiments, the shape / size change feature can facilitate ease of insertion of the tube into the eardrum and exhibit better post-insertion performance. In certain embodiments, this shape change and size change during the shape change can be used to make a smaller or otherwise differently sized catheter that reaches its desired size after soaking, such as Fig.24A This method can be used to achieve shapes and sizes that would otherwise be difficult or more expensive to manufacture. In certain embodiments, such as Fig.24A As shown in (view a), the conduit has a first region 2401 with low cross-link density and a second region 2402 with high cross-link density. This embodiment may also be useful for designing a shape that is small enough in the first configuration to be easily inserted into a small perforation 2403 (e.g., in the tympanic membrane 2404) in the tympanic membrane 2404. Fig.24A (view b)), but once a droplet of a liquid of interest 2406 (e.g., oil) is placed on the inserted catheter (e.g., Fig.24A (view c)), which may be expanded in a second configuration or have a flange 2405 to better secure it in place ( Fig.24A, view d). In certain embodiments, the shape / size changing feature may be achieved by tube expansion and vibration or other stimulation.
[0317] Fig.24A The invention shows how the size of the catheter can be reduced prior to insertion to minimize invasiveness during a myringotomy according to certain embodiments. In certain embodiments, the shape of the catheter presented is oval to match the elongated shape of the incision. Additional embodiments of the size-increasing shape-changing catheter are shown, for example, in Fig. 27 and 31 Shown in.
[0318] Fig. 24B Shown in certain embodiments, as an example, how medical grade silicone MED 4960D undergoes an increase in radial dimension after swelling in medical grade silicone oils with various viscosities (50, 100 and 350 cP) at 85°C. The degree of swelling can be adjusted by varying the silicone oil properties to achieve a dimensional change ranging from 0% to 20%, and typically from 0% to 500%. The swelling ratio can be further adjusted by varying the combination of tube matrix material, crosslink density, porosity, layer structure and swelling agent.
[0319] exist Figures 25A-25C The mechanical integrity was analyzed in . The compression tests were performed on an electromechanical universal test system with a 10N load cell. The applied load was measured during compression extension at a rate of 0.5mm / min. The compressive load was measured by a uniaxial compression tester, whereby the sample is placed between two flat plates, where the upper point moves towards the lower plate at a fixed rate. Fig.25A Compression of silicone tubing 2501 under applied load is shown. The compressive load is applied by a uniaxial test apparatus 2502. Fig.25B The plots are shown along two axes (along the lumen ( Fig.25B a) and across the lumen ( Fig.25B b) compression) of the "test" tube. Along the lumen, both the unperfused and perfused "test" tubes deformed similarly, requiring significantly less force to achieve the same amount of compression. Across the lumen, the perfused "test" tube showed a measurable reduction in stiffness, demonstrating greater compressibility that can facilitate implantation and handling by surgeons. Fig.25CThe elasticity and fatigue resistance of the silicone tympanic myringotomy tube are shown along two axes. The "test" tube filled with oil maintained enhanced flexibility and compressibility over multiple loading cycles. In the embodiments described elsewhere in this disclosure, in certain embodiments, it is also desirable to increase the compressibility of the catheter to facilitate better handling by medical professionals during implantation and removal. This can be achieved by designing the shape or thickness of the catheter, selecting materials, increasing porosity or changes in cross-link density, incorporating multi-material designs, inlays or hardening of the overall geometry, or coatings.
[0320] According to certain embodiments, the shape-changing behavior of the described material can be implemented into the commercial software ABAQUS / Standard through a user-defined material subroutine and used to solve the inverse problem, that is, to study the complete deformation response of the final 3D tube so as to inversely calculate the original shape / size of the manufactured tube that will undergo shape transformation. According to certain embodiments, this will enable a customized method to develop customized manufacturing of the tube. In some embodiments, the tube can be exposed to a customized shape-changing agent for a variety of desired medical indications. In order to simulate the mechanical deformation of the tube during expansion, a finite element analysis (FEA) model of the expansion geometry was created using the commercial ABAQUS / Standard software. The FEA model is created by taking the final desired geometry as input and solving the inverse expansion problem to obtain the manufacturing geometry required to achieve the final geometry. The FEA model takes into account the anisotropic expansion that changes linearly in the radial direction. A linear elastic material model is used for simulation, and tension is applied by a uniform expansion coefficient. The model is subdivided radially into various concentric cuts with different expansion coefficients (which are fitted to data empirically measured from the experimental process). Considering the axisymmetric nature of the problem, the final output of the numerical model provides a cross-sectional description of the geometry, which can subsequently be used for fabrication prior to the expansion operation. Fig.26 The expansion stress of the catheter is shown before expansion 2601 and after expansion 2602. According to certain embodiments, Fig.26 (View a) and Fig.26 (View b) shows a cylindrical conduit geometry and a curved conduit geometry, respectively.
[0321] In some embodiments, the tympanostomy catheter is made of a programmable material that can change shape and size as needed. The shape-changing property is particularly advantageous for the intelligent design of the flange (to minimize the invasiveness of the catheter before and after the myringotomy). Shape-changing materials change their shape and / or size in response to one or more stimuli (light, temperature, pressure, action of electric or magnetic fields, or chemical stimuli) through external influences. Among these materials, some change their shape without changing their size, while other materials retain their shape but change their size. Some also change both parameters simultaneously. The shape change can occur to equal or unequal degrees in all dimensions. In some embodiments, the shape-changing material can have thermostrictive, piezoelectric, electroactive, chemostrictive, magnetostrictive, photostrictive, or pH-sensitive properties. In Fig.42 An embodiment of a shape-changing ear catheter is shown in , which depicts regions of material having high and low crosslink densities that change shape when introduced into an incision in the eardrum. In this example, the shape change is caused by the low crosslink density material absorbing a liquid (e.g., oil). In this example, when stimulated, the radius of the catheter increases. In an alternative embodiment, as Fig. 27 As shown, the catheter can have a uniform cross-linking density, and the catheter can expand uniformly. In some embodiments, as Fig.28 (View d) shows that the conduit changes from a cylindrical shape to a conical shape (or other shapes in other embodiments), thereby forming a flange. In certain embodiments, the amount of expansion along the length of the conduit can be controlled by controlling the cross-link density along the length of the conduit. Fig.28 , 29 Other examples of shape changing flange and conduit structures are shown in 30A-B.
[0322] Fig.28 28 is a schematic diagram of several exemplary shape-changing tympanic membrane puncture catheters having flanges 2801 that change shape or size when exposed to a stimulus. In certain embodiments, the flange expands in size ( Fig.28 a), expands in size and changes shape ( Fig.29 b), expand ( Fig.28 c) or changing the shape to allow fluid transport through a funnel structure or other flow-directed design ( Fig.28 d) in the Fig.28 In the embodiment shown in (view a), the flange 2801 can be radially expanded into a disc shape. Fig.28In the embodiment shown in (view b), flange 2801 can expand radially into a conical or curved shape. In certain embodiments, if the density of crosslinks varies along the length of the flange, a conical shape can be formed when the flange is exposed to a stimulus. For example, if the density at the proximal end of flange 2802 is less than the density at the distal end of flange 2803, the proximal end can have a larger diameter. Fig.28 In the embodiment shown in A (view c), flange 2801 can be expanded. In some embodiments, the flange can be expanded if the cross-link density varies throughout the thickness of the catheter wall. For example, if the cross-link density of the inner surface of flange 2804 is less than the cross-link density of the outer surface of flange 2805, the inner surface will expand more when exposed to a stimulus, thereby causing curling or stretching out from the flange. In addition, in some embodiments, if the cross-link density of the inner surface of flange 2804 is less than the cross-link density of the outer surface of flange 2805, the inner surface will expand more when exposed to a stimulus, thereby causing curling or stretching out from the flange. Fig.28 As shown in (view d), the cylindrical tube may have two tapered flanges 2810 that form at opposite ends when exposed to one or more stimuli.
[0323] In certain embodiments, such as Fig.29 As shown, the tympanic membrane puncture catheter comprises a double-layer structure that causes shape change. In this embodiment, the catheter is formed of two materials with different expansion properties (e.g., different cross-linking densities). The two layers of the catheter can expand at different rates, thereby causing the shape change. In certain embodiments, such as Fig.29 As shown, if the material of the inner surface 2901 has a lower cross-linking density than the material of the outer surface 2902, the wall of the conduit will bend inward. In other embodiments, if the material of the inner surface 2901 has a higher cross-linking density than the material of the outer surface 2902, the wall of the conduit will bend outward.
[0324] In some embodiments, as shown in FIG. 30 AB, the deformable flange 3001 expands when expanded to clamp the two sides of the tympanic membrane ( Fig. 30A ), or lock onto the middle ear cavity when expanded ( Fig. 30B ). In certain embodiments, Fig. 30A As shown, the catheter can have stimulus-responsive materials at the proximal and distal ends of the catheter. In this embodiment, the stimulus-responsive material expands radially when exposed to a stimulus to form distal and proximal flanges that sandwich the tympanic membrane. In certain embodiments, such as Fig. 30B As shown, a deformable flange retainer 3002 can be used to retain the pivoting flange 3001 that locks the tube in place. In this embodiment, the flange retainer 3002 is like a cover for the flange 3001. In some embodiments, the retainer can be biodegradable, or can be actuated by external stimuli to separate from the flange 3001. In some embodiments, the retainer contains a therapeutic agent to be delivered to the middle ear. In some embodiments, the retainer 3002 can be shaped to be easily inserted.
[0325] In certain embodiments, the catheter design mimics an expandable stent structure with or without a delivery balloon. For example, Fig.31 Depicts a stent-like design of a catheter that expands to form a larger structure when it changes shape. In certain embodiments, such as Fig.31 As shown in and as described above, the shape change can include local changes, such as creating a flange on one or more ends of the tube that was not present prior to the shape change. In some embodiments, a stent-like design includes a shape memory material that expands when inserted into the tympanic membrane. In some embodiments, additional shape-constant material 3201 is incorporated into the catheter to facilitate insertion of the catheter into the tympanic membrane (see Fig.32 In some embodiments, the shape-constant material forms a protrusion on the distal end of the catheter, such as Fig.32 In some embodiments, the protrusion allows the catheter to be attached to a surgical tool. Upon insertion, the expandable material 3202 can expand while the shape-constant material 3201 maintains its shape and size.
[0326] In certain embodiments, the change in geometry occurs in the conduit or flange to cause a transient reconfiguration that improves or reduces or redirects or prevents fluid transport, as described in the previous section. In other embodiments, the dynamic structural or chemical changes can be used for extrusion, targeted delivery or other guided fluid transport purposes.
[0327] B. Insertion mechanism for inducing shape change
[0328] In certain embodiments, the insertion mechanism for the catheter comprises two stages. Fig.33 An example of a two-stage insertion mechanism is shown in . For example, the two steps include: (1) inserting an initially small catheter or tube 3301 for minimal invasiveness through a first compartment 3302 of a two-in-one tip system attached to a catheter inserter, and (2) adding a lubricant to the catheter through a second compartment 3303 of a two-in-one tip system attached to a catheter inserter to cause anti-fouling, guided transport and shape change of the catheter. In some embodiments, the second compartment may include a reservoir 3304 for filling the catheter with lubricating fluid after insertion, wherein the tip is configured to be attached to a special myringotomy tool. In some embodiments, an unfilled catheter is inserted into the tympanic membrane and filled through the reservoir after insertion. In other embodiments, similar designs can be introduced for other shape-changing stimuli (effects of light, temperature, pressure, electric or magnetic fields or chemical stimulants). In any previous and subsequent embodiments, the form of the catheter is a flat, curved, round, tubular, sharp, meshed or rough surface of a catheter, catheter, cable or wire.
[0329] C. Tympanostomy catheter with anisotropic mechanical properties
[0330] For example, Fig.34 As shown, the tympanic membrane has a circular / radial fibrous collagen structure in the lamina propria, which is important for allowing sound conduction to the ossicular chain at low and high frequencies. In some embodiments, the conduit 3401 includes a flange 3402 with radial stiffness, which matches the portion of the tympanic membrane 3403 that is perforated to allow more efficient sound conduction. In some embodiments, stiffness is imparted by additional stiffening fibers 3404 that point in the desired direction that matches the directional fibers in the tympanic membrane (i.e., along the tense part 3405) or by using a mechanically anisotropic material or composite material. Non-limiting examples of fibrous collagen, polyurethane, silicone, polyester, polycarbonate or polyether. In some embodiments, the flange can be made of a non-biodegradable material and can be removed by the conduit, while in other embodiments, the flange can be made of a biodegradable material that is incorporated into the tympanic membrane and encourages cells to reshape it into tissue with a similar structure to repair perforations or incisions 3406. Fig.34 An example of a tympanostomy catheter having a flange stiffness that matches the portion of the tympanic membrane in which it is placed is shown.
[0331] D. Tympanostomy catheter with controlled extrusion
[0332] Grommet-type tympanostomy tubes tend to extrude between 9 and 18 months after insertion. Tympanic membrane epithelial migration can produce a more or less orderly sequence of events, including 1) accumulation of squamous debris under the outer tube flange, 2) elevation and rotation of the tube, 3) extrusion of the inner flange, 4) closure of the tympanic membrane perforation, and 5) outward migration of the tube with cerumen. In approximately 20% of children, this does not occur. Some tubes remain in place despite years of accumulation of surrounding squamous debris. Tubes that can remain in place may result in persistent conductive hearing loss, infection, or tympanic membrane perforation. In addition, tubes that remain in place in children may result in the need to return to the operating room for removal, increasing the risks associated with general anesthesia.
[0333] In certain embodiments, such as Fig.45A -C, stimulus responsive or shape changing materials can enable controlled extrusion of tubes. In some embodiments, solutions can use excess lubricant or liquid or stimulus (temperature, pH, light, electric and magnetic fields, expansion, deswelling, etc.) that smooths the flange or causes the flange to twist, roll, collapse, or cause an array of periodic or non-periodic features (wells, bumps, holes, etc.) to achieve controlled extrusion of tube 4501 from membrane 4502 at a desired time point, such as Fig.45A -C. In certain embodiments, Fig.45AAs shown, stimulation 4503 causes flange 4504 on the middle ear 4505 side to collapse to enable controlled extrusion and removal through the external ear 4506. In some embodiments, controlled extrusion is achieved by causing a size or shape change in the outer surface of the catheter or peeling / dissolving an outer thin layer 4507 around the catheter, such as Fig.45B In such an embodiment, the outer surface of the catheter can be coated with a thin layer of stimulus-responsive material that separates from the outer surface of the catheter by dissolving or peeling off in response to an external stimulus. In this embodiment, when the layer separates from the outer surface, a gap is retained between the outer surface of the catheter and the tympanic membrane, enabling controlled extrusion.
[0334] In some embodiments, an actuator 4508 formed of a shape-changing material may also be placed on the outer surface of the catheter for built-in control of the extrusion of the catheter from the tympanic membrane by external stimulation. For example, the actuator may expand or contract, or undergo another type of size / shape and / or chemical transformation to cause extrusion from the membrane, such as Fig.45C As shown. Fig.45C In the illustrated embodiment, the actuator expands when stimulated, pushing outward from the tympanic membrane to form a gap between the outer surface and the tympanic membrane, thereby achieving controlled extrusion.
[0335] In some embodiments, passive extrusion may occur, whereby the grommet extrudes after deswelling of one or more components on the device. This mechanism may control extrusion by interrupting the application of a lubricant or other liquid. As the lubricant or other liquid seeps from the device into the surrounding material and tissue, the expanded components may gradually deswell until the device is loosened from the hole in which the catheter is placed, allowing it to fall out or be easily removed. To speed up this process, another liquid may be placed on the tube that displaces the original lubricant and quickly evaporates or leaves the tube, allowing the material to deswell. In this way, the patient or provider will be able to control the extrusion time by controlling the gradual or controlled deswelling of the implant.
[0336] E. Tympanostomy catheter with sensing component
[0337] In certain embodiments, such as Figures 35A-35B As shown, relevant body biomarkers including at least one of temperature, humidity level, pH, pressure difference, osmotic pressure, drug concentration, surfactant, fluid viscosity, etc. can be introduced into the catheter 3501 through built-in antennas and sensors. Fig.35A An example of a catheter with an adjustable printed antenna 3502 for sensing temperature, pH, and pressure changes is depicted. In this embodiment, the wires can be printed onto the catheter by photolithography. Fig.35BAn example of a catheter with a built-in sensor 3503 is depicted for monitoring changes, including, for example, temperature, pH, and / or pressure changes, in the middle ear 3504 and / or the outer ear 3505. In some embodiments, the tympanostomy catheter changes color upon exposure to certain stimuli, and the catheter has a colorimetric indicator based on an acid-chromogenic, chromogenic photonic crystal material. Fig.36 Depicted is a tympanostomy catheter that changes from a first color 3601 to a second color 3602 when exposed to certain stimuli. In some embodiments, the catheter changes color when exposed to a biomarker or infectious agent. In certain embodiments, the color change may indicate that the patient should apply a topical antibiotic. In certain embodiments, the catheter may change color to indicate an improvement in the patient's condition through normal levels of a biomarker to justify removal of the catheter.
[0338] In certain embodiments, the catheter with antenna collects data from the patient, tracking at least one of various relevant body biomarkers: temperature, humidity level, osmotic pressure, pH, pressure differential, drug concentration, surfactant, viscosity of fluid, etc. This will allow remote monitoring of the child's condition and transport of the results to a computer or mobile device or wearable health tracking device. In some embodiments, the catheter can do so via antenna 3502 and / or sensor 3503.
[0339] In certain embodiments, such as Fig.37 As shown, the catheter is capable of molecular detection of relevant biomarkers 3701 to monitor diseases (mucus, effusions, cytokines, bacterial endotoxins and exotoxins, eosinophil cationic proteins, antibodies, aptamers, nanoparticles, lipases, esterases, proteases, growth factors, histamine, hormones, apoptotic cells, cytoplasm of macrophages or other immune cells, blood or external pollutants such as diesel exhaust particles and other air pollutants. These biomarkers can be captured on the surface of the catheter or in the matrix of the catheter by capture elements 3702 for further release on demand. In certain embodiments, the biomarkers can be captured or immobilized on the surface or within the matrix based on the specific interaction between the capture element and the biomarker. When exposed to a stimulus, the capture element can release the biomarker, for example due to a conformational change or a disruption of the interaction between the biomarker and the capture element. In certain embodiments, the capture element is activated by antibodies, aptamers, nanoparticles, lipases, esterases, proteases, growth factors, histamine, hormones, apoptotic cells, cytoplasm of macrophages or other immune cells, blood, pH, salt levels, temperature.
[0340] In certain embodiments, the catheter undergoes shape and chemical transformations enabled on demand for temporary point-of-care applications, where local or "global" transformations occur for a limited or unlimited amount of time for enhancing, reducing, redirecting, or preventing fluid transport (e.g., for drug delivery and protecting the middle and / or inner ear from external conditions) or for controlled extrusion purposes. Although the description below and above includes certain embodiments involving tympanostomy catheters and / or subannular ventilation catheters, these designs can also be used in other medical or non-medical applications, such as microfluidic devices, membranes, bioreactors, nozzles, transport of coolants and other chemicals by machinery, discharge of reaction waste, sensors, food and beverage industry, cosmetics and perfumes, and other applications, porous networks, conjugated particles, nanotextured surfaces, or enzymes.
[0341] VI. Tympanostomy catheters as medical devices for effective therapeutic delivery for the treatment of ear diseases
[0342] In certain embodiments, the catheter provides a solution for treating many middle and inner ear diseases and disorders. In certain embodiments, the catheter is specifically designed to enable effective "first-in-class" drug delivery, thereby reducing treatment time and morbidity, as well as the direct and indirect costs associated with failed treatments.
[0343] A. Tympanostomy catheter to introduce therapeutic agents into the middle ear
[0344] Many ear diseases (including bacterial infections, sensorineural hearing loss and Meniere's disease) can be treated with local therapeutic agents. The characteristic of local delivery systems is that there is no systemic effect, which is advantageous if systemic effect is not required. For example, systemic administration of antibiotics for otitis media can lead to Clostridium difficile (C.diff) infection and antibiotic-resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA). Systemic steroids for sensorineural hearing loss have many significant side effects, including avascular necrosis and psychosis from anxiety and reflux to hip joints. Systemic reactions to local antibiotics and steroids are extremely rare. In addition, the use of topical agents allows for simultaneous modification of the local microenvironment. For example, the pH of the external auditory canal is generally weakly acidic. Applying antibiotics with acidic drops helps to restore and strengthen this normal host defense mechanism. Otological drugs are usually cheaper than systemic drugs.
[0345] Another example of an ear disease that can benefit from topical drug administration is Meniere's disease, which is treated with gentamicin and steroids. For example, gentamicin and / or steroids can be injected through the eardrum into the tympanic membrane or middle ear. This can be done with a minor surgical procedure performed in the office. Gentamicin is used in patients to stop vertigo attacks. This is a drug that is toxic to the inner ear but more toxic to the vestibular cells than the hearing cells of the inner ear. This can allow for the elimination of enough vestibular cells to stop vertigo attacks without noticeably changing hearing.
[0346] The need for repeated surgeries can be reduced by placing a tympanostomy catheter of a certain design for short-term or long-term use. In fact, alternatively, in some patients, a tympanostomy catheter placed on the tympanic membrane can replace intratympanic injection, and the drug can be injected through the catheter or the patient can use drops for self-treatment at home. Many therapeutic agents can be more effectively delivered through the catheter disclosed herein, and non-limiting examples include: antibiotics, antiseptics, antivirals, anti-inflammatory agents, small molecules, immunosuppressants, nanoparticles, genetic therapies including viral-based and lipid-based therapies, chemotherapy, stem cells, cell therapy agents, growth factors, proteins, radioactive substances, or other liquid-based and gas-based drug compounds.
[0347] In some embodiments, the catheter comprises a single-channel, dual-channel, or multi-channel catheter with patterned chemistry and texture, as described elsewhere in this disclosure. In certain embodiments, the different channels of the catheter are optimized for delivery of topical drugs to the middle ear (e.g., Fig.21B In some embodiments, these channels are combined with or without flanges, and in some embodiments, can have a conical geometry to specify the flow rate into the middle ear. The flanges can also be specially designed to wick the ear drops into the tympanic membrane.
[0348] In certain embodiments, the catheter comprises a porous material in the lumen that exhibits a) a channel array or a three-dimensional b) periodic or a) aperiodic (sponge-like) interconnected network of pores ranging in size from 0.01 to 1000 μm, wherein specific chemical modification of the pores allows for selective therapeutic delivery into the tympanic membrane. Tailored surface functionality may include: perfluorooctyltrichlorosilane triethoxysilylbutyraldehyde, bis(2-hydroxyethyl)-3-aminopropyltriethoxysilane, 3-chloropropyltriethoxysilane, 3-(trihydroxysilyl)-1-propanesulfonic acid, n-(triethoxysilylpropyl)-α-polyethylene oxide urethane, n-(trimethoxysilylpropyl)ethylenediaminetriacetic acid, n-octyltriethoxysilane, n-octadecyltriethoxysilane, (3-trimethoxysilylpropyl)diethylenetriamine, methyltriethoxysilane, hexyltrimethoxysilane, 3-aminopropyltriethoxysilane, hexadecyltriethoxysilane 3-mercaptopropyltrimethoxysilane, dodecyltriethoxysilane; or chiral functionality such as N-(3-triethoxysilylpropyl)glucamide or (R)-N-triethoxysilylpropyl-O-quinuclidine urethane).
[0349] In some embodiments, as shown in FIG38 , a programmable catheter is inserted into the tympanic membrane 3801. In some embodiments, a small incision 3802 is formed in the tympanic membrane by a surgical tool 3803. A deactivated tube 3804 having a small size can be inserted into the incision. The deactivated tube can be closed so that fluid cannot pass through the lumen of the deactivated tube. In response to a stimulus 3805, the tube can be transformed into an activated tube 3806 so that fluid can pass through the lumen of the tube. In some embodiments, the catheters are dynamic and / or programmable so that they can be reversibly actuated as needed to facilitate the expansion of the catheter radius ( Fig.38B a) and / or changes in texture, surface chemistry, microstructuring and macrostructuring of stimuli-responsive ciliary and hair-like fibers 3807, lamellae, columns and other structures on the inner side of the wall 3808 of the conduit (e.g. Fig.38B b) to temporarily or permanently open the lumen for delivery to the middle ear. For example, the cilia can retract to open the lumen and allow fluid to pass through the lumen. In some embodiments, the wall of the lumen can be coated with a material 3809 ( Fig.38B c). In certain embodiments, the texture 3810 of the wall of the tube can change in response to a stimulus that opens the lumen. In this embodiment, when the tube is first inserted, fluid cannot pass through the lumen, but is able to pass through the lumen after the texture changes. Non-limiting examples of texture changes include increased roughness, decreased roughness, formation of grooves, formation of raised structures, formation of recessed structures, textures due to texture additives such as micron-sized particles (in the range of 1 to 1000 μm).
[0350] In some embodiments, the surface chemistry 3811 of the wall can change in response to a stimulus to open the lumen. In this embodiment, when the tube is first inserted, fluid cannot pass through the lumen, but can pass through the lumen after the surface chemistry is changed. Non-limiting examples of surface chemistry changes include hydrophobicity, hydrophilicity, superphobicity, or peptide or polymer conjugation. In some embodiments, such as Fig.38C (view c), the lumen may contain a material having pores 3812 that are closed when the tube is inserted. The pores may open in response to stimulus 3805. The porous material within the lumen is described with reference to FIG. 21. In these embodiments, the catheter is placed into the tympanic membrane in a closed, deactivated state and activated on demand by one or more stimuli (light, temperature, pressure, electric or magnetic fields or chemical stimuli, pH, light, expansion, deswelling, humidity, electron transfer, or other) for drug delivery or other related medical treatments (e.g., Figures 38B-38C shown).
[0351] In certain embodiments, the stimulus responsive material can have thermostrictive, piezoelectric, electroactive, chemostrictive, magnetostrictive, photosensitive and photostrictive or pH sensitive properties. These materials can utilize light-driven therapeutic cargo control, where ultraviolet light triggers the cargo to flow through the catheter. In certain embodiments, the material can utilize controlled conductance. In certain embodiments, the top layer of the liquid medium is conductive, or the liquid medium has a solid conductive confining surface on top of the device. In other embodiments, the tip of the microstructure is also modified with a conductive material. In certain embodiments using conductance, the conductance of the surface or the entire system can be controlled by chemically induced mechanical actuation of the microstructure.
[0352] In certain embodiments, as described in U.S. Pat. No. 9,651,548, "Self-regulating chemo-mechano-chemical systems," issued May 16, 2017, which is incorporated herein by reference, a self-regulating, adaptively reconfigurable, tunable nano- or microstructure with a tip having appropriate functionalization (chemically or physically) embedded in a hydrogel. The dynamic system incorporates the motion of a "skeletal" high aspect ratio microstructure (rods, sheets, etc.) through a polymeric "muscle" provided by the expansion / contraction capabilities of the hydrogel in which the microstructure is embedded. In certain embodiments, the layers are arranged vertically, one stacked on top of the other. In certain embodiments, the system can also be designed to be horizontal, with the two layers placed side by side.
[0353] B. Tympanostomy catheter with vascular network for drug delivery to the surface of the tympanic membrane
[0354] OM can present itself as an infection within the middle ear space due to fluid accumulation or as an infection on the tympanic membrane itself. Fig.39 As shown, the tympanostomy catheter allows for preferential delivery of the drug to the surface of the tympanic membrane 3901 or the middle ear space, depending on the droplet 3902 used. For example, in certain embodiments, the tympanostomy catheter 3903 incorporates a vascular network 3904 within its wall (see, e.g., Fig.39 ), such as from short-acting porogens or patterned channels, which allow antibiotic droplets to travel throughout the vascular network due to capillary forces, thereby landing on the surface of the tympanic membrane. In some embodiments, the droplets diffuse out of the vascular network and onto the tympanic membrane. In some embodiments, the droplets are designed to match the material properties of the tympanic membrane puncture catheter to allow better adhesion. For example, in some embodiments, the liquid-perfused tympanic membrane puncture catheter has droplets encapsulated in the same liquid (e.g., oil). In some embodiments, it is desired that the droplets enter the middle ear space rather than the surface of the tympanic membrane, and the droplets are made of different liquids that are difficult to enter these channels, such as aqueous solutions filled with surfactants. In other embodiments, the droplets are encapsulated in microparticles that cannot fit into these microchannels and therefore can only travel through the main inner cavity in the center. In some embodiments, these microparticles can be made of any biodegradable polymer.
[0355] Many therapeutic agents can be effectively delivered through the vascular network, including but not limited to antibiotics, antiseptics, antivirals, anti-inflammatory agents, small molecules, immunological drugs, nanoparticles, genetic therapies including viral-based and lipid-based therapies, chemotherapy, stem cells, cell therapeutics, growth factors, proteins, radioactive materials, and other liquid- and gas-based pharmaceutical compounds.
[0356] C. Drug Delivery Through Lubricant Overlay
[0357] Certain embodiments relate to a medical device for delivering a therapeutic agent to a patient's body tissue, and methods of using such medical devices. For example, in some embodiments, a drug eluting tube incorporates a surface of a synthetic slippery perfusion lubricant for repelling fluids of biological origin while allowing effective release of the drug from the tube. In certain embodiments, the drug contained in the drug eluting tube disclosed herein can be incorporated into a solid matrix or other liquid-like matrix that supports the trapped liquid and then diffuses through the lubricating layer to the surrounding tissue over time, or the drug can be incorporated into the lubricating layer and then diffuses to the surrounding tissue. According to certain embodiments, the drug can be incorporated into the solid matrix and the lubricating layer. In certain embodiments, the drugs used in these applications can be very hydrophobic or hydrophilic and may be difficult to dissolve in the lubricating layer. Therefore, even if the drug can be introduced into the underlying solid substrate, the drug cannot diffuse through the lubricating layer and will remain trapped. The lubricant that can be used in embodiments related to delivery through a lubricant overlay should allow for a sufficiently low surface energy while allowing effective release of the drug from the tube. Non-limiting examples of entrapped liquids include oils, hydrogels, organogels, or reconfigurable molecules with long chains that are highly flexible, such as long polydimethylsiloxane polymers or other types of polymers and copolymers, including random or block silicone copolymers with other siloxane co-monomers characterized by alkyl, aryl, aralkyl substituents on the silicon atoms that can be grafted to the solid surface.
[0358] A range of surface structures with different feature sizes and porosities can be used. The feature size can range from tens of nanometers to micrometers (e.g., 10 to 1000 nm) and have an aspect ratio of about 1: 1 to 10: 1. In certain embodiments, the surface has a large surface area that is easily wetted by the lubricating fluid and carries the lubricating fluid and holds it on the substrate surface.
[0359] In certain embodiments, more than one drug or bioactive ingredient may be used according to certain aspects. The compound may be released from the lubricating layer by diffusion, degradation, or other mechanisms or combinations of mechanisms that provide the desired release characteristics. Other suitable drugs, therapeutic materials, etc. for inclusion in the stent are disclosed in U.S. Pat. No. 8,147,539 to McMorrow et al., issued April 3, 2012, the contents of which are incorporated herein by reference.
[0360] In certain embodiments, the drug can be incorporated into a lubricating layer, a solid matrix supporting the trapped liquid, or any combination thereof. According to certain embodiments, the drug eluting stent can be prepared by mixing the drug with a polymer melt and then casting the melt to form a stent. In certain embodiments, the drug can also be encapsulated in particles or micelles and then dispersed in oil. The example of such a dispersion of the encapsulated drug includes forming a complex with cyclodextrin and oil to produce these particles. In certain embodiments, the drug can also be encapsulated in a carrier made of lipid molecules, block copolymers, or both. In certain embodiments, the drug can also be encapsulated in a particle carrier made of lipid molecules, polymers, or combinations, or both, and these particles can be added to the drug suspension applied to the outer chamber of the tube.
[0361] The following examples further describe and demonstrate embodiments within the scope of the present invention. These examples are given for illustrative purposes only and should not be construed as limitations of the present invention, as many changes can be made without departing from the spirit and scope of the present invention.
[0362] In certain embodiments, the release of the drug is moderate, and the release profile can be adjusted by reducing the drug load in the lubricating layer and adjusting the thickness of the lubricating layer. If it is desired to release the drug slowly over a period of several months, one possibility is to load the underlying substrate with the drug and allow the drug to diffuse slowly through the lubricating layer over time. In a non-limiting example, the drug is paclitaxel and the lubricating layer is castor oil. If the lubricating layer is depleted over time, the drug may also be released from the substrate of the catheter after such depletion occurs. Many parameters can be adjusted to obtain the desired release profile. For example, the following parameters can be considered to generate a certain drug release profile: oil layer thickness, oil layer viscosity, drug concentration in the oil layer, surface area of the tube coated with the oil layer, drug concentration in the porous matrix / substrate, and the material used for the porous matrix / substrate.
[0363] D. Tympanostomy catheter for delivering drugs to the inner ear
[0364] The cochlear window (RW) and the oval window (OW) are two openings from the middle ear into the inner ear including the cochlea. The cochlear window membrane (RWM) and the oval window membrane (OWM) vibrate with the sound energy transmitted from the tympanic membrane to the ossicles, thereby allowing the mechanical energy to be converted into the nerve potential at the level of hair cells in the inner ear. Considering the anatomical position, the RWM can be a site for drug delivery to the inner ear. The RWM can be used as a site for cochlear implantation. The RWM can serve as a barrier for middle ear ototoxins and participate in the secretion and absorption of substances. Animal experiments show that the behavior of the RWM is similar to a semipermeable membrane. Many low-molecular-weight and high-molecular-weight substances have been shown to pass through the RWM when placed in the cochlear window niche. These substances include sodium ions, antibiotics, preservatives, arachidonic acid metabolites, local anesthetics, toxins and albumin. The permeability of the RWM may be affected by factors such as the size, configuration, concentration, fat solubility and charge of the substance and the thickness and condition of the RWM.
[0365] Fig.40 An embodiment of the present invention is shown in which a catheter 4001 is placed into the middle ear 4003 through an opening in the tympanic membrane 4002 and extends across the middle ear to the surface of the cochlear window 4004. Since the cochlear window is generally impermeable to most small molecules and growth factors that can be used as therapeutic agents in hair cell regeneration, these molecules can be transferred by a carrier solution according to certain embodiments. In certain embodiments, a tube can be placed near the entrance of the semicircle for delivering therapeutic agents to assist in balance disorders. In certain embodiments, the tube can be designed so that the perilymph or endolymph of the inner ear cannot leave, while a drug solution can enter the tube. In certain embodiments, the tube can be designed so that the perilymph or endolymph can leave above a certain pressure value, thereby allowing pressure equalization in the cochlea and preventing overpressure after drug delivery.
[0366] In some embodiments, the distal end 4005 of the catheter can be placed adjacent to tissue (chemically attached to the tissue via an adhesive), or mechanically attached to the tissue via a mechanism including at least one hook, macroneedle, or microneedle 4006 to enable drug delivery into the inner ear through the cochlear window. Fig.40As shown, this mechanism can be made up of biodegradable and / or non-biodegradable materials. According to certain embodiments, these mechanisms can be used for anchoring the distal end of the implant in a suitable position or guiding the therapeutic agent to the region of interest by capillary action, diffusion or the pressure applied outside the proximal end of the conduit. The design can be used for delivering therapeutic agents, such as steroids, antibiotics, antivirals, growth factors, small molecules, proteins, gene therapy agents, chemotherapeutic agents, radioactive substances, nanoparticles, cell therapy agents. In certain embodiments, the design can deliver growth factors to restore the function in the cochlear hair cells to restore the hearing of the patient suffering from hearing loss. In certain embodiments, the distal end of the conduit is attached to the oval window 4007 or other components of the cochlea, the semicircular canals of the vestibular system or blood or its vicinity. In other embodiments, the distal end of the conduit is placed in the middle ear space to deliver the therapeutic agent through the tympanic membrane. According to certain embodiments, therapeutic delivery can be facilitated by (i) solid microneedles for skin pretreatment to increase skin permeability, (ii) microneedles coated with a drug that dissolves in the skin, (iii) polymer microneedles that encapsulate the drug and completely dissolve in the skin, and / or (iv) hollow microneedles for infusing the drug into the skin.
[0367] In certain embodiments, the interaction of the administered drug-containing solution with the lubricating layer or the physical structure of the implant can cause a physically or chemically induced phase change of the solution. In some embodiments, a mechanism can be used to increase the viscosity of the solution to retain it within the middle ear space. Non-limiting examples of such mechanisms include bubbling, gelling, or increased cross-linking. These mechanisms can be used to prevent the solution from leaking through the Eustachian tube or out of the tympanostomy tube after passing through the tympanic membrane.
[0368] In certain embodiments, the inner cavity may contain a porous network that introduces a phase into the liquid to produce a foamed composition in a physically induced phase change. In other embodiments, surface properties on the inner cavity surface may cause turbulent mixing of the solution with air to produce a foamed composition. Surfactants may be incorporated into the applied solution or lubricant coating to assist in stabilizing the bubbles in these foams.
[0369] In certain embodiments, molecular organic gelling agent converts oil into gel by forming a self-assembled fiber network in a chemically induced phase transition. In certain embodiments, gelation can be activated by contacting oil with an immiscible solvent (water). The synthetic small molecules referred to as organic gelling agent have the ability to self-assemble into long fibers when introduced into an organic liquid (oil). These fibers are entangled and interconnected into a three-dimensional (3-D) network, thereby converting oil into an elastic organic gel. Gelation can be achieved in response to external stimuli or environment (such as temperature, redox state, pH, ultrasound or light). When irradiated with light, gelling agent photoisomerization can be made, so that it becomes an active gelling agent. Therefore, according to certain embodiments, light can be used as a "switch" for activating gelling agent. In other embodiments, lubricants may be included in the cross-linking mechanism of introducing covalent, ionic, van der Waals forces or other increased interactions between molecules in the solution. Non-limiting examples of cross-linking mechanism include hydrogen bonding, alkyne-azide click reaction of calcium ions, poly (2-hydroxyethyl methacrylic acid) cross-linking, phospholipid polymers for alginate solutions.
[0370] In certain embodiments, such as Fig.41 As shown, the tube 4101 includes an expandable reservoir 4102 on the middle ear side 4103 of the tube, as shown in FIG. Fig.41 (View a). Non-limiting examples of reservoirs include porous polymers, hydrogels, or balloon-like structures. When a therapeutic agent 4104 (e.g., an antibiotic, steroid, or another drug) is introduced through the ear canal side of the tube or the external ear canal 4105, the therapeutic agent can travel through the tube collector in the reservoir. The reservoir then absorbs the therapeutic agent. In certain embodiments, the reservoir can expand to cover the surface of the tympanic membrane ( Fig.41 b) or contact with some part of the middle ear space ( Fig.41 c). In some embodiments, the reservoir expands in response to stimulus 4106. In some embodiments, the reservoir may be designed to allow the therapeutic agent to pass through the surface of the reservoir to the surface of the tympanic membrane, the inner surface of the middle ear, the ossicles, the surface of the cochlear window, or the surface of the oval window. In this embodiment, contact with these structures or tissues allows targeted delivery of the therapeutic agent. In other embodiments, the reservoir may be designed to generally elute the therapeutic agent into the middle ear space. In some embodiments, additional fluid or pressure may be added on the ear canal side of the tube to promote or increase the elution rate of the therapeutic agent from the reservoir.
[0371] E. Tympanostomy catheter with pinning to reduce and / or prevent ingress of ambient water
[0372] In certain embodiments, the lumen of a tympanostomy catheter can be gated with another material that allows certain fluids or fluids under certain conditions to be transported into the catheter while preventing other fluids from entering. Fig.42 As shown, the lumen of the catheter can be opened in response to a stimulus to allow delivery of a therapeutic agent, such as an antibiotic droplet, at a specific time. For example, it may be desirable for the antibiotic droplet to enter the catheter 4201, while ordinary water 4202 comes out. In certain embodiments, the liquid can be propelled by capillary forces caused by light-induced asymmetric deformation (e.g., in liquid crystal elastomers), wettability gradients, or the Marangoni effect. Fig.42 An inner cavity with expansion controlled by deposition of specially designed droplets is shown according to certain embodiments. In certain embodiments, this expansion occurs due to droplets containing ionic crosslinkers or fluids that can be absorbed by the stimulus responsive polymer 4203 (e.g., a crosslinked polymer or hydrogel lining the inner cavity). Fig.42 (view b), this swelling closes the channel to prevent water from entering until the swelling subsides or the patient inserts another type of drop into his ear. In other embodiments, Fig.43 As shown, the inner cavity contains a polymer 4301 that expands in response to a stimulus such as light or heat ( Fig.43 of view a) or shrink ( Fig.43 b). In some embodiments, when the polymer swells, the lumen of the tube 4302 is closed and water 4303 cannot enter. In some embodiments, when the tube is exposed to a stimulus 4305, such as light, the polymer contracts, thereby opening the lumen and allowing oil 4306 or water to enter. In some embodiments, light-sensitive surfactants are added to the droplets to enhance the effect. In some embodiments, light actuation is replaced by heat, ultrasound, or an electric field.
[0373] In other embodiments, the lumen of the tympanostomy catheter is gated by another material that allows the transport of certain fluids and the exchange of gases between the environment and the middle ear space. Fig.44 As shown in (view a), a plug 4401 at the proximal end 4402 of the tube 4403 that allows exchange of air 4404 including oxygen and nitrogen 4405 with the environment but is water impermeable (e.g. silicone) allows the child to swim while still equalizing air pressure buildup for OM situations where fluid expulsion is not required, as shown in Fig.44 In certain embodiments, Fig.44 As shown (view b), the plug has a mechanism to open and allow certain fluids to flow into or out of the catheter based on the type of fluid or the amount of fluid present. For example, in some embodiments, mucus leaves the catheter when a certain pressure is reached inside the catheter. In some embodiments, if the antibiotic droplets 4406 contain a surfactant to "loosen" the perimeter of the door, they enter the catheter. In some embodiments, the plug 4401 can be rotated in the direction of arrow 4410 to allow certain fluids to flow into or out of the catheter.
[0374] I. Embodiment
[0375] A. Animal Model
[0376] The chinchilla (Chinchilla lanigera) animal model is the most widely used animal in middle ear research due to the size and anatomy of the tympanic membrane (TM). Female chinchillas (total 6) were anesthetized in a conventional manner for auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) testing. For ABR / DPOAE, the anesthetized animals were placed in a sound-treated chamber. Needle ABR wires were placed in a standard conventional manner, and bilateral ABR and DPOAE thresholds were obtained at 0.5, 1, 2, 4, 8, and 16kHz using the Eaton-Peabody Laboratories Cochlear Function Test Suite (EPL CFTS) written in LabVIEW. Digital stimulus generation and data acquisition were controlled using the EPL CFTS using an input / output board mounted on a PXI rack. Thresholds of the same animal have been measured in separate cases with highly reproducible values. Differences between ABR and DPOAE testing may indicate the presence of conductive hearing loss.
[0377] After ABR / DPOAE testing, tympanostomy tubes were placed in both ears in a sterile surgical setting, such as Fig.46 Shown are sequential images taken representing a tube placed in the ear from left to right. Fig.46 (View a) shows the placement of the Summit Medical collar tube, Fig.46 (View b) shows the placement of the oil-infused silicone collar tube. Using rigid 0° and 30° Storz A pole endoscope was used to visualize the TM. Betadine was placed into the ear canal to disinfect the external auditory canal. Using a myringotomy scalpel, a radial 2 mm incision (myringotomy) was made in the tympanic membrane to insert the TT. One ear received a control tube (silicone collar button, ID = 1.27 mm, VT-1002-01, Summit Medical) and the other ear received a "test" tube (silicone TT with "H" geometry, ID = 1.28 ± 0.02 mm filled with oil).
[0378] Prior to placement, all test TTs were sterilized by autoclaving at 121°C with a 25-min wet and 15-min dry cycle and then exposed to UV germicidal irradiation, and the TM was inserted prior to myringotomy surgery. After TT placement, animals were allowed to recover for 2 weeks, and the TT was closely monitored weekly by otoendoscopy.
[0379] After a 2-week recovery period, the animals were given a second round of general anesthesia for ABR / DPOAE testing as described above. After ABR / DPOAE testing, the TT was removed from the TM. To do this, a 30° Storz The ear canal was evaluated with a pole endoscope. Then, using a sterile rosen needle, the tube was gently removed from the previous myringotomy. The tube was gently grasped with alligator forceps and lifted from the ear canal under direct visualization and then delivered to a vial with PBS for further analysis. Otoendoscopic images of the TM were obtained before and after removal of the TT. The same procedure was performed on the contralateral ear. The animals were then allowed to recover for an additional 10 weeks. Photographs of the TM obtained by endoscopy were obtained weekly while the animal was awake to document healing of the perforation.
[0380] B. Assessment of hearing loss
[0381] Throughout the study, no chinchilla subjects in either the experimental or control groups were observed to show any signs of distress. Fig.47 As shown, the experimental tubes performed similarly, with no clear differences in ABR / DPOAE when compared directly to controls and between surgeries. There were no observable differences between the in vivo experimental ABR and DPOAE in the tubes implanted at week 2, confirming that the transplanted tubes did not induce any sensorineural hearing loss. There were only minor differences in the in vivo experimental DPOAE in the tubes implanted at week 2, which was explained by the approximately 30% greater mass of the tubes.
[0382] C. Tissue reaction to tympanostomy tube
[0383] The ear canals containing control tubes generally had a moist environment adjacent to the tubes. The immediate area around the tubes and some areas of the tympanic membrane were shiny and sometimes showed mucus. The degree of inflammation visible on otoscopy was obvious. On the other hand, five of the six ear canals containing test tubes had a dry environment. The degree of inflammation was significantly lower in these animals. Several animals whose tympanic membranes contained control tubes without perfusion oil had signs of inflammation or accumulation around the tubes, compared to animals with implanted perfusion oil test tubes that had no signs of inflammation or granulation. In contrast to some of the control tubes, the tympanic membrane healed well around all test tubes within 12 weeks of removal. All control and sample tubes remained open (no obstructions and provided free passage) when observed during the extraction surgery.
[0384] D. Bacterial adhesion on the tympanic membrane puncture tube
[0385] Surgically removed TT from chinchillas were placed in a vial with 1.2 mL PBS and sonicated at 40 kHz for 2 minutes to remove bacteria. The sonicated solution was serially diluted 10-fold, and 100 μL of the neat solution and dilutions (up to 10-3) were plated in triplicate on blood, chocolate, and Sabouraud agar (Becton Dickinson) plates. Blood and chocolate agar plates were plated at 5% CO 2 Incubate at 37°C in an incubator. Incubate Sabouraud agar plates at 37°C in atmosphere. After 24 hours of incubation, determine the number of colony forming units / mL. Sample different colonies and restreak on new plates for DNA extraction and sequence-based identification.
[0386] The bacterial colonies of interest sampled from the in vivo assay plate were grown for another 24 hours on separate plates of the same type as those found. The 16S rDNA sequences were amplified using primers 8F and 1493R flanking all 16S variable regions. The amplified products were purified and sequenced (Genewiz). Geneious 8.0 was used to compare and edit the sequences obtained. The BLAST (blastn algorithm) program using default parameters was used to search for sequence identity in GenBank.
[0387] Fig.48 Depicted is a comparative study of bacterial adherence to commercial control silicone tubing and medical grade silicone MED4960 infused in medical grade 100 cP silicone oil, demonstrating that the liquid infused silicone sheets were devoid of bacteria forming units of Staphylococcus aureus (identified by sequencing), as shown in the photograph of the agar plate.
[0388] II. Materials
[0389] A. Catheter Materials
[0390] According to certain embodiments, polymers that can be used to form the tube include, but are not limited to, biostable or bioabsorbable polymers. Non-limiting examples include isobutylene-based polymers, polystyrene-based polymers, polyacrylates and polyacrylate derivatives, vinyl acetate-based polymers and copolymers thereof, polyurethanes and copolymers thereof, silicones and copolymers thereof, ethylene vinyl acetate, polyethylene terephthalate, thermoplastic elastomers, polyvinyl chloride, polyolefins, cellulosics, polyamides, polyesters, polysulfones, polytetrafluoroethylene, polycarbonates, acrylonitrile butadiene styrene copolymers, acrylics, polylactic acid, polyglycolic acid, polycaprolactone, polylactic acid-polyethylene oxide copolymers, cellulose, collagen, alginate, gelatin, chitin, and combinations thereof.
[0391] Other non-limiting examples of polymers that can be used to form a tube or a tube for use as a stent, for example, include, but are not limited to, polyester, poly(ethylene terephthalate), polycarbonate, polymethyl methacrylate, polypropylene, polyalkylene oxalates, polyvinyl chloride, polyurethane, polysiloxane, nylon, poly(dimethylsiloxane), polycyanoacrylate, polyphosphazene, poly(amino acids), ethylene glycol I dimethacrylate, poly(methyl methacrylate), poly(2-hydroxyethyl methacrylate), polytetrafluoroethylene, poly(HEMA), polyhydroxyalkanoates, polytetrafluoroethylene, poly(hydroxyethyl methacrylate), ... Ethylene, polycarbonate, poly(co-glycolide-lactide), polylactic acid, poly(γ-caprolactone), poly(γ-hydroxybutyrate), polydioxanone, poly(γ-ethylglutamate), polyiminocarbonate, poly(orthoesters), polyanhydrides, alginate, dextran, chitin, cotton, polyglycolic acid, polyurethane, gelatin, collagen, or derivative forms thereof, i.e., polymers modified to contain, for example, attachment sites or cross-linking groups such as RGD, wherein the polymer retains its structural integrity while allowing attachment of cells and molecules such as proteins, nucleic acids, and combinations thereof.
[0392] In certain embodiments, the tube may also be made of a non-polymer. Non-limiting examples of useful non-polymers include sterols, such as cholesterol, stigmasterol, β-sitosterol and estradiol, and cholesterol esters, such as cholesterol stearate; 12 -C 24 Fatty acids, such as lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, and lignoceric acid; C 18 -C 36 Mono-, di- and triacylglycerides, such as monoolein, monolinolein, monolaurin, monobehenin, monomyristic, monodecenoin, dipalmitolein, disechinain, disechinain, disechinain, dodecenoin, tribehenin, trimyristin and, tridecenoin, tristearin and mixtures thereof; sucrose fatty acid esters, such as sucrose distearate and sucrose palmitate; sorbitan fatty acid esters, such as sorbitan monostearate, sorbitan monopalmitate and sorbitan tristearate; C 16 -C 18Fatty alcohols, such as cetyl alcohol, myristyl alcohol, stearyl alcohol and cetostearyl alcohol; esters of fatty alcohols and fatty acids, such as cetyl palmitate and cetearyl palmitate; anhydrides of fatty acids, such as stearic anhydride; phospholipids, including phosphatidylcholine (lecithin), phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol and lysogenic derivatives thereof; sphingosine and its derivatives; sphingomyelins, such as stearyl, palmitoyl and tricosyl sphingomyelin; ceramides, such as stearyl and palmitoylceramide; sphingolipids; lanolin and lanolin alcohol; and combinations and mixtures thereof. Particularly useful non-polymers include cholesterol, monostearate, tristearate, stearic acid, stearic anhydride, monooleate, monolinoleate, acetylated monoglycerides and combinations thereof.
[0393] The materials listed in these embodiments for catheter design can be selected from FDA approved materials such as silicones and fluoroplastics, nylons, polyethylene terephthalate, polycarbonate, acrylonitrile-butadiene-styrene, poly(p-phenylene oxide), polybutylene terephthalate, acetals, polypropylene, polyurethanes, polyetheretherketone, hydroxyapatite, ultra-high molecular weight polyethylene, high density polyethylene, low density polyethylene, high impact polystyrene, polysulfones, polyvinylidene fluoride, polystyrene, polymethyl methacrylate, latex, polyacrylates, polyalkyl acrylates, substituted polyalkyl acrylates, polystyrene, poly(divinylbenzene), polyvinyl pyrrolidone, poly(vinyl alcohol), polyacrylamide, poly(ethylene oxide), polyvinyl chloride, polyvinylidene fluoride, polytetrafluoroethylene and mixtures thereof. In addition, they can include polyelectrolyte hydrogels: ionic (including anions or cations) and amphoteric (including both anions and cations), for which incorporation of more hydrophilic or hydrophobic monomers into the hydrogel composition will allow the volume transition behavior of the hydrogel to be adjusted. Non-limiting examples include materials that form hydrogels, such as acrylates, polyacrylates, methacrylic acid, (dimethylamino)ethyl methacrylate, hydroxyethyl methacrylate, poly(vinyl alcohol) / poly(acrylic acid), 2-acrylamido-2-methylpropane sulfonic acid, [(methacrylamido)-propyl]trimethylammonium chloride, poly(N-vinyl-2-pyrrolidone / itaconic acid). Another class of materials can be represented by non-ionic hydrogels. Non-limiting examples include poly(ethylene glycol), ethylene glycol diacrylate, polyethylene glycol diacrylate poly(ethylene oxide), diacrylates, acrylamide, polyacrylamide, methylene bisacrylamide, N-isopropylacrylamide, poly(vinyl alcohol) and mixtures thereof. In some embodiments, the hydrogel can be made of natural materials, such as proteins (e.g., collagen and silk) and polysaccharides (e.g., chitosan, dextran and alginate) and combinations thereof. In some embodiments, the tube can be made of metal or metal oxide.
[0394] In certain embodiments, the material can also include colloidal particles dispersed or suspended in another substance. Non-limiting examples of suitable colloidal particles that can be used in hydrogel-based sensors include polystyrene and polymethyl methacrylate, melamine resins (with a large number of reactive amino and imino groups for the fixation of different metal ions or metal nanoparticles), silica and polydivinylbenzene microparticles. In some embodiments, the colloidal particles are made of one or more of the following polymers: poly(methyl methacrylate), polyacrylates, polyalkyl acrylates, substituted polyalkyl acrylates, polystyrene, poly(divinylbenzene), polyvinyl pyrrolidone, poly(vinyl alcohol), polyacrylamide, poly(ethylene oxide), polyvinyl chloride, polyvinylidene fluoride, polytetrafluoroethylene, other halogenated polymers, hydrogels, organogels or combinations thereof. Other polymers of different structures can also be used, such as random and block copolymers, side chains, star-shaped and dendritic polymers and supramolecular polymers. In certain embodiments, colloidal particles are (biopolymer colloids) of natural origin, such as materials based on proteins or polysaccharides, silk fibroin, chitin, shellac, cellulose, chitosan, alginate, gelatin or its mixture. In certain embodiments, colloidal particles include one or more metals, such as gold, palladium, platinum, silver, copper, rhodium, ruthenium, rhenium, titanium, osmium, iridium, iron, cobalt or nickel, or its combination. In certain embodiments, colloidal particles include one or more oxides, such as silicon dioxide, aluminum oxide, beryllium oxide, noble metal oxide, platinum group metal oxide, titanium dioxide, tin oxide, zirconium oxide, hafnium dioxide, molybdenum oxide, tungsten oxide, rhenium oxide, vanadium oxide, tantalum oxide, niobium oxide, chromium oxide, scandium oxide, yttrium oxide, lanthanum oxide, cerium oxide, thorium oxide, uranium oxide, other rare earth oxides or its combination. The particles of other categories to be included are ferromagnetic, ferromagnetic or superparamagnetic particles (diameter is usually 10 nanometers or less). Exemplary nanoparticles include iron, nickel, and cobalt containing particles, such as magnetite or hematite, Colloidal particles useful in the conduits described herein can be charged or uncharged, hydrophilic, hydrophobic, or amphiphilic. In some embodiments, the conduit can include two or more colloidal particles.
[0395] In any of the foregoing embodiments, according to certain embodiments, the precursor composition may include one or more additives selected from small molecules, dispersed droplets or microparticle fillers, nanoparticle fillers (e.g., antioxidants, UV stabilizers, plasticizers, antistatic agents, pore formers, slip agents, processing aids, foaming agents or defoamers, nucleating agents, and fillers) to enhance mechanical properties or roughness, and control optical properties or viscosity and uniformity of application.
[0396] In certain embodiments, for medical and non-medical fluid applications, the materials listed in the present invention for catheter design may include a metal selected from the group consisting of Li, Be, B, Na, Mg, Al, Si, K, Ca, Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Rb, Sr, Y, Zr, Nb, Mo, Ru, Rh, Pd, Ag, Cd, In, Sn, Sb, Cs, Ba, Hf, Ta, W, Re, Os, Ir, Pt, Au, Ti, Pb, Bi, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, and oxides thereof or combinations thereof. In certain embodiments, the metal-containing catheter comprises aluminum, and the roughened metal-containing surface comprises boehmite. In certain embodiments, the metal-containing sol-gel precursor comprises a pore former.
[0397] The material for conduit design may include metal foam or porous metal substrate. In certain embodiments, these porous substrates can be formed by the solidification process of the mixture of the foaming agent of the pre-molten metal and the gas / release gas injected or by compressing the metal powder into special tools to form different shapes and forms (such as plates, cylindrical shapes, hollow cylinders, etc.). Metal foam can be manufactured with closed-cell or open-cell structures (i.e., the interconnected network of metal). The metal foam of different materials (such as aluminum, titanium, nickel, zinc, copper, steel, iron or other metals and alloys) can be used, and it has been produced by a variety of methods, such as direct foaming and powder compaction melting method, which is widely discussed in J.Banhart, Prog.Mater.Sci46,559-632 (2001), which is incorporated herein by reference.
[0398] B. Surface characteristics
[0399] According to certain embodiments, a range of surface structures with different characteristic sizes and porosities can be used for catheter design. The characteristic size can range from hundreds of nanometers to micrometers (e.g., 100 to 1000 nm) and have an aspect ratio of about 1:1 to 10:1. In certain embodiments, the surface has a large surface area that is easily wetted by the lubricating fluid and carries the lubricating fluid and holds it on the substrate surface. The roughened surface material can be selected to be chemically inert to the lubricating fluid and have good wetting properties relative to the lubricating fluid. In addition, the roughened surface topography can be varied within a certain range of geometries and sizes to provide the desired interaction with the lubricating fluid, such as wettability. In certain embodiments, the roughened surface can be the surface of a three-dimensional porous material. The porous material can be any suitable porous network having a thickness sufficient to stabilize the lubricating fluid, such as a thickness of about 5 μm to about 1 mm. In addition, the porous material can have any suitable pore size to stabilize the lubricating fluid, such as about 10 nm to about 100 μm.
[0400] In other embodiments, the roughened surface is further functionalized to improve wetting by a lubricating fluid. Surface coating can be achieved by methods known in the art, including plasma-assisted chemical vapor deposition, chemical functionalization, solution deposition, and vapor deposition. For example, surfaces containing hydroxyl groups (ie, -OH) can be functionalized with various commercially available fluorosilanes (e.g., (1H, 1H, 2H, 2H-tridecafluorooctyl)-trichlorosilane) to improve wettability of low surface tension fluids. In certain embodiments, many materials with native oxides can be activated to include -OH functional groups using techniques such as plasma treatment. After activation, silanes can be attached using vapor deposition or solution deposition techniques so that surfaces with low surface energy can be produced. For vapor deposition, deposition can be performed by exposing the surface to silane vapor. For solution deposition, deposition can be performed by immersing the surface in a silane solution, then rinsing and drying after deposition. For layered deposition, a mixture of sacrificial beads and lubricating fluid is applied after layered deposition of the underlying coating, dried and cured. The beads are removed to produce a continuous porous surface.
[0401] In certain embodiments, the roughened surface can have pores comparable to or smaller than the material to be repelled. For example, pore sizes smaller than the size of protozoa (e.g., 10 μm), bacteria (e.g., 1 μm), viruses (e.g., 0.1 μm), etc. can be used.
[0402] C. Lubricating fluid
[0403] The lubricating fluid can be selected from a variety of different fluids. These fluids can be selected based on their suitability for biocompatibility, low toxicity, antifouling properties, drug release, and chemical stability under physiological conditions. In one or more aspects, the lubricating fluid is a chemically inert, high-density biocompatible fluid, non-limiting examples of which include castor oil, silicone oil, fluocinolone acetonide oil, olive oil, and mineral oil.
[0404] The lubricating fluid penetrates, wets and stably adheres to the substrate. In addition, it is chemically inert to the solid substrate and the fluid to be repelled. The lubricating fluid is non-toxic. In addition, the lubricating fluid according to certain aspects is capable of repelling immiscible fluids having any surface tension. In one or more aspects, the lubricating fluid is a chemically inert and high-density biocompatible fluid. In addition, the lubricating fluid is capable of repelling immiscible fluids, particularly biological fluids having any surface tension. For example, the mixing enthalpy between the fluid to be repelled and the lubricating fluid can be high enough (e.g., water and oil) to separate them from each other when mixed together. In one or more embodiments, the lubricating fluid is inert relative to the solid surface and the biological fluid. The lubricating fluid easily flows into the grooves of the rough surface and, when provided on the rough surface, generally has the ability to form an ultra-smooth surface. Some exemplary suitable lubricating fluids include perfluorinated hydrocarbons, organosilicone compounds (e.g., silicone elastomers), hydrophobic materials, and the like. In particular, tertiary perfluoroalkylamines (e.g., perfluorotri-n-pentylamine, 3M's FC-70, perfluorotri-n-butylamine FC-40, etc.), perfluoroalkyl sulfides and perfluoroalkyl sulfoxides, perfluoroalkyl ethers, perfluorocyclic ethers (e.g., FC-77) and perfluoropolyethers (e.g., DuPont's KRYTOX series lubricants), perfluoroalkylphosphines and perfluoroalkylphosphine oxides and mixtures thereof, and mixtures thereof with perfluorocarbons and any and all members of the above classes can be used for these applications. In addition, long-chain perfluorinated carboxylic acids (e.g., perfluorooctadecanoic acid and other homologues), fluorinated phosphonic acids and sulfonic acids, fluorinated silanes and combinations thereof can be used as lubricating fluids. The perfluoroalkyl groups in these compounds can be linear or branched, and some or all of the linear and branched groups can be only partially fluorinated. In certain embodiments, hydrophobic materials such as olive oil, silicone oil, hydrocarbons, etc. can be used as lubricating fluids. In certain embodiments, ionic liquids can be used as lubricating fluids.
[0405] In certain embodiments, the lubricating fluid used to promote repulsion is selected to produce an essentially smooth, stable and defect-free fluid surface. The lubricating fluid of certain embodiments penetrates, wets and stably adheres to the substrate. In addition, the lubricating fluid of certain embodiments should be chemically inert with respect to the solid matrix and the fluid to be repelled. The lubricating fluid of certain embodiments should provide sufficient drug release and be non-toxic. In addition, the lubricating fluid according to certain aspects is capable of repelling immiscible fluids with any surface tension. In one or more aspects, the lubricating fluid is a chemically inert and high-density biocompatible fluid.
[0406] According to certain embodiments, the lubricating fluid can be selected from a variety of different fluids. These liquids can be selected based on their suitability for drug release, biocompatibility, low toxicity, anticoagulant properties and chemical stability under physiological conditions. In one or more aspects, the lubricating fluid is a chemically inert, high-density biocompatible fluid, non-limiting examples of which include vegetable oils. Vegetable oil refers to oils derived from plant seeds or nuts. Exemplary vegetable oils include, but are not limited to, almond oil, borage oil, black currant oil, castor oil, corn oil, safflower oil, soybean oil, sesame oil, cottonseed oil, peanut oil, olive oil, rapeseed oil, coconut oil, palm oil, canola oil, etc. Vegetable oils are typically "long-chain triglycerides" that are formed when three fatty acids (usually about 14 to about 22 carbons long, with different numbers and positions of unsaturated bonds, depending on the source of the oil) form ester bonds with three hydroxyl groups on glycerol. In certain embodiments, highly purified grades (also known as "super-refined") of vegetable oils are typically used to ensure the safety and stability of oil-in-water emulsions. In certain embodiments, hydrogenated vegetable oils produced by controlled hydrogenation of vegetable oils can be used in the systems disclosed herein.
[0407] Other oils can also be used, but the composition may need to be changed to provide sufficient dissolution of the drug in the oil. For example, perfluorinated hydrocarbons or organosilicon compounds (such as silicone elastomers) etc. can be used. In particular, in certain embodiments, tertiary perfluoroalkylamines (such as perfluorotri-n-pentylamine, 3M's FC-70, perfluorotri-n-butylamine FC-40 etc.), perfluoroalkyl sulfides and perfluoroalkyl sulfoxides, perfluoroalkyl ethers, perfluorocyclic ethers (such as FC-77) and perfluoropolyethers (such as DuPont's KRYTOX series lubricants), perfluoroalkylphosphines and perfluoroalkylphosphine oxides and mixtures thereof, and mixtures thereof with any and all members of perfluorocarbons and the above-mentioned categories can be used for these applications. In addition, in certain embodiments, long-chain perfluorinated carboxylic acids (such as perfluorooctadecanoic acid and other homologues), fluorinated phosphonic acids and sulfonic acids, fluorinated silanes and combinations thereof can be used as lubricants. In certain embodiments, the perfluoroalkyl in these compounds can be straight or branched, and some or all of the straight and branched groups can be only partially fluorinated. To improve drug solubility in these other oils, in certain embodiments, a surfactant may be included in the composition.
[0408] For use in certain non-medical applications, the lubricant may be selected from fluorinated lubricants (liquids or oils), silicones, mineral oils, vegetable oils, water (or aqueous solutions, including physiologically compatible solutions), ionic liquids, polyolefins, including polyalphaolefins (PAOs), synthetic esters, polyalkylene glycols (PAGs), phosphate esters, alkylated naphthalenes (ANs) and silicates, or any mixtures thereof.
[0409] In some embodiments, the lubricant has a high density. For example, a lubricant with a density greater than 1.0 g / cm 3 , 1.6g / cm 3 Or even 1.9g / cm 3 lubricant.
[0410] In certain embodiments, the lubricant has a low freezing temperature, such as below -5° C., -25° C., or even below -80° C. Having a low freezing temperature will allow the lubricant to maintain its slippery properties at reduced temperatures and repel various liquids or solidified liquids.
[0411] In certain embodiments, the lubricant can have a low evaporation rate, for example less than 1 nm / s, less than 0.1 nm / s, or even less than 0.01 nm / s. At a typical lubricant thickness of about 10 μm and an evaporation rate of about 0.01 nm / s, the surface can remain highly liquid-repellent for a long time without any refilling mechanism.
[0412] In certain embodiments, the viscosity of the oil is in the range of about 1 to 2000 cSt. In certain embodiments, the viscosity of the oil is in the range of about 1 to 500 sCt.
[0413] In certain embodiments, the viscosity of the oil is in the range of about 8 to 1500 cSt. In certain embodiments, the viscosity of the oil is in the range of about 10 to 550 cSt. In certain embodiments, the viscosity of the oil is in the range of about 8 to 80 cSt. In certain embodiments, the viscosity of the oil is in the range of about 8 to 350 cSt. In certain embodiments, the viscosity of the oil is in the range of about 80 to 350 cSt. In certain embodiments, the viscosity of the oil is in the range of about 80 to 550 cSt.
[0414] D. Stimuli-responsive materials
[0415] The stimulus responsive valve for the lumen of the catheter or the catheter itself may comprise nematic, smectic, chiral, dicotic, bowl-shaped liquid crystals having thermotropic, lyotropic and metallotropic phases. The liquid crystal may also be cholesteric (chiral nematic) liquid crystal, smectic A, smectic C or smectic C* (chiral smectic C), ferroelectric or antiferroelectric smectic liquid crystals, liquid crystal compounds containing bent core molecules, columnar mesophase liquid crystals, discotic liquid crystal porphyrins or lyotropic liquid crystals or any combination thereof. The next example is a photoresponsive liquid crystal composition consisting of a liquid crystal compound and a gelling agent mixed with the liquid crystal compound to form a gelled mixture, wherein the liquid crystal compound can be controlled to be oriented in one direction by irradiation with light. As specific liquid crystal compounds, compounds having a nematic phase at room temperature can be used, such as cyanobiphenyl compounds, phenylcyclohexane compounds, benzalaniline compounds, phenylbenzoate compounds, phenylacetylene compounds and phenylpyrimidine, cyanobiphenyl compounds such as 4-pentyl-4'-cyanobiphenyl, benzylideneaniline compounds such as 4-methoxybenzylidene-4'-butylaniline, phenylcyclohexane compounds such as 4-(trans-4-pentylcyclohexyl)benzonitrile. In addition, isoleucine derivatives having an azobenzene structural part, BDH-17886 of Merck Ltd., and liquid crystal composition p-methyl-oxy-n-p-benzylidenebutylaniline (MBBA) can be used. The liquid crystal mixture with the polymer may include polyurethane (PU), polyethylene oxide (PEO), polyacrylonitrile (PAN), polyvinyl acetate (PVA), cellulose acetate; polyaniline, polypyrrole, polythiophene, polyphenol, polyacetylene, polyphenylene, poly(lactic acid) (PLA), poly(methyl methacrylate) (PMMA), poly(glycolic acid) (PGA), poly(ethylene oxide), polyacrylates, polyesters, polyamides, polyolefins, polyvinyl chloride (PVC), poly(amic acid), polyimides, polyethers, polysulfones and any combination thereof.
[0416] In one embodiment, the shape responsive layer comprises a liquid crystal elastomer. The shape change of a monodomain LCE with a uniformly arranged liquid crystal (LC) director can be 10% to 400% of the initial LCE size. In some embodiments, the LCE is a multidomain liquid crystal elastomer. In some embodiments, the LCE comprises a nematic director and a liquid crystal element (liquid crystal molecule) associated with a polymer. In some embodiments, the liquid crystal element content of the LCE is about 20% molar content to about 90% molar content of the liquid crystal elastomer. In some embodiments, the liquid crystal element is generally a molecule that produces a liquid crystal phase at room temperature and may include at least one of the following: an aromatic ring, an aliphatic ring, a polyaromatic ring, a polyaliphatic ring, a phenyl, a biphenyl, a cyanobiphenyl, benzene and a combination thereof. In some embodiments, the liquid crystal element is functionalized with one or more functional groups such as olefins, alkanes, alkynes, carboxyls, esters, halogens and combinations thereof. In certain embodiments, the liquid crystal element is 4-methoxyphenyl 4-(3-butenyloxy) benzoate.
[0417] In some embodiments, the liquid crystal element in the LCE is a cross-linked polymer. In some embodiments, the polymer includes at least one of the following: polysiloxane, poly(methyl)siloxane (PMS), poly(dimethyl)siloxane (PDMS), polymethylhydrogensiloxane (PMHS), poly(methyl methacrylate), polyethylene, polypropylene, poly(butyl acrylate) network chain and combinations thereof.
[0418] The polymer can be associated with the mesogen in various arrangements. For example, in some embodiments, the mesogen can be cross-linked to the polymer. The cross-linking agent can be any reactive molecule that produces a physically or chemically cross-linked elastomeric network. For example, a di(methacrylate) cross-linking agent or a diacrylate cross-linking agent is used. The concentration of the cross-linking agent can be varied to increase or decrease the modulus of the elastomer at a higher or lower cross-linking agent content, respectively. Other catalysts or methods can be used to cross-link the network, including thermal annealing or more or less reactive platinum catalysts. The solvent content can also be varied during the synthesis process.
[0419] In some embodiments, multiple mesogens can be covalently coupled to a single polymer chain. In some embodiments, multiple mesogens can be covalently coupled to multiple polymer chains. In some embodiments, the mesogens and polymers can be entangled within a matrix. LCEs can be prepared using methods known in the art.
[0420] In yet another embodiment, a conductive material can be added to the shape responsive layer. As an example, a conductive filler can provide an electrical, magnetic or light induced response to the LCE nanocomposite. For example, the LCE can include one or more wires. Alternatively or in addition, carbon nanotubes, carbon black nanoparticles or conductive gold nanoparticles can be used.
[0421] In addition to tympanostomy catheters, embodiments of the present disclosure may also enhance the field of other catheter-like medical implants, such as, but not limited to, surgical drains, vascular stents, catheters, dialysis tubes, feeding catheters, colostomy catheters, and Eustachian tube implants.
Claims
1. A device comprising: A catheter, the catheter comprising: Proximal, The distal end is opposite to the proximal end. wherein the catheter has a first inner radius at the proximal end and a second inner radius at the distal end, wherein the second inner radius is greater than the first inner radius, an inner surface that is continuously curved from the proximal end to the distal end, the inner surface having a varying angle from the proximal end to the distal end, the inner surface forming a proximal angle at the proximal end and a distal angle at the distal end, and the inner surface comprising a surface feature, connecting the outer surfaces of the proximal and distal ends, and a proximal flange disposed on the proximal end of the catheter; in, The first inner radius, the second inner radius, the angle of the inner surface, the distal angle, the proximal angle, and the surface characteristics of the inner surface are selected such that the catheter is configured as: allowing a fourth material to enter the proximal end of the catheter, allowing the fourth material to be transported through the catheter along the inner surface toward the distal end, and allowing the fourth material to exit from the distal end of the catheter, and preventing the second material from entering the proximal end of the catheter; and The Young-Laplace pressure of the fourth material is less than the Young-Laplace pressure of the second material.
2. The device of claim 1, wherein when the second material enters the proximal end, the advancement angle of the second material at the proximal end is greater than 90°.
3. The device of claim 1, wherein one or more of the first inner radius at the proximal end and the second inner radius at the distal end is 3 mm or less.
4. The device of claim 3, wherein the catheter is a tympanostomy tube or a ventilation tube.
5. The device of claim 1, wherein the catheter comprises a distal flange disposed on a distal end of the catheter.
6. The device of claim 5, wherein the device is a tympanostomy tube and the distal flange has a radial stiffness that matches a portion of the tympanic membrane.
7. The device of claim 1, further comprising: A portion of a conduit provided with a smooth surface, the smooth surface comprising: A partially or fully stabilized lubricating fluid layer on at least a portion of an inner or outer surface of a conduit, the lubricating fluid layer wets and adheres to at least a portion of the conduit to form a slippery surface on a portion of the conduit.
8. The device of claim 7, wherein the lubricating fluid increases the advancing angle of the second material.
9. The device of claim 7 or 8, wherein the lubricating fluid increases the effective surface tension of the second material.
10. The device of claim 7 or 8, wherein the lubricating fluid is on an inner surface of the conduit.
11. The device of claim 7 or 8, wherein the lubricating fluid is on an outer surface of the catheter.
12. The device of claim 7 or 8, wherein the lubricating fluid is on an inner surface of at least one of the proximal flange and the distal flange.
13. The device of claim 7 or 8, wherein the lubricating fluid is one or more of the following: silicone oil, partially or fully fluorinated oil, mineral oil, carbon-based oil, castor oil, fluocinolone acetonide oil, food-grade oil, water, surfactant / surfactant solution, organic solvent, perfluorinated hydrocarbon and mixtures thereof.
14. The device of claim 1, wherein the surface characteristic comprises a chemical gradient or pattern on at least a portion of at least one of an inner surface and an outer surface.
15. The device of claim 14, wherein the chemical gradient or pattern is disposed on an inner surface of the conduit.
16. The device of claim 14 or 15, wherein the chemical gradient or pattern is provided on an outer surface of the conduit.
17. The device of claim 14 or 15, wherein the chemical gradient or pattern is disposed on at least one of a proximal flange at the proximal end of the catheter and a distal flange at the distal end of the catheter.
18. The device of claim 14 or 15, wherein the chemical gradient or pattern increases the effective surface tension of the second material when the second material is disposed on the chemical gradient.
19. The device of claim 14 or 15, wherein the chemical gradient or pattern comprises a wicking layer configured to transport fluid along the wicking layer from one of the proximal end and the distal end to the other of the proximal end and the distal end or a central portion of the catheter.
20. The device of claim 1, wherein a portion of the conduit has a gradient or pattern disposed thereon.
21. The device of claim 20, wherein the gradient or pattern increases the effective surface tension of the second material.
22. The device of claim 20 or 21, wherein the gradient or pattern is provided on at least a portion of the inner surface of the conduit.
23. The device of claim 20 or 21, wherein the gradient or pattern is disposed on at least a portion of an outer surface of the conduit.
24. The device of claim 20 or 21, wherein the gradient or pattern is provided on at least one of the distal flange and the proximal flange at the distal end of the catheter.
25. The device of claim 20 or 21, wherein the gradient or pattern is selected from: geometrically patterned channels, macroporous channels, microporous channels, three-dimensional periodic networks of pores, sponge-like networks of pores, surface roughness, grooves, ridges, indentations, micropillars and microridges.
26. The device of claim 1, wherein the catheter comprises a stimulus-responsive portion, the stimulus being selected from one or more of light, temperature, pressure, electric field, magnetic field, expansion, deswelling, or a chemical composition.
27. The device of claim 26, wherein the stimuli-responsive portion is selected from the group consisting of: thermostrictive, piezoelectric, electroactive, chemostrictive, magnetostrictive, photostrictive, swellable, or pH-sensitive materials.
28. The device of claim 26 or 27, wherein the stimulus is a chemical composition, and the chemical composition comprises a lubricating fluid.
29. The device of claim 26 or 27, wherein the stimulus-responsive portion comprises a distal flange disposed at or near a distal end of the catheter; and Wherein the distal flange is capable of transitioning between a first configuration and a second configuration in response to the stimulus.
30. The device of claim 29, wherein the distal flange changes at least one of a size of the distal flange or a shape of the distal flange when transitioning between the first configuration and the second configuration.
31. The device of claim 29, wherein one of the distal end and the distal flange comprises a protrusion comprising a shape-constant material to facilitate insertion of the distal end of the catheter.
32. The device of claim 26 or 27, wherein the stimulus-responsive portion is a valve disposed within the conduit, the valve being capable of closing in response to a stimulus.
33. The device of claim 32, wherein the valve is selected from the group consisting of: stimuli-responsive polymers, gas selective movement membranes, stimuli-responsive ciliated and hair-like fibers, lamellae, pillars, reconfigurable and tunable nanostructures or microstructures with functionalized tips, and combinations thereof.
34. The device of claim 26 or 27, wherein the stimulus-responsive portion further comprises a proximal flange disposed at or near the proximal end of the catheter, and Wherein the proximal flange is capable of transitioning between a first configuration and a second configuration in response to a stimulus.
35. The device of claim 26 or 27, wherein the stimuli-responsive portion comprises a first layer of a first stimuli-responsive material and a second layer of a second stimuli-responsive material.
36. The device of claim 35, wherein the stimulus is swelling and the first stimulus responsive material and the second stimulus responsive material have different cross-link densities.
37. The device of claim 26 or 27, wherein In a first configuration, the conduit has a first diameter, and In a second configuration, the conduit has a second diameter.
38. The device of claim 26 or 27, wherein the stimulus-responsive portion is disposed on an inner surface of the catheter.
39. The device of claim 26 or 27, wherein the stimulus-responsive portion expands in response to the stimulus.
40. The device of claim 26 or 27, wherein the catheter further comprises a lumen defined by the inner surface and extending from the distal end to the proximal end, The stimulus responsive portion is disposed in the inner cavity.
41. The device of claim 40, wherein the stimulus-responsive portion comprises pores disposed throughout the lumen, and the pores close in response to the stimulus.
42. The device of claim 26 or 27, wherein the stimulus-responsive portion is disposed on an outer surface of the catheter.
43. The device of claim 42, wherein the stimulation causes the stimulus-responsive portion to separate from the catheter.
44. The device of claim 42, wherein the stimulus-responsive portion comprises an actuator configured to expand when exposed to the stimulus.
45. The device of claim 1, wherein the catheter comprises a tube, and wherein the device further comprises a second catheter, the second catheter comprising a tube having a proximal end and a distal end, the proximal end of the second catheter being disposed near the proximal end of the catheter and the distal end of the second catheter being disposed near the distal end of the catheter.
46. The device of claim 1, wherein the first inner radius, the second inner radius, the angle of the inner surface, the distal angle, the proximal angle, and the surface characteristics of the inner surface are selected such that the catheter is configured to allow a third material to enter the proximal end of the catheter, allow the third material to be transported through the catheter along the inner surface toward the distal end, and prevent the third material from exiting the proximal end of the catheter; The Young-Laplace pressure of the third material is less than the Young-Laplace pressure of the second material, but lower than the breakthrough pressure at the distal end.
47. The device of claim 46, wherein at least a portion of the inner surface is configured to pin a third material thereto.
48. The device of claim 47, wherein the at least a portion comprises one of a surface chemistry or a texture that promotes pinning of a third material.
49. The device of claim 46 or 47, wherein the catheter further comprises a valve configured to prevent the third material from exiting the proximal end of the catheter.
50. The device of claim 46 or 47, wherein the difference between the Laplace pressure of the second material and the Laplace pressure of the third material is between 1 Pa and 1000 Pa.
51. The device of claim 46 or 47, wherein the distal end is configured to have a breakthrough pressure at least 1 Pa higher than the Young-Laplace pressure of the third material at the location of the distal end to prevent the third material from leaving the distal end.
52. The device of claim 46 or 47, wherein when the third material enters the proximal end, the advancement angle of the third material at the proximal end is less than 90°.
53. The device of claim 46 or 47, wherein the third material is selected from the group consisting of lubricating fluids, cross-linking agents, aqueous and oil-based solutions of antibiotics, preservatives, antivirals, anti-inflammatory agents, small molecules, immunological agents, nanoparticles, genetic therapies including viral-based and lipid-based therapies, chemotherapy, stem cells, cell therapeutics, growth factors, proteins, radioactive materials, other liquid or gas-based pharmaceutical compounds and combinations thereof, cerumen dissolving agents, deferoxamine, dihydroxybenzoic acid, glutathione, D-methionine and N-acetylcysteine.
54. The device of claim 53, wherein the cerumen dissolving agent is selected from the group consisting of: squalene, chlorhexidine and EDTA.
55. The device of claim 53, wherein the third material is present in the form of a foam and an emulsion.
56. The device of claim 1, wherein a difference between the Young-Laplace pressure of the second material and the Young-Laplace pressure of the fourth material is in the range of 1 Pa to 1000 Pa.
57. The device of claim 1 or 56, wherein at least one of the angle or surface characteristics of the inner surface is changed to maintain the Young-Laplace pressure of the fourth material substantially constant or decreasing from the proximal end to the distal end.
58. The device of claim 1 or 56, wherein at least one of an angle or a surface characteristic of the inner surface is changed such that there is substantially no pinning of the fourth material from the proximal end to the distal end.
59. The device of claim 1 or 56, wherein when the fourth material enters the proximal end, the advancement angle of the fourth material at the proximal end is less than 90°.
60. The device of claim 1 or 56, wherein the distal end is configured to have a breakthrough pressure for a fourth material that is at least 1 Pa lower than the Young-Laplace pressure of the fourth material at the location of the distal end to enable it to leave.
61. The device of claim 1 or 56, wherein the angle of the inner surface increases at the proximal end to reduce a breakthrough pressure of the fourth material at the proximal end.
62. The device of claim 1, wherein the fourth material is selected from oil-based, water-based, and other solvent-based therapeutic agents comprising at least one of: antibiotics, preservatives, antivirals, antivirals, anti-inflammatory agents, small molecules, immunological agents, nanoparticles, air for ventilation, genetic therapies including viral-based and lipid-based therapies, chemotherapy, stem cells, cell therapeutics, growth factors, proteins, radioactive materials, other liquid or gas-based pharmaceutical compounds, and combinations thereof.
63. The device of claim 1, wherein the first inner radius, the second inner radius, the angle of the inner surface, the distal angle, the proximal angle, and the surface characteristics of the inner surface are selected such that the catheter is configured to allow a first material to enter the distal end of the catheter, allow the first material to be transported through the catheter along the inner surface toward the proximal end, and allow the first material to exit from the proximal end of the catheter; and The Young-Laplace pressure of the first material is less than the Young-Laplace pressure of the second material.
64. The device of claim 63, wherein the difference between the Young-Laplace pressure of the first material and the Young-Laplace pressure of the second material is in the range of 1 Pa to 1000 Pa.
65. The device of claim 63, wherein the conduit has a selectivity between 1 and 10, the selectivity comprising a normalized pressure difference between the Young-Laplace pressure of the first material and the Young-Laplace pressure of the second material.
66. The device of any one of claims 63 to 65, wherein at least one of an angle or a surface property of the inner surface changes to maintain a Young-Laplace pressure of the first material substantially constant or decreasing from the distal end to the proximal end.
67. The device of any one of claims 63 to 65, wherein at least one of an angle or a surface characteristic of the inner surface is altered such that there is substantially no pinning of the first material from the distal end.
68. The device of any one of claims 63 to 65, wherein at least one of an angle or a surface property of the inner surface is varied to maintain a Young-Laplace pressure of the first material that varies by 10% or less from the distal end to the proximal end.
69. The device of any one of claims 63 to 65, wherein when the first material enters the distal end, the advancement angle of the first material at the distal end is less than 90°.
70. The device of any one of claims 63 to 65, wherein the proximal angle is increased to reduce a breakthrough pressure of the first material at the proximal end.
71. The device of claim 63, further comprising: A portion of a conduit provided with a smooth surface, the smooth surface comprising: A partially or fully stabilized lubricating fluid layer on at least a portion of an inner or outer surface of a conduit, the lubricating fluid layer wets and adheres to at least a portion of the conduit to form a slippery surface on a portion of the conduit.
72. The device of claim 71, wherein the lubricating fluid reduces an advancing angle of the first material.
73. The device of claim 71, wherein the diffusion coefficient of the first material on the lubricating fluid is greater than zero, and wherein the lubricating fluid forms a coating around the first material.
74. The device of claim 71, wherein the lubricating fluid reduces the effective surface tension of the first material.
75. The device of claim 63, wherein the surface characteristic comprises a chemical gradient or pattern on at least a portion of at least one of the inner surface and the outer surface.
76. The device of claim 75, wherein the chemical gradient or pattern is disposed on an inner surface of the conduit.
77. The device of claim 75 or 76, wherein the chemical gradient or pattern reduces the effective surface tension of the first material when the first material is disposed on the chemical gradient.
78. The device of claim 63, wherein a portion of the conduit has a gradient or pattern disposed thereon.
79. The device of claim 78, wherein the gradient or pattern reduces the effective surface tension of the first material.
80. The device of claim 63, wherein the catheter comprises a stimulus-responsive portion, the stimulus being selected from one or more of light, temperature, pressure, electric field, magnetic field, expansion, deswelling, or a chemical composition.
81. The device of claim 80, wherein the catheter further comprises a lumen defined by the inner surface and extending from the distal end to the proximal end, The stimulus responsive portion is disposed in the inner cavity.
82. The device of claim 81, wherein the stimulus-responsive portion comprises a distal flange disposed at or near a distal end of the catheter; and Wherein the distal flange is capable of transitioning between a first configuration and a second configuration in response to the stimulus.
83. The device of claim 82, wherein the lumen is open to the first material in the first configuration and closed to the first material in the second configuration.
84. The device of claim 63, wherein the first material is selected from the group consisting of: effusion, pus, blood, plasma, tears, breast milk, amniotic fluid, serum, synovial fluid, cerebrospinal fluid, urine, saliva, sputum, sweat, other body fluids, water, water containing surfactant, perilymph, endolymph, mucus, and any combination thereof.
85. The device of claim 1 or 63, wherein the second material is selected from the group consisting of water, aqueous solutions, foams and emulsions, ototoxic agents, soaps, pool water, fresh water, saline water or sediment, foams and emulsions.
86. The device of claim 1 or 63, wherein the conduit comprises one or more of: hydrogels, chemically cross-linked polymers, supramolecular polymers, metals, metal oxides, porous materials, geometrically patterned pores or channels in materials, membranes and sponges, colloid and surfactant templated pores, grooves and ridges, periodic and non-periodic arrays of indentations, nano- and microstructures: nano-forests, nanoscale patterned films, micro-platelets, micro-pillars and micro-ridges.
87. The device of claim 1 or 63, wherein the conduit comprises one or more of: biostable or bioabsorbable polymers, isobutylene-based polymers, polystyrene-based polymers, polyacrylates and polyacrylate derivatives, vinyl acetate-based polymers and copolymers thereof, polyurethanes and copolymers thereof, silicones and copolymers thereof, ethylene vinyl acetate, polyethylene terephthalate, thermoplastic elastomers, polyvinyl chloride, polyolefins, cellulosics, polyamides, polyesters, polysulfones, polytetrafluoroethylene, polycarbonates, acrylonitrile butadiene styrene copolymers, acrylics, polylactic acid, polyglycolic acid, polycaprolactone, polylactic acid-polyethylene oxide copolymers, cellulose, collagen, alginate, gelatin, and chitin.
88. The device of claim 1 or 63, wherein the conduit comprises one or more of: dacron polyester, poly(ethylene terephthalate), polycarbonate, polymethyl methacrylate, polypropylene, polyalkylene oxalate, polyvinyl chloride, polyurethane, polysiloxane, nylon, poly(dimethylsiloxane), polycyanoacrylate, polyphosphazene, poly(amino acids), ethylene glycol I dimethacrylate, poly(methyl methacrylate), poly(2-hydroxyethyl methacrylate), polytetrafluoroethylene poly(HEMA), polyhydroxyalkanoate, polytetrafluoroethylene, polycarbonate, poly(glycolide-lactide) copolymer, polylactic acid, poly(gamma-caprolactone), poly(gamma-hydroxybutyrate), polydioxanone, poly(gamma-ethylglutamate), polyiminocarbonate, poly(orthoesters), polyanhydrides, alginate, dextran, chitin, cotton, polyglycolic acid, polyurethane, gelatin, collagen, or derivatives thereof.
89. The device of claim 1 or 63, wherein the conduit comprises one or more of Li, Be, B, Na, Mg, Al, Si, K, Ca, Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Rb, Sr, Y, Zr, Nb, Mo, Ru, Rh, Pd, Ag, Cd, In, Sn, Sb, Cs, Ba, Hf, Ta, W, Re, Os, Ir, Pt, Au, Ti, Pb, Bi, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, and oxides thereof.
